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Abstract 
Background 
The endometrium is a highly dynamic tissue undergoing up to 400 cycles of proliferation, 
differentiation and breakdown in an average woman’s reproductive life. The mechanisms of 
this proliferative potential are the subject of active study and one candidate is Adult Stem 
Cells (ASCs). Endometriosis is a benign proliferative endometrial disease resulting from 
ectopic growth of endometrial tissue comprising glands and stroma with unknown 
pathogenesis. ASCs have also been implicated in the pathogenesis of endometriosis and 
attempts have been made in recent years to characterise and isolate this cell population 
within the endometrium. A great deal of investigation into cellular and molecular processes 
governing this disease has been undertaken with conflicting results. A useful tool to guide 
future investigation is the emerging discipline of bioinformatics.  
Objectives: 
One of the difficulties with investigating endometriosis and endometrial ASCs is the lack of 
suitable in-vitro models to study the benign yet abnormal growth of endometrial epithelial 
cells in culture. Ex-vivo culture models using a multicellular culture system are highly 
desirable for future work and the present study aimed to investigate two of the features 
associated with ASCs: proliferation and differentiation potential. A crudely fractionated 
epithelial population of endometrial cells in a neonatal kidney explant model was used to 
assess this.  
The kidney is an ideal tissue for use in co-culture with endometrial cells as the 
endometrium and the kidney both embryologically derive from the intermediate 
mesoderm. Furthermore, it has been shown previously that human endometrial cells can 
generate endometrial-like tissue, including glandular structures, when transplanted into the 
kidneys of immune-compromised adult mice. To investigate whether an in vitro model 
using neonatal kidney cells could support the growth and differentiation of endometrial 
cells, endometrial epithelial cells were grown in a chimeric explant model using kidney 
tissue isolated from CD1 neonatal mice. Chimeras were generated using a recently 
developed reaggregation protocol. Controls comprised explants of reaggregated kidneys 
that did not contain any endometrial cells.  Explants were cultured at an air-medium 
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interface for 2 hours (0 Days), 3 Days and 7 Days respectively before being fixed, processed 
and analysed with immunofluorescence and RT-qPCR to detect the presence of 
endometrial-derived glandular structures, and endometrial differentiation markers. 
Markers of interest for analysis of the chimeras included: Laminin, Progesterone Receptor 
and Mucin1. A human-specific cytoplasmic antibody was used to identify human cells in the 
chimeras. 
This work was further extended to assess nephrogenesis and endothelial cell survival in the 
neonatal kidney explants. In the study of the developmental processes governing the 
mammalian kidney progress has been achieved through the use of embryo explant models. 
These models are useful for studying early developmental processes such as reciprocal 
induction but are less suitable for studying later maturation events (e.g. foot process 
formation in podocytes), due to the fact that the endothelial cell population dies. 
Podocytes depend upon interactions with the glomerular basement membrane (GBM) to 
achieve maturity and the GBM is known to be formed, at least in part, from factors 
secreted by endothelial cells. If an explant model could be established with an intact 
endothelial population there is potential to study these maturation processes. Markers of 
interest for neonatal kidney explants included: WT1, Pecam, Synaptopodin, Laminin and 
Calbindin. 
Bioinformatics tools were employed to examine existing microarray data sets of normal 
endometrium during various stages of the menstrual cycle with the aim of identifying 
molecular pathways of interest and generating suitable hypotheses. The same process was 
carried out for endometrium from patients with endometriosis with the future goal of 
comparing these datasets. 
Results: 
Analysis of chimeric explants indicated that a large proportion of the endometrial cells died 
in culture with only a small population present by Day 7 that showed no evidence of 
forming glandular structures. A degree of nephrogenesis appeared to have occurred in the 
neonatal kidney explant model with evidence of endothelial cells surviving and forming 
cord like structures in culture. 
Initial investigation of the transcriptomic datasets associated with normal endometrium 
and patients with endometriosis was submitted to Ingenuity Pathways Analysis (IPA) and 
4 
 
Cytoscape. A large amount of output was obtained and specific pathways suitable for 
further investigation were identified including: Super Oxide Radicals Degradation, 
Tryptophan Degradation to 2-amino-3 Semi Aldehyde and Wnt/β Catenin Pathway. 
Conclusions: 
The three main conclusions were as follows. 1 Human endometrial cells were not able to 
survive in the chimeric model of ex-vivo culture, indicating that this is unlikely to be a 
suitable model system for studying the formation of endometrial cell-derived glandular 
structures. 2 Nephrogenesis may be occurring in the reaggreagted neonatal explants, and 
the endothelial population appeared to have survived and formed capillary like structures 
in vitro. This is an important observation because in explants of embryonic kidneys, the 
endothelial cells do not survive. 3. Investigation of the molecular processes at play in the 
normal endometrium and endometriosis has generated some interesting hypotheses that 
will be further investigated using ‘wet’ laboratory techniques. 
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Figure 2: Microscopic Structure of the 
Endometrium 
Fig2. Microstructure of the human endometrium. 
A: Luminal Epithelium, B: Glandular Epithelium, C: 
Stroma. The functionalis and basalis layers are not 
histologically distinct. (Gargett, 2008)  
1.1 Gross Structure of the Uterus 
The human uterus is a thick walled muscular organ located within 
the pelvic cavity. It is roughly 7.5 cm in length and is continuous 
superiorly with the fallopian tubes, which are encased in the broad 
ligament. Inferiorly the uterus is continuous with the cervix, vagina 
and vulva (Figure 1) (Drake RL, 2010). The structure of the uterus is 
made up of three layers with the outermost layer being parietal 
peritoneum continuous with the broad ligament. The middle layer is 
myometrium composed of smooth muscle fibers and the innermost 
layer of the uterus is the endometrium (Drake RL, 2010).  
1.2 Microscopic Structure of the Endometrium 
The endometrium is the reproductive tissue lining the uterine cavity. It possesses immense 
proliferative potential evidenced by the fact that it is able to undergo up to 400 cycles of 
growth differentiation and shedding within an average woman’s reproductive years 
(Gargett and Masuda, 2010). The endometrium is functionally divided into a superficial 
‘functionalis’ layer which is shed during menstruation and a deeper ‘basalis’ layer which is 
retained and from which the new functionalis is regenerated each month.  
Histologically the endometrium can be separated into two 
distinct cell populations, the Epithelium and the Stroma 
(Figure 2). The epithelium is further subdivided into the 
Luminal Epithelium (LE, Figure 2A), which lines the uterine 
cavity serving as the point of contact for the implanting 
blastocyst and the Glandular Epithelium (GE, Figure 2B), 
which lines the glands penetrating deep into the basalis 
(Jabbour et al., 2006). The second population is the stroma 
(Figure 2C), which constitutes the supporting parenchyma 
of the endometrium. The stroma and the basalis glands 
form a rough boarder with the myometrial cells, which 
make up the body of the uterus (Uduwela et al., 2000). 
 
 
Fig1. Anatomy of the human female 
reproductive system (Drake RL, 2010) 
Figure 1: Anatomy of the 
Female Reproductive 
System  
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 1.3 Embryology of the Uterus  
The uterus, cervix, fallopian tubes and cranial portion of the vagina are formed from the 
paired Paramesonephric or ‘Mullerian’ ducts which were first described in 1825 and derive 
from the intermediate mesoderm (Gargett). Both the reproductive and urinary systems are 
derived from this structure which lies between the paraxial and the lateral plate mesoderm 
along the posterior wall of the abdominal cavity (Sadler, 2004). The luminal epithelium 
emerges first with the glands being a late fetal development shallow in nature until further 
development occurs postnatally (Ma, 1973). The stromal cells and myometrium are derived 
from the urogenital ridge mesenchyme and there is evidence that their differentiation is 
regulated by the surrounding epithelium (Brody and Cunha, 1989). This highlights the idea 
of crosstalk between these structures and indicates the importance of studying both cell 
populations when investigating endometrial physiology (Brody and Cunha, 1989). 
1.4 Menstrual Cycle 
The human menstrual cycle refers to a set of dynamic changes involving proliferation and 
differentiation that occur within the premenopausal endometrium according to the 
corresponding cyclical ovarian hormonal changes, for which the endometrium is the target 
organ (Figure 3). The cycle can be split 
into events occurring in the ovary 
(Figure 3A), and events occurring in the 
endometrium (Figure 3B). The 
standardised menstrual cycle is 28 days 
in duration with day 1 defined as the 
start of the menstrual phase. Ovulation 
occurs at approximately day 14 which 
signifies the transition from 
proliferative to secretory phase 
(Gargett, 2008). 
 
 
 
Fig3. The histological and hormonal changes associated with the human ovarian and 
menstrual cycles.  
Figure 3: Ovarian and Menstrual Cycles 
B
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1.5  The Ovarian Cycle 
The ovaries are the female gonads and are responsible for producing the ova which will 
form the maternal portion of the zygote, they undergo a series of cyclical changes in 
tandem with the endometrium releasing Oestrogen and Progesterone under the influence 
of Follicle Stimulation Hormone (FSH) and Luteinising Hormone (LH) (Impey, 2012, Gargett, 
2008). The ovarian cycle is divided into follicular and luteal phases (Figure 4).  
1.5.1 Follicular phase 
The follicular phase is characterised by the pulsatile release of 
FSH and LH from the anterior pituitary under the influence of 
Gonadotrophin releasing Hormone (GnRH) (Figure 4A). FSH 
acts to stimulate the development of several primordial 
follicles which release oestrogen and inhibin to inhibit FSH in a 
negative feedback response. As oestrogen levels increase 
however they begin to exert a positive feedback response 
stimulating a ‘surge’ of LH at day 14 (Figure 4A) with follicle 
rupture and ovulation occurring usually within 36 hours of this 
event (Gargett, 2008).  
1.5.2 Luteal Phase 
Ovulation signifies the beginning of the luteal phase as the ruptured follicle degenerates to 
form the corpus luteum. This structure secretes both oestrogen and progesterone, though 
progesterone is dominant, along with inhibin A, the levels of which peak around day 21 
(Figure 4B). Progesterone acts to prevent degeneration of the oestrogen primed 
endometrium and stimulates decidualization (Impey, 2012). Unless the corpus luteum is 
maintained by Human Chorionic Gonadotrophin (HCG) released as the result of 
implantation it will degenerate with the subsequent fall in progesterone triggering 
menstruation (Figure 4B). 
1.6 Endometrial Cycle 
The endometrial cycle can be split into three broad phases: Proliferative, Secretory and 
Menstrual each of which are characterised by structural and functional changes highlighting 
the varied and dynamic nature of this tissue. 
Figure 4: Ovarian Cycle 
Fig4. Illustration of cyclical hormonal changes 
during the ovarian cycle. A: Hormones acting 
on the ovaries, FSH, LH. B: Hormones released 
by the ovaries, Oestrogen (E2) and 
Progesterone (P) 
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1.6.1 Proliferative Phase 
The endometrial changes seen in the proliferative phase are thought to be regulated by the 
dominant hormone in the tissue at this time, oestrogen. The early proliferative phase is 
characterised by initial repair of the denuded endometrial surface, a process commenced 
by epithelial cells suggesting that this population is required for stromal responsiveness 
later in the cycle (Bigsby, 2002). As the proliferative phase continues all cell types multiply 
under the influence of oestrogen which is thought to assert its effects via Insulin-like 
Growth Factors along with Epidermal Growth Factors and Transforming Growth Factor Beta 
(TGF-β) (Gargett et al., 2008). A vast array of additional molecules have also been 
implicated in the proliferation of the endometrium at this time including: growth factors, 
cytokines, fibronectin, integrins and matrix metalloproteinases (MMPs) (Thie and Denker, 
2002). An interesting aspect of these repair and proliferation processes is that they enable 
the endometrium to heal without scarring, a phenomenon only previously documented in 
fetal skin wounds (Samuels and Tan, 1999).  
1.6.2 Secretory Phase 
The Secretory Phase commences at around day 14 of the cycle and is characterised by 
functional differentiation of the endometrial tissue to promote an environment suitable for 
embryo implantation (Gargett, 2008). The key hormone driving these processes is 
progesteronewhich acts on oestrogen primed cells. The secretory phase can be 
histologically subdivided into: Early, Mid and Late phases based on the criteria of Noyes et 
al (Noyes and Haman, 1953). 
 Early Secretory Phase: sub-nuclear vacuoles are observed in epithelium 
 Mid Secretory Phase: increased gland tortuosity with increased secretory activity. 
This phase also represents the implantation window (Psychoyos, 1973). 
 Late Secretory Phase: the differentiation of stromal cells known as decidualization 
occurs. This spontaneous non reversible change involves fibroblast type cells close 
to spiral arterioles becoming enlarged and rounded. Progesterone receptor A is 
dominant at this time (Alexander et al., 1996). 
There are a number of factors secreted into the uterine lumen during the secretory phase, 
including: proteins, ions, glucose, cytokines, enzymes, growth factors and proteases, 
collectively known as the histotroph (Kane et al., 1997). 
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1.6.3 Menstruation 
Menstruation is the term used for the sequence of tissue breakdown and endometrial 
bleeding occurring at the end of each menstrual cycle during which the functionalis layer of 
the endometrium is shed leaving the basalis intact (Gargett et al., 2008). These changes are 
initiated by a fall in oestrogen and progesterone preceded by the breakdown of the corpus 
luteum.  Various mechanisms governing menstruation have been proposed, one of which is 
hypoxia (Markee, 1978) however is it also likely that menstruation is an inflammatory 
process characterised by  tissue oedema, inflammatory cell recruitment and pro 
inflammatory cytokine release (Finn, 1986). As the endometrial vasculature may play a key 
role in the tissue breakdown associated with menstruation, studies have considered various 
pro inflammatory and vasoactive agents associated with this structure e.g. Prostaglandin F2 
alpha, Cyclo-oxygenase 2 and Endothelin 1 (Salamonsen et al., 1999a, Salamonsen et al., 
1999b). 
1.7 Endometriosis 
A wide variety of factors contributing to the regenerative capacity of the endometrium 
have been proposed and research is ongoing. In addition, widening the understanding of 
normal physiology may provide insights into pathological processes and there are several 
endometrial diseases which share this characteristic of a large proliferative potential. One 
such disease is endometriosis which is defined as the presence and growth of tissue similar 
to endometrium comprising glands and stroma outside of the uterus and represents a 
major detriment on the quality of life of affected patients (Impey, 2012). 
1.7.1 Epidemiology 
There is difficulty in accurately documenting the incidence and prevalence of endometriosis 
as symptoms often do not correlate with severity of disease, and invasive surgical 
procedures such as laparoscopy are required for definitive diagnosis. In the UK 1-2% of 
women are diagnosed, though up to 20% of women may have endometriotic lesions which 
may not be symptomatic (Guideline, 2008). Endometriosis is estimated to cost the UK £2.8 
billion per year in days taken off work (EndometriosisUK, 2013).  
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1.7.2 Clinical Features 
The clinical features of endometriosis are broad and highly varied but common signs and 
symptoms include: pelvic pain, dysmenorrhoea, deep dyspareunia, dyschezia, subfertility 
and infertility. Other rare symptoms that may suggest extensive disease include: cyclical 
haematuria, rectal bleeding and bleeding from the umbilicus (Impey, 2012). 
1.7.3 Investigations and Diagnosis 
Serum CA 125 levels may be raised in patients with endometriosis however this is of limited 
diagnostic value and reliable biomarkers of the disease are currently lacking. Direct 
visualisation of endometriotic lesions at laparoscopy is required for definitive diagnosis with 
or without tissue biopsy and histological analysis (Guideline, 2008).  If there is clinical 
evidence of deeply infiltrating endometriosis, bladder and bowel involvement are assessed 
with MRI, plus or minus intravenous pyelogram and Barium studies (Guideline, 2008). On 
inspection of the abdominal cavity lesions may be diffusely spread and thorough 
investigation is necessary for accurate staging. Common sites include: utero-sacral 
ligaments, utero-vesical fold, utero-rectal pouch, sigmoid colon and the ovary 
(endometrioma) (Impey, 2012) (Figure 5A). 
There are four different characteristic appearances of endometriotic lesions commonly 
visualised at laparoscopy (Figure 5B) which may represent different stages of disease 
activity and different cellular processes. More active lesions appear as red vesicles with 
white scars or brown spots (powder burn) followed by fibrotic lesions representing more 
longstanding disease (Impey, 2012). Another laparoscopic finding more commonly found in 
endometriosis patients is the Allen Masters Peritoneal Window which may be the result of 
a prolonged inflammatory state (Burney and Giudice, 2012). 
Figure 5: Common Sites and Morphology of Endometriotic Lesions 
 
 
 
 
 
Fig5. Common sites and phenotypes associated with endometriosis lesions.  A. Common sites of endometriotic lesions within 
the pelvic cavity. (Impey, 2012)   B. Phenotypic subtypes of peritoneal endometriosis. (A) Red vesicular lesion. (B) Powder-
burn lesion. (C) Fibrotic lesion. (D) Allen-Masters peritoneal defect (Burney., 2012).  
A B 
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1.7.4 Staging of Endometriosis 
The revised American fertility society criteria for endometriosis scores the disease extent 
based on the presence and location of lesions. There are four stages (Impey, 2012): 
 Grade 1 (Minimal) 
 Grade 2 (Mild) 
 Grade 3 (Moderate) 
 Grade 4 (Severe) 
It should be noted that the severity of disease assessed by the grading system does not 
correlate well with patient symptoms. 
1.7.5 Management of Endometriosis 
The treatment of endometriosis can be divided into conservative, medical and surgical 
treatment. However this is governed primarily by patient symptoms as no treatment is 
required for asymptomatic lesions found incidentally at laparoscopy. The exception to this 
are endometriomas which are occasionally removed in this situation as there is a small risk 
of misdiagnosing ovarian cancer (Guideline, 2008). 
 Medical Management 
First line medical management is analgesia to provide symptom control e.g. Non Steroidal 
Anti Inflammatory Drugs (NSAIDs) such as mefenamic acid and naproxen (Impey, 2012). 
However efficacy of this class of drugs in endometriosis has not been proven by 
randomized control trial and significant adverse effects e.g. gastric ulceration should be 
considered (Guideline, 2008). Hormonal therapy is also used in endometriosis and is based 
on the principle that endometriosis is an oestrogen dependent disease noted to regress at 
times of reduced oestrogen exposure e.g. pregnancy and the menopause. Treatments 
offered either mimic pregnancy (Combined oral Contraceptive e.g. Microgynon) or the 
menopause (GnRH Agonist e.g. Zoladex) however these therapies are also associated with 
side effects e.g. vaginal dryness, hot flushes osteopenia and osteoporosis (Guideline, 2008). 
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 Surgical Management 
Surgical management aims to remove the endometriotic lesions from the abdominal cavity 
and is only considered if medical therapy has been ineffective.  At laparoscopy laser or 
bipolar diathermy can be used to ablate lesions. Other options include radical dissection of 
lesions or hysterectomy with bilateral salpingo-opherectomy however these options should 
be considered as a last resort as they entail major surgery and are associated with adhesion 
formation. Laparoscopy itself has also been associated with endometriosis lesion induction 
(Harirchian et al., 2012). 
1.7.6 Endometriosis and Fertility 
Endometriosis is a disease associated with sub-fertility, for example lesions are found in 
25% of laparoscopies carried out for subfertility (Impey, 2012); the mechanisms of this sub 
fertility are not yet clear, though implantation failure is thought to be one mechanism, and 
this affects management. A Cochrane review has found that medical treatment will not 
increase fertility if the fallopian tubes are unaffected but that laparoscopic ablation may, 
particularly when adhesions are present (Jacobson et al., 2002). Many patients with 
advanced endometriosis will be of reproductive age and the best chance for achieving 
pregnancy will be In Vitro Fertilisation (IVF). With this in mind it is essential to attempt to 
understand the processes behind this disease as it impacts upon so many aspects of a 
patient’s life and several different approaches need to be considered.   
1.8 Pathogenesis of Endometriosis 
Whilst the clinical features of endometriosis are well described the cause of this 
proliferative disease is still unknown. Several theories have been proposed and these 
include: 
 Retrograde Menstruation 
 Coelomic Metaplasia 
 Induction Theory 
 Mullerian Rest Theory 
 Genetic Inheritance 
 Stem cell theory 
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These proposed mechanisms of pathogenesis can be broadly divided into those where 
ectopic tissue implants onto the abdominal wall e.g. retrograde menstruation, and those 
where the endometrial tissue arises de novo e.g. Coelomic Metaplasia (Gargett, 2008). 
1.8.1 Retrograde Menstruation 
Retrograde menstruation is the most widely accepted theory for endometriotic lesion 
induction and was first proposed by Sampson in 1927 (Sampson, 1927). It is suggested that 
at the point of menstruation some of the shed endometrium, instead of passing through 
the cervix and vagina, enters the abdominal cavity via the fallopian tubes and implants 
there, the result being a lesion (Sampson, 1927). There is some clinical evidence to support 
this theory in the increased prevalence of endometriosis noted in women with uterine 
outflow obstruction e.g. cervical stenosis (Jenkins et al., 1986).  
1.8.2 Coelomic Metaplasia and Induction Theory  
Coelomic metaplasia and induction theory are two interrelated ideas implicating metaplasia 
of extra-uterine cells in the pathogenesis of endometriosis. Coelomic metaplasia states that 
normal peritoneal tissue is transformed by an as yet undefined stimulus to ectopic 
endometrial tissue. Similarly induction theory proposes that extra-uterine metaplasia may 
be induced by either a hormonal or immunological factor, while study is ongoing these 
‘factors’ have not yet been defined (Levander and Normann, 1955). Some indirect evidence 
for these theories can be found in the form of case reports of ovarian endometriosis in 
patients with Mayer-Rokitansky-Kuster-Hauser syndrome, a condition characterised by 
uterine agenesis including absence of the endometrium (Yan et al., 2011). 
1.8.3 Mullerian Rest Theory 
This theory relates to the development of the female reproductive tract through the 
Mullerian duct. It is suggested that cells derived from the Mullerian duct maintain a 
differentiation potential, giving them the capacity to transform into endometrial cells at the 
onset of puberty under hormonal stimulation (Longo, 1979). 
1.8.4 Genetics of Endometriosis 
 
Investigation has been undertaken into the prospect of endometriosis as a familial disease 
with a genetic basis however as previously mentioned epidemiological study of the disease 
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is limited due to the requirement for laparoscopy to make a diagnosis (Zondervan et al., 
2001, Kennedy et al., 2001). Some correlation has been found but the trait is likely to be 
complex (Simpson and Bischoff, 2002). 
1.9 Proposed Mechanism of Lesion Establishment 
Sampson’s theory of retrograde menstruation is the most widely excepted model of 
endometriosis; however it poses several questions that need to be examined in more detail 
to fully understand the pathogenesis of this disease. 
One such issue is the observation that ‘retrograde menstruation’ occurs in up to 90% of 
pre-menopausal females (Halme et al., 1984) however only 5-10% experience the disease  
(Cramer and Missmer, 2002, Missmer and Cramer, 2003), which would suggest other 
factors are important in determining lesion establishment. In a recent review, Burney and 
Guidice summarised these as: escape from immune clearance, attachment to peritoneal 
epithelium, invasion of the epithelium, establishment of local neurovascularity, and 
continued growth and survival (Burney and Giudice, 2012). Looking at these processes and 
how they may vary between women with and without the disease has yielded a group of 
potential biomarkers. However, investigation in this area is still early with many 
publications offering conflicting evidence.  The variation of these putative biomarkers 
throughout the menstrual cycle is also not always considered in their analysis, a factor 
which must be taken into account to ensure findings are relevant (May et al., 2011).  
Bioinformatics is a useful tool which could help gain a ‘whole view’ of the endometrium as 
it can consider vast amounts of data, however there is a difference between identifying 
biomarkers and confirming their role in pathogenesis. The work presented below indicates 
that further investigation is required in order to more fully understand the pathogenesis of 
this disease. 
 
1.9.1 Continued Growth and Survival of Endometrial Cells 
As retrograde menstruation occurs in such a high percentage of women with only 10-20% 
developing endometriosis it has been suggested that endometrial cells of patients with the 
disease are in some way different so as to increase their chances of surviving in the 
abdominal cavity allowing a lesion to be established. A great deal of work has been carried 
out in this area however the evidence is conflicting (May et al., 2011). Some studies have 
looked at regulators of apoptosis and cell cycle with one group proposing evidence for an 
29 
 
anti-apoptotic environment in patients with endometriosis characterised by increased MCL-
1 and reduction in Bak expression in secretory phase glandular epithelium (Burlev et al., 
2006). Another group has demonstrated up-regulation of the anti-apoptotic gene BCL-2 in 
the endometrium of affected patients (Wingfield et al., 1995). Telomerase activity is 
another factor increasing the survival potential of endometrial cells and has been detected 
increased in secretory phase endometrium of patients with the disease, it was also noted 
that  mean telomere length may also be increased (Hapangama et al., 2008, Hapangama et 
al., 2009). A further consideration is the presence of endometrial stem cells in 
endometriosis lesions. 
 
1.9.2 Attachment to the Peritoneal Epithelium and Tissue Remodelling 
It is thought that damaged peritoneum could be a risk factor for implantation of ectopic 
tissue, one in vitro study has shown that fragments of endometrial tissue were only 
adherent in a model of ectopic implantation when extracellular matrix (ECM) was exposed 
due to induced damage (Gerhard et al., 1991). This is also consistent with work in baboons 
demonstrating that laparoscopy may be a risk factor for lesion establishment (Harirchian et 
al., 2012). 
1.9.3 Matrix Metalloproteinases 
Another potential mechanism of peritoneal damage is the action of MMPs, a group of 
enzymes associated with degradation of the extracellular matrix and tissue remodelling 
previously thought to play a role in normal endometrial physiology (Eyster et al., 2002). It is 
suggested that inappropriate action of these enzymes in patients with endometriosis may 
result in degradation of the ECM associated with the pelvic peritoneum allowing refluxed 
endometrial cells to implant and establish lesions (Osteen et al., 2003). Both MMP2 and 
MMP3 mRNA have been detected upregulated in endometriosis patients, (Di Carlo et al., 
2009, Sotnikova et al., 2010, Kyama et al., 2006). These findings have been corroborated 
using immunohistochemistry, RT-PCR and Enzyme-Linked Immuno-absorbent Assay (ELISA) 
(Gilabert-Estellés et al., 2007). In a separate study MMP7 was found upregulated in 
epithelial cells (Matsuzaki et al., 2010b). There is however much conflict within this area of 
research and some studies have found no difference in expression e.g. of MMP3 (Meola et 
al., 2010). Tissue Inhibitors of Metalloproteinases (TIMPS) are responsible for inhibiting the 
action of MMPs and maintaining a homeostatic balance of tissue maintenance and 
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remodelling. This group of enzymes has also been investigated in endometriosis with 
similarly conflicting results (Gilabert-Estellés et al., 2003, Ramón et al., 2005, Gilabert-
Estellés et al., 2007). 
1.9.4 Angiogenesis in Endometriosis 
It has been observed in cancer that any tissue growth above a critical mass must establish a 
blood supply for itself. For this reason angiogenesis has been investigated in endometriosis 
and interest in this area is enhanced by the finding of a chimeric circulation in the work 
performed by the Masuda group (Masuda et al., 2007).  Vascular Endothelial Growth Factor 
(VEGF) is a molecule that has been extensively investigated with increased expression 
detected in the late secretory epithelium of patients with the disease (Donnez et al., 1998). 
A subtype of the molecule VEGF-A is has also been found upregulated in women with 
endometriosis as well as down regulation of VEGF receptor 1 and 2 possibly indicating 
decreased sensitivity (Bourlev et al., 2006). These studies indicated that VEGF might be 
elevated at a certain point in the cycle in endometriosis, which would make sense as it is a 
hormone responsive disease. More recent investigation however has suggested increased 
VEGF expression might persist throughout the cycle (Gilabert-Estellés et al., 2007). 
1.9.5 Cytokines, Steroid Hormones and Cell Adhesion Molecules 
Many other intra and extracellular molecules have been investigated with regard to their 
involvement in the pathogenesis of endometriosis. Interleukins are a group of cytokines 
thought to be differentially expressed in endometriosis. For example IL-1R Type II has 
demonstrated downregulation in epithelium throughout several studies (Akoum et al., 
2001, Kharfi and Akoum, 2001, Kharfi et al., 2002, Lawson et al., 2008) whereas IL-8 has 
been found up-regulated in epithelial cells (Ulukus et al., 2005). The chemokine ‘Regulated 
on Activation, Normal T Cell Expressed and Secreted’ (RANTES) has been found 
differentially expressed in endometriosis, but further work is needed to fully elucidate its 
association with the disease as its expression appears to also be cycle phase dependent 
(Kyama et al., 2008). Other molecules thought to be differentially regulated are vast in 
number and diverse in function. These molecules  have been summarised (May et al., 2011) 
but some notable examples include: IGF protein 3 (Akoum et al., 1999), Osteopontin  
(Burney et al., 2007) and Beta Catenin (Matsuzaki et al., 2010a). Cell adhesion molecules 
such as: Cadherins, Integrins, Selectins, Immunoglobulins are also thought to be important 
to the pathogenesis of this disease and research is ongoing (May et al., 2011). 
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1.9.6 Stem Cells in Endometriosis  
The cellular and molecular processes investigated in relation of endometriosis often relate 
to increased cell survival within the peritoneal cavity and proliferation of a cell population 
in response to a stimulus (in this case, oestrogen). These are properties shared by Adult 
Stem Cells (ASCs) or Progenitor Cells (PCs) and it is for this reason that ASCs have been 
hypothesised to play a role in the pathogenesis of endometriosis. Some experimental 
findings have backed up this hypothesis including investigation of epithelial glands in 
endometriosis which were monoclonal in some lesions suggesting they descend from a 
single PC (Gargett and Masuda, 2010). Experimental models of lesion induction in baboons 
have also demonstrated that introducing endometrial cells into the abdominal cavity was 
associated with lesion development (Harirchian et al., 2012). As progenitor cells are 
thought to reside in the basalis it has been suggested that in women with endometriosis 
these may become inappropriately dislodged and refluxed (Leyendecker et al., 2002). 
1.10 Future Directions of Endometriosis Research 
It is clear that potential molecules involved in the pathogenesis of endometriosis have been 
extensively studied using laboratory techniques with potential applications including 
peripheral blood tests to aid diagnosis and the development of disease modifying 
pharmacological interventions. While this work is undoubtedly useful there is a great 
variability in results and to a degree it may be beneficial to introduce a standardised 
method within the field e.g. in accounting for cycle phase. Another tool that would be 
useful in guiding this research, and could provide useful insights into cellular and molecular 
processes occurring in both normal endometrium and endometriosis, is bioinformatics. 
1.11 A Bioinformatics Approach to the Endometrium and Endometriosis 
The structural and functional complexities of the endometrium pose a great challenge for 
investigators, particularly when trying to study a proliferative disease such as 
endometriosis, as our understanding of the normal physiology is incomplete. As previously 
described a number of potential biomarkers and target molecules have been identified 
both in normal physiology and disease (May et al., 2011). However, considering that the 
human genome contains in excess of 22000 genes (Birney et al., 2006), the variable 
expression of which influences these processes it would be useful to gain a wider 
perspective on intra and extra cellular events.  
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Studies using mouse models have provided useful insights into potential disease processes 
in endometriosis (Masuda et al., 2007). Humans however are more biologically complex 
organisms and although this is not demonstrated by an increased number of genes within 
the genome, it can be seen in Protein Superfamily expansion, particularly in the 
extracellular compartment (Vogel and Chothia, 2006). This is logical as the extracellular 
compartment is a far less stable environment than the intracellular compartment and as a 
result adaptations must be more rapid. Given that many of the markers postulated to play a 
role in the pathogenesis of endometriosis are associated with the extracellular 
compartment, it is important to observe their expression specifically in humans as the 
molecular processes may differ between species (Vogel and Chothia, 2006). A potential tool 
to help overcome these challenges is bioinformatics. 
1.11.1 Bioinformatics 
Bioinformatics can be most simply described as the ‘combination of biology and 
information technology’ and can incorporate any tools or methods used to analyse and 
manipulate large sets of data (Westhead DR, 2002). This rapidly growing area of 
investigational biology uses a multidisciplinary approach to increase understanding of 
complex organisms in a quantitative and discrete way not previously possible. Bioinformatic 
study consists of three main components: 
 The creation of databases allowing storage and manipulation of large biological 
datasets 
 The development of algorithms and statistics to determine relationships between 
members of these large datasets. 
 Use of these tools for analysis and interpretation of various types of biological data, 
including DNA, RNA and protein sequences, protein structures gene expression 
profiles and biochemical pathways (Westhead DR, 2002). 
Investigation using these components involves the generation of vast quantities of data 
which represents a great challenge within the discipline as it can seem difficult to know 
where to begin with analysis. This factor can also be a great strength though as correct 
interpretation allows structural and functional links to be made between relevant 
molecules (Arthur, 2008). It is for this reason that bioinformatics must use a 
multidisciplinary approach as the appropriate scientific knowledge is required to guide 
research.  
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With this in mind the three components described are utilised in order to achieve three 
main objectives: (Arthur, 2008). 
 To understand integrated aspects of the biology of organisms, viewed as coherent 
complex organisations at microscopic and macroscopic levels 
 To interrelate sequence, three dimensional structure, expression pattern, 
interaction and function of individual proteins, nucleic acids and protein-nucleic 
acid complexes 
 To support applications in medicine, agriculture and technology (Arthur, 2008). 
The potential of bioinformatics study to aid scientific discovery and influence clinical 
practice is becoming increasingly realised with several scientific papers in the field of 
Obstetrics and Gynaecology utilising this tool in recent years (Nguyen et al., 2012). Within 
this context the main focus is on drug target and biomarker discovery using tools such as: 
Microarrays, Mass Spectrometry and Proteomic Data Analysis (Arthur, 2008). As it is the 
case with bioinformatics study that a large amount of information is generated and 
recorded analysis is not always exhaustive. It was with this in mind that a component of this 
study was proposed in order to investigate differential gene expression in ‘normal’ 
endometrium and endometrium of patients with endometriosis. With this view it is thought 
that potential drug targets and biomarkers could be discovered and avenues for further 
‘wet’ lab investigation identified. 
1.12 Stem Cells 
While hypotheses can be generated from in silico work it is also important to investigate 
current models of physiology and disease within the laboratory setting. One such model 
relating to both normal endometrial function and endometriosis is the idea of stem cells in 
the endometrium. Stem Cells are defined as a population of undifferentiated cells, the key 
characteristics of which are self renewal and differentiation into one or more descendant of 
highly differentiated cell lineage (Till and McCulloch, 1961). They can be subdivided 
according to their ability to reconstitute tissues associated with an organism: (Wagers and 
Weissman, 2004) 
 Totipotent: (All embryonic and extra embryonic cell types) 
 Pluripotent (All cell types of the embryo proper) 
 Multipotent (Subset of Cell Lineages) 
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 Unipotent (Only one mature cell type) 
 
Stem Cells can also be categorised as either Embryonic Stem Cells (ESCs) or Adult Stem Cells 
(ASCs) (Evans and Kaufman, 1981). 
1.12.1 Embryonic Stem Cells 
ESCs are defined as pluripotent cells isolated from the blastocyst inner cell mass before 
implantation and are capable of differentiating into structures constituting all 3 germ layers 
in vitro (Evans and Kaufman, 1981). ESCs are not widely used for investigation within the 
endometrium and given the associated ethical concerns this population is not utilised in 
this study. 
1.12.2 Adult Stem Cells 
Adult Stem Cells (ASCs) reside within mature tissues and demonstrate the stem cell 
properties of self renewal and limited differentiation potential, being either multipotent or 
unipotent (Wagers and Weissman, 2004). This means that whilst maintaining a steady 
population within their tissue of origin e.g. the endometrium, they are able to form cell 
colonies specific to their lineage, a concept arising from studies involving Haematopoietic 
Stem Cells (Harrison, 1980). 
ASCs may be responsible for processes such as growth and repair after injury in mature 
tissue and are believed to be surrounded by a physiological microenvironment referred to 
as the ‘Stem Cell Niche’ (Schofield, 1978). This environment is thought to be comprised of a 
group of supporting ‘niche cells’ which communicate with their resident ASC stimulating 
either proliferation or differentiation (Gargett, 2007). Interactions between the ASC and its 
niche are vital for normal function of adult tissues, a process characterised in gut epithelial 
tissue (Gargett, 2007). 
ASCs have been studied in many tissues, however due to their primitive nature and rarity 
they have been difficult to isolate. This has been achieved in some tissues e.g. rat neural 
crest cells (Morrison et al., 1999) and it is hoped that they can be identified and isolated in 
human endometrium. If this can be achieved, insights into the processes underlying the 
normal menstrual cycle and proliferative endometrial disease such as endometriosis may 
be elucidated. Progress within this field would serve to both improve scientific 
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understanding and aid clinical management of a variety of endometrial pathologies 
including menstrual disorders and endometriosis.  
One tissue in which ASCs have been extensively studied relevant to the endometrium is the 
intestine. In this tissue the epithelial cells are arranged in a glandular structure similar to 
that of the endometrium; the gland base, or crypt of Lieberkuhn, has been identified as the 
area where proliferation occurs. This is evidenced by studies demonstrating activation of 
the canonical Wnt/Beta Catenin signalling pathway in basal cells, a key regulator of an 
undifferentiated state associated with ASC activity (Fevr et al., 2007, Valentijn et al., 2013).  
Being located at the base of the crypt allows these ASC/progenitor cells to be surrounded 
by a niche, as described by Schofield, composed of extracellular matrix and other cells 
(Spradling et al., 2001). This would not be possible higher up the crypt as the more 
differentiated cells migrate upwards through the ‘transit amplifying zone’ before being 
shed (Spradling et al., 2001). Specific markers have also been identified in the intestine, 
notably Musashi1, Hes1 and CD133 (Iovino F, 2009). Any tissue containing ASCs may be 
associated with a rapid turnover of cells. One danger recognized with this rapid 
proliferation is the increased risk of mutations which may lead to tumour formation 
(Wagers and Weissman, 2004). It has been noted in Colon Cancer that tumours expressing 
the marker CD133 have been demonstrated residing at the base of normal glands leading 
to the hypothesis that the aberrant proliferation of ASCs may play an early role in the 
formation of these tumors (Salven et al., 2003, Yin et al., 1997). The progenitor cells 
isolated in the intestine also show a higher telomerase activity with longer telomere 
lengths, another ASC property currently being investigated in the endometrium (Schepers 
et al., 2011, Valentijn et al., 2013) 
Given the similarities between endometrial glands and the small intestine epithelial glands 
this tissue has been used as a model for endometrial research. An example of this is the 
investigation of Sox9, a molecule associated with proliferation known to be present in the 
small intestine which a group at the University of Liverpool has recently investigated in the 
endometrium using IHC (Valentijn et al., 2013).  
Much of the work discussed so far focuses on the detection and isolation of Adult Stem 
Cells from mature tissue. However a recent alternative approach has been aimed at the 
generation of ASCs from terminally differentiated cells. These cells, with pluripotent 
properties, were first generated in 2006 by Yamanaka et al generating ASCs from mouse 
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fibroblasts (Takahashi and Yamanaka, 2006). This was achieved via the retroviral induction 
of 4 transcription factors: Oct4, Klf4, c-myc and Sox2, the actions of which are thought to 
reprogram the cell to a pluripotent phenotype (Jaenisch and Young, 2008).  
This is an emergent field and several modifications to the procedure including the induction 
of different transcription factors e.g. Nanog and different methods of induction have been 
used to reduce potential teratogenicity. Since 2006 iPS cells have also been generated from 
human cells (Yu et al., 2007). 
There are a great number of potential therapeutic applications using this technology e.g. 
the generation of organs for transplant which, as they would be derived from a patients 
own cells, would potentially be free from the ethical concerns of using embryonic stem cells 
and the risks of immune rejection currently associated with transplant surgery. Indeed one 
recent development was the generation of ‘Liver buds’ using iPS cells to form hepatocytes 
(Takebe et al., 2013).  However a number of concerns have been raised over the use of iPS 
cells, primarily the potential for tumour formation given the relatively undifferentiated 
state of the cells combined with a high proliferation capacity, and recent reports 
demonstrating immunogenicity of iPS cells (Zhao et al., 2011). There is a great amount of 
progress still to be made in the field of iPS cells however early results are promising and the 
potential therapeutic applications are many.  
1.12.3 Adult Stem Cell Plasticity 
One of the interesting potential benefits of isolating an ASC population within the 
endometrium centres on the concept of ‘Stem Cell Plasticity’. This property allows an ASC 
population to ‘transdifferentiate’, a process by which ASCs could contribute to cell types of 
different lineages (Wagers and Weissman, 2004). If this is possible then endometrial ASCs, 
easily obtained in the out-patient clinic and ethically safe, could represent a great source of 
autologous tissue for transplant. Endometrial ASCs could be extracted from a tissue sample, 
grown in vitro before differentiation into the population of choice e.g. dopaminergic 
neurons for to treat Parkinson’s disease and transplanted. 
 
This ‘plasticity’ has been investigated in many tissues including the endometrium (Taylor, 
2004) and it is thought that transdifferentiation could depend on the ASC niche (Blau et al., 
2001). Focus in this area of research has primarily been on the observation of 
transdifferentiation and little investigation has been made into the potential mechanisms 
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underlying this process. A number of alternate mechanisms need to be ruled out in order to 
accurately demonstrate this phenomenon (Figure 6) (Wagers and Weissman, 2004). 
A. ASC Transdifferentiation: Lineage conversion of the cells occurs. A dormant lineage 
differentiation program is activated to alter the lineage specificity of the cell 
(Wagers and Weissman, 2004).  
B. De-differentiation of an ASC occurs to a more primitive phenotype before re-
differentiation This is a phenomenon observed in animal models (Brockes and 
Kumar, 2002). 
C. A heterogeneous population of ASCs is present in the test population.  
D.  A rare pluripotent stem cell is present in the tissue 
E. Cell fusion is taking place. This process is associated with normal cell physiology e.g. 
in the formation of skeletal myofibroblasts (Anderson, 2000). 
Figure 6: Explanations for apparent ASC Transdifferentiation Observed Experimentally  
 
 
 
 
 
 
 
 
 
 
 
To date, many of the studies reporting ASC transdifferentiation within the endometrium 
have not satisfactorily ruled out these events. It is possible either that transdifferentiation 
within the endometrium is extremely rare, a finding consistent with findings from our 
laboratory in the University of Liverpool (Da Silva, 2012). Alternatively, progenitor cells 
within the endometrium could be unipotent; a property associated with the more 
terminally differentiated Transit Amplifying (TA) cells.  
 
 
 
 
Fig6. Explanations for apparent ACS transdifferentiation observed in culture. When documenting ASC 
transdifferentiation e.g. in endometrial cells it is essential to account for alternative events. A-E Described above 
(Wagers and Weissman, 2004). 
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1.12.4 Transit Amplifying Cells 
 
Transit Amplifying cells represent a temporary cell population more differentiated than 
ASCs but which still have a limited self renewal capacity both in vitro and in vivo (Seaberg 
and van der Kooy, 2003). These cells are unipotent and hormone responsive; it is unclear to 
what extent they are identified in assays of ASC function in the endometrium (Gargett, 
2008). In fact one theory is that TA cells and ASCs are in fact the same population of cells 
exhibiting a differing phenotype depending on the conditions of their niche (Quesenberry 
et al., 2005).   
 
1.13 Evidence for ASCs in the Endometrium 
The high regenerative capacity of the endometrium has long been a source of interest to 
clinicians and it has been thought for many years that a population of ASCs residing in this 
environment could account for the vast proliferation potential observed. The first 
publication recognising this possibility was Prianishnikov in 1978 who outlined a theory of 
ASCs within the endometrial epithelial population (Prianishnikov, 1978).  This paper 
suggests there are three populations of ACSs in the endometrium divided by their response 
to oestrogen and progesterone: 
 ASCs responsive to oestrogen  
 ASCs responsive to oestrogen and progesterone 
 ASCs responsive to progesterone only  
Prianishnikov thought that the growth of these ‘stem cells’ was regulated by oestrogen and 
progesterone acting on the cells directly. It is possible that ASCs themselves are hormone 
independent but that their nearest descendants (TA cells) become hormone dependent and 
it was suggested that the ASC and TA cells receptor status would be mediated in an 
oestrogen dependent manner (Prianishnikov, 1978).   
An initial population of TA cells responsive to oestrogen during the proliferative phase 
would then give rise to a daughter population with both oestrogen and progesterone 
receptors. These cells would then further differentiate to only become responsive to 
progesterone. In this way, the progesterone receptor could be seen as a late marker of 
differentiation of endometrial epithelial cells (Prianishnikov, 1978). This hypothesis was 
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backed up with the experimental finding that oestrogen will induce the synthesis of 
progesterone receptors in uterine tissue cells thereby making them susceptible to 
progesterone (Wiest WG, 1971). Prianishnikov described the characteristics of this putative 
progenitor population and his theory states that these cells would be found in the base of 
endometrial glands which lie within the basalis layer not shed during menstruation. This is 
consistent with studies of ASC distribution in the human gut (Barker et al., 2007) and would 
seem logical as the ASCs would need to regenerate the endometrium after each menstrual 
cycle (Prianishnikov, 1978). Functional kinetic studies of human endometrial growth also 
suggest a progenitor population may be found in basalis tissue (Ferenczy et al., 1979). 
Further genomic investigation of the endometrium suggested that this basal population 
may be sparsely distributed, as endometrial glands have been characterised as monoclonal 
for the deletion of the Phosphate and Tensin Homologue (PTEN) gene. This finding suggests 
that all cells within this gland and surrounding glands had descended from a common 
progenitor (Lacey et al., 2008) and is backed up by analysis of endometriosis lesions 
demonstrating a similar monoclonality, a finding which also implies a stem cell origin of this 
disease (Van Gorp et al., 2004). 
These studies seem to describe a sparsely distributed population of progenitor cells residing 
in the endometrial basalis responsible for cyclical proliferation; however this would be 
counter to the theory of induction of endometriosis by retrograde flow as only the 
functionalis is shed at menstruation. One potential explanation would be lesion induction 
by hormone responsive TA cells which may be located in the functionalis. Alternatively 
sections of the endometrial basalis may become dislodged inappropriately and implant in 
the abdominal cavity (Leyendecker et al., 2002). 
In an attempt to both understand endometrial physiology and pathogenesis of 
endometriosis the characterisation of this progenitor population has been the subject of 
intense investigation in the 35 years since Prianishnikovs’ initial publication. It is currently 
thought that the endometrium contains two ASC populations, a stromal progenitor and an 
epithelial progenitor (Gargett, 2008). 
1.14 Characterisation of Endometrial Progenitor Cells  
Several methods have been utilised with the aim of demonstrating the key characteristics 
of an ASC in an endometrial cell population, these are generally accepted to be: Self 
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renewal, Multi/Unipotency, Quiescence and high proliferative capacity (Snippert and 
Clevers, 2011). 
 Techniques used include: 
 Label Retaining Technique  
 Side Population method  
 Specific Marker Identification 
 In vivo xenotransplantation studies. 
The final method attempts to demonstrate the ‘Gold Standard’ for identifying a putative 
ASC population which is demonstration of in vivo re-constitution of the tissue from which 
the ASC population was isolated (Joseph and Morrison, 2005). The majority of this work has 
been performed using endometrial stromal cells. This is partly because it is thought that a 
relatively large population of ASCs will be found here (Holinka and Gurpide, 1987) but also 
due to the challenges posed by epithelial cell culture, particularly the need for 3D culture to 
more accurately reflect the in vivo environment. As a result work characterising the 
epithelial progenitor population is sparse. 
1.14.1 Label Retaining Technique  
The Label Retaining Technique (LRT) aims to identify Label Retaining Cells (LRCs) using the 
DNA binding dye Bromodeoxyuridine (BrdU) (Chan and Gargett, 2006). The cell nuclei are 
pulse labelled followed by a ‘chase’ period in which the tissue is analysed at varying time 
intervals.  Rapidly dividing cells will lose their ’Label’ as the BrdU is diluted to undetectable 
levels. The LRT is based on the feature of ‘quiescence’ exhibited by ASCs meaning they will 
retain their ‘Label’ for longer (Chan and Gargett, 2006). Stained tissues can then be 
analyzed using Immunohistochemistry (IHC) to identify putative ASC populations and their 
surrounding niche (Chan and Gargett, 2006). 
Using this technique, observations have been made in the endometrium regarding the 
proximity of stromal LRCs to the surrounding vasculature leading to the hypothesis that this 
environment may represent the endometrial ASC niche (Kaitu'u-Lino et al., 2012). Another 
hypothesis generated from the distribution of epithelial LRCs is that the epithelial glands 
may contain one ASC at the base which is responsible for regenerating the entire gland 
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(Ferenczy et al, 1979). This is backed up by work demonstrating the monoclonality of 
endometrial epithelial glands with the HUMARA assay showing clonality of adjacent glands 
up to 1mm in diameter (Tanaka et al., 2003). The HUMARA assay is a laboratory technique 
examining monoclonality of cells e.g. in a tumour by looking at X chromosome inactivation. 
If a group of cells are monoclonal they will all have the same X-chromosome inactivated 
and are likely to have a common parent cell; this assay specifically examines the Human 
Androgen Receptor (HUMARA) on the X chromosome (Tanaka et al., 2003). 
The LRT is a good method for identifying non-specific quiescent cells, a characteristic 
associated with ASC populations. Transit Amplifying calls are also of interest in the 
endometrium however and the LRT would not be suitable for detecting this population due 
to the rapid proliferation they exhibit (Gargett, Gargett, 2008). For this reason it would be 
sensible to also use alternative methods to investigate a progenitor population within the 
endometrium 
1.14.2 Side Population Method 
Side Population (SP) cells are a group of primitive cells thought to represent an ASC 
population characterised by the presence of ABCG2 transporter proteins which are not 
present in mature cells (Zhou et al., 2001). SP cells are identified by staining with Hoechst 
33342 dye which is rapidly extruded by the ABCG2 proteins these cells posess but not by 
the surrounding more differentiated cells. This method has been validated in mouse models 
to isolate a putative ASC population (Goodell et al., 1996) and the SP phenotype is 
considered synonymous with an ASC population (Challen and Little, 2006).The labelled cells 
can then be isolated e.g. using Fluorescence Activated Cell Sorting (FACS). 
Cells with the SP phenotype were first identified in human endometrium in 2007 and the 
population has been identified in both stromal and epithelial cultures in vitro (Kato et al., 
2007).  When isolated in culture these cells initially demonstrated limited proliferative 
capacity, being mostly in G0 phase of the cell cycle which indicates quiescence (Tsuji et al., 
2008). This finding of limited proliferation is contrary to what would be expected of a 
progenitor population. However, a greatly increased proliferative potential was observed 
when labelled endometrial SP cells were cultured unfractionated (i.e. all populations 
together) suggesting that the correct ‘niche’ may be essential to the proliferation of 
endometrial progenitor cells (Tsuji et al., 2008). 
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There are difficulties associated with studies relating to SP cells in the endometrium, some 
of which aim to demonstrate plasticity of the endometrial progenitor population using 
isolation of an SP population as a starting point (Miyazaki et al., 2012). The first difficulty 
comes from the strict requirements necessary to demonstrate the plasticity these studies 
sometimes claim to exhibit in endometrial SP cells. The second limitation comes from the 
2D culturing techniques used in the majority of studies.  2D culture represents a 
confounding factor as it is not always possible to distinguish between morphological 
changes known to be associated with culture (Kaur et al., 2004) and those arising as a result 
of SP plasticity. While these factors limit the ability of SP study to demonstrate ASC 
plasticity it can be said that an SP population with high proliferative potential can be 
isolated from the endometrium (Kato et al., 2007). More recent studies attempting to 
isolate endometrial SP cells suggest that they represent a mixed population of epithelial, 
endothelial and stromal cells (Masuda et al., 2010). 
1.14.3 Specific Marker Identification 
Specific markers have been identified for a population of endometrial stromal cells with 
high proliferative potential; the co-expression of CD146 and Platelet Derived Growth factor 
Beta (PDGF-B) (Schwab and Gargett, 2007) has identified a group of cells expressing 
signaling pathways associated with self renewal and multipotency (Spitzer et al., 2012). 
These cells are mainly found in the basalis and vessels of the functionalis (Schwab and 
Gargett, 2007).  A second candidate marker is W5C5 which was identified by screening 
endometrial tissue with perivascular markers (Masuda et al., 2012). W5C5+ cells have 
reconstructed stromal tissue in vivo when transplanted under the kidney capsule of severe 
combined immunodeficient  (SCID) NOD/Shi-scid/IL-2Rγnull (NSG) immunodeficient mice 
(Masuda et al., 2012). It is currently thought that CD146 and PDGF-B represent the same 
population of stromal cells (Gargett, 2007). 
Attempts have also been made to find a specific marker of an epithelial progenitor 
population. A recent study characterising the endometrial basalis using IHC identified cells 
expressing markers of proliferation including Sox9 and Nuclear β Catenin located, as with 
intestinal epithelium, as the base of epithelial glands (Valentijn et al., 2013). Cells with high 
proliferative potential as evidenced by higher capacity for spheroid formation in 3D 
matrigel culture were positive for the embryonic stem cell marker Stage Specific Embryonic 
Antigen 1 (SSEA1) which was proposed as a potential marker of a progenitor population 
43 
 
within the endometrial epithelium, these cells also having longer mean telomere lengths 
than SSEA1-ve cells (Valentijn et al., 2013). Work into the epithelial progenitor population is 
much scarcer than the stromal population and attempts to work with this population 
further may represent and interesting avenue for further research. 
 
1.14.4 In-vivo reconstitution Assay 
As previously mentioned, the Gold Standard for characterising an ASC population is 
demonstration of in vivo reconstitution of the tissue from which the cells were isolated 
(Joseph and Morrison, 2005). A series of studies using this assay on endometrial cells have 
been carried out by Masuda and co-workers (Masuda et al., 2010). The aim was to build on 
the previous work identifying the LRC and SP populations to demonstrate regeneration and 
multipotency of an endometrial progenitor population (Cervelló et al., 2007, Chan and 
Gargett, 2006, Kaitu'u-Lino et al., 2010, Szotek et al., 2007). As well as being the Gold 
Standard this model has the advantage that is permits the cells to be studied in a stable 
long term environment as well as allowing the investigation of differential expression of 
genes and proteins between the two species (Humans and Mice) through the use of specific 
antibodies and PCR primers (Masuda et al., 2010). 
In an initial study, the parameters of which were also used for subsequent experiments, SP 
cells (2% of total population) were identified in both stromal and epithelial fractions of 
human endometrium and isolated using FACS (Masuda et al., 2010). These isolated cells 
were then transplanted under the kidney capsule of NSG mice which were then treated 
with a 17-Bestradiol pellet for 8-10 weeks. The kidney capsule was chosen as it provides a 
rich vascular supply for the transplanted tissue whilst also containing it within a defined 
region (Xin et al., 2005). 
In this study cystic masses were observed in only a few (2/24) mice though staining for 
human specific markers identified positive cells in many of the animals with some evidence 
of this population beginning to invade the kidney, however a relatively low level of 
proliferation was observed and there was no evidence of glandular tissue formation.  
The experiment was repeated, this time isolating and labelling the SP cells and mixing them 
with main population cells before injection under the kidney capsule. This modification was 
introduced as it was thought that the main population might represent the ‘niche’ the SP 
44 
 
cells would need to proliferate and differentiate (Masuda et al., 2012). The results of this 
experiment showed a greatly increased proliferation potential of the introduced human 
cells demonstrated by the formation of large blood filled cystic masses beneath the kidney 
capsule of a greater number of experimental mice which exhibited hormone dependent 
changes breaking down in response to progesterone withdrawal in a manner similar to 
menstruation (Masuda et al., 2012). Characterisation of the cysts also detected the 
presence of human progesterone receptor which is an indication of an intact oestrogen 
pathway and mature endometrial cells (Jabbour et al., 2006). 
An interesting finding associated with this study is the detection of human derived vessels 
from the injected endometrial tissue invading the renal parenchyma of the mouse and 
forming a chimeric circulation as the result of neovascularisation (Masuda et al., 2012). As it 
is known that angiogenesis is necessary for endometriotic lesion establishment further 
characterisation was undertaken. 
Immunofluorescence demonstrated ABCG2+ve cells distributed in close proximity to 
endothelial ‘vessel like structures’ leading to the hypothesis that the epithelial and stromal 
progenitor population is likely to be perivascular and that in the case of the stromal cells 
this is backed up by previous work on co-localisation of PDGFR-β and CD146 and previous 
LRC studies (Schwab and Gargett, 2007, Masuda et al., 2012). 
This series of experiments has been useful in investigating the potential ASC population 
within the endometrium, generating the hypothesis that progenitor epithelial and stromal 
populations exits, with a perivascular niche, as well as an endothelial population. It is also 
possible that a progenitor population exists in the functionalis, though the action of TA cells 
needs to be considered studying this potential population. One limitation however of much 
of this work is the use of a mouse model.  
This is a good animal model to use as it shares several common characteristics with 
humans, however there are also important limitations to this system. For example mouse 
endometrium undergoes apoptosis and regeneration instead of menstruation and 
therefore will not spontaneously develop endometriosis (Lipschutz et al., 1999). Another 
aspect to consider is the immune compromised nature of these mice which means that 
several elements of the immune response and inflammatory processes, thought to be 
crucial to the pathogenesis of endometriosis, cannot be investigated as the ectopic 
environment does not exhibit an immune response (Awwad et al., 1999). Furthermore, a 
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recent publication regarding the differences in inflammatory response and sepsis in 
humans and mice indicates that the two species are also not comparable in this respect 
(Seok et al., 2013). 
1.15 The Future of Stem Cells in the Endometrium 
Progress has been made in isolating the putative ASC population in the endometrium, 
particularly within the stromal compartment. Assays used have demonstrated some of the 
features of ASCs and some specific markers have been identified though it is possible that 
these represent more differentiated TA cells with a third possibility being that ASCs and TA 
cells represent the same population with a different phenotype dependent on the niche 
(Quesenberry et al., 2005). Further work will be needed in the future to characterise and 
isolate this elusive population though it is important to consider the niche when conducting 
these experiments.  However it can be said with a degree of certainty that a population of 
ASC/progenitor cells has been demonstrated within the endometrium and that the 
proliferative potential exhibited by this organ can be attributed to their action.  
1.16 Disease Models of Endometriosis 
As an enigmatic, proliferative disease, endometriosis has been the subject of active 
investigation for several years. This has led to the establishment of ‘disease models’, two 
categories of which are in vitro and animal models. These models are useful in modeling the 
disease and also share some overlap with the study of an endometrial progenitor 
population. Whilst these models have provided some useful insights into the disease there 
are also associated limitations which constrain the interpretation of the findings. 
1.16.1 In vitro Models 
The in vitro study of endometriosis has several advantages as the methods used are cheap 
and easily reproducible. A variety of strategies have been previously employed including: 
Chick Chorioallantotic Membrane (CAM), Peritoneal Explants, Amniotic Membrane Model 
(AMM) and Peritoneal Mesothelial Cell (PMC) monolayer. These methods attempt to model 
the interactions between endometrial cells and the peritoneum in humans in order to study 
the processes of attachment and invasion in endometriotic lesion establishment. 
The use of CAM in endometriosis research has allowed investigators to monitor processes 
essential to lesion establishment e.g. Angiogenesis (Maas et al., 2001) and invasion of cells, 
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however this particular technique is limited in that it does not allow the study of specific 
marker expression (Griffith et al., 2010). Other methods can be used to compensate for this 
and the AMM is one example. The AMM allows the modelling of invasion of endometrial 
cells onto a strip of de-epithelialised amniotic membrane which can then be analysed by 
immunocytochemistry for marker expression (Liotta et al., 1980). One limitation to this 
technique is that endometrial cancer cell lines have been used to model the invasion 
process which do not represent normal physiology (LaRocca and Rheinwald, 1984).  
As human endometriosis is the condition under study, explant models using human tissue 
have been developed. The culture of endometrial cells on a PMC monolayer has produced 
some useful observations, notably that an intact peritoneum is protective against 
attachment of endometrial cells and consequently endometriotic lesion establishment 
(Groothuis et al., 1999). The attachment of both endometrial epithelial and stromal cells to 
PMCs in monolayer has also been modeled and found to be a rapid process occurring 
within 1 hour with invasion occurring by 24 hours, providing an insight into lesion 
establishment (Witz et al., 2001). 
The use of 2D culture methods however is problematic due to morphological changes 
previously identified, an issue particularly pertinent for epithelial cells. This limitation is 
being overcome however with the use of 3D culture in some developing models (Valentijn 
et al., 2013). This is achieved by culturing cells in Matrigel, a widely used basement 
membrane matrix derived from mouse sarcoma (Kleinman et al., 1986) and studies using 
this method have demonstrated that endometriotic lesion cells are as ‘invasive’ as 
endometrial cancer cells (Zeitvogel et al., 2001).  
1.16.2 Animal Models 
A different experimental approach to models of endometriosis is exemplified by animal 
models, using techniques which attempt to observe aspects of the disease pathogenesis in 
the in vivo setting. Several different animals have been used with the two most important 
being baboons and mice. 
Baboons represent a good model for studying endometriosis as only humans and non-
human primates spontaneously develop the disease (Story and Kennedy, 2004)  This is 
logical if Sampson’s theory is considered as only animals that shed their endometrium have 
the capacity for retrograde menstruation (Lipschutz, 1999). To study the disease in 
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baboons, lesions have been experimentally induced either by creating a uterine outflow 
obstruction or by inserting endometrial tissue laparoscopically (D'Hooghe et al., 1999). 
These studies have demonstrated the importance of immune interactions when studying 
lesion establishment as well as the role of peritoneal inflammation (D'Hooghe et al., 2001). 
However they are limited by the physiological differences between humans and non human 
primates (Legrand et al., 2009) as well as ethical considerations. 
 
A large amount of work has been carried out on mouse models of endometriosis. These 
have the advantage of being relatively cheap to perform with fewer ethical considerations 
and are divided into homologous and heterologous models. Homologous murine models 
involve the transplant of endometrial tissue from syngeneic animals into an 
immunocompetent host allowing the study of lesion development (Cummings and Metcalf, 
1995). The animal’s hormonal exposure is controlled by ovariectomy at the beginning of the 
experiment followed by exogenous oestrogen treatment (Tirado-González et al., 2010).  
 
Heterologous murine models involve the transplant of human endometrial tissue into 
immunocompromised e.g. SCID mice. This allows the study of human tissue in an ectopic 
environment and several variations of the model have been developed (Story and Kennedy, 
2004, Zamah et al., 1984, Nisolle et al., 2000). A notable example is the work described by 
Masuda et al, studying the proliferative potential of human endometrial cells transplanted 
under the kidney capsule of NSG mice (Masuda et al., 2007). There are advantages and 
disadvantages to this model previously described however it has been a key focus in the 
development of the field of endometrial research due to its relative inexpensiveness and 
the desire of investigators to use in vivo models. 
 
It is clear that to be physiologically accurate ex vivo models of endometriosis need to 
comprise human endometrium derived from patients, rather than cell lines. Furthermore, a 
model system should permit the analysis of specific marker expression and of immune 
interactions with the ectopic environment. In addition, models should be relatively cheap, 
reproducible and free from ethical concerns. The current literature does not provide a 
completely satisfactory model for the disease and there is scope for further development. 
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1.17 The Kidney 
Following the work done by Masuda et al transplanting endometrial cells into live SCID 
mice, the potential to investigate the epithelial population of progenitor cells was 
considered using a similar concept for the present study. Investigating the behaviour of 
these cells in a different niche would be of interest to see if a progenitor population could 
exhibit the ASC characteristics of proliferation and differentiation. The mouse kidney would 
be considered a suitable environment as the kidney and endometrium share a common 
embryological origin and an explant model would be developed using tissue from culled 
mice in accordance with the principles of the 3 Rs. Developing a kidney explant model 
would also provide the opportunity to investigate aspects of glomerular maturation.  
1.17.1 Embryology of the Mammalian Kidney 
Both the kidney and the endometrium are embryologically derived from a cell population 
termed the intermediate mesoderm. While development of the mammalian kidney 
represents a complex set of processes it can be broadly divided into 3 stages:  
 Pronephros  
 Mesonephros  
 Metanephros 
These structures are similar in all mammals; however, some details specific to mice are 
included in this report. In mice, the pronephric tubules arise from the pronephric duct at 8 
days of gestation. These tubules are transient structures and the rostral component of the 
structure they comprise soon degenerates to form the ‘Wolffian duct’ (Saxen, 1987). As this 
degeneration occurs a new set of tubules are induced in the adjacent mesenchyme forming 
a structure known as the mesonephros. The Mesonephros does not represent a functioning 
kidney structure and also regresses via apoptosis. However it does have 2 functions:  
 To act as a source of haematopoietic stem cells 
 To persist in males to form the epididymis and vas deferens (Wintour et al., 1996) 
The final structure in the kidney development of mammals is the metanephros, which is 
formed through a series of interactions referred to as ‘reciprocal induction’ between the 
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mesenchymal and epithelial cell populations of the developing kidney, the metanephric 
mesenchyme (MM) and the Ureteric Bud (UB) (Gilbert, 2010).  
1.17.2 Reciprocal Induction 
The MM acts upon the UB structures, causing them to branch, and the UBs induce the MM 
to undergo MET so that they form condensed aggregates adjacent to the UBs. These 
aggregates will eventually form glomeruli and progress through a series of well-described 
developmental structures: 
 Comma Shaped Body  
 S-Shaped Body 
 Capillary Loop 
 Mature Glomerulus 
It during the capillary loop structure that the epithelial cells of the MM differentiate into 
the mature cell types found in the nephron (Grobstein, 1955). The first glomeruli with 
capillary loops can be detected at day 14 of gestation in rodents and will continue to form 
until one week postnatally (Gilbert, 2010). The nascent nephrons fuse with branching UB 
structures, which upon maturation, give rise to the mature collecting ducts and calyces, 
thus forming a continuous path for the renal filtrate. This process of nephron formation has 
been documented in vitro and it has been observed that when the UB and MM are 
separated and cultured in isolation there is no branching or differentiation of either cell 
population; each requires signals and interactions with the other to form the mature 
nephron (Grobstein, 1955). 
1.17.3 Vasculogenesis in the Developing Kidney 
It is clear that ‘reciprocal induction’ represents an immensely complicated set of biological 
processes, the cellular mechanisms of which have been the subject of recent study. One 
area of particular interest is the origin and development of endothelial cells and capillaries. 
This population has only become the subject of active 
research in recent years, this may be due to the discovery 
of the potential role it plays in the formation of the 
Figure 7: Dual Secretion of 
GBM Components 
Fig7. Glomerular Basement Membrane 
components are formed from both 
Podocyte and Endothelial Cell 
populations (Abrahamson, 2009). 
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glomerular basement membrane (GBM) (Abrahamson, 2009). 
The ‘Comma’ and ‘S-Shaped’ bodies described during nephron formation have their 
characteristic appearance due to the formation of a space into which primitive endothelial 
cells (angioblasts) migrate in order to for the glomerular capillaries, known as the ‘vascular 
cleft’ (Abrahamson, 2009). These angioblasts differentiate into endothelial cells and 
assemble a thin layer of basement membrane matrix around themselves (Figure 7) which 
separates them from the podocytes of the Bowman’s capsule which also deposit a layer of  
a matrix (Figure 7)  (Abrahamson, 2009).  
This dual secretion means that the early GBM is a layered structure which then fuses to 
form one membrane, an idea backed up by studies demonstrating that podocytes and 
endothelial cells both actively secrete extra cellular matrix proteins during GBM 
development (Abrahamson, 1987, Lelongt et al., 1987, Reeves et al., 1980, Abrahamson, 
1985, Kanwar et al., 1984).  
1.17.4 Maturation Processes of Podocytes are not fully Understood  
Progress has been made in elucidating the mechanisms that regulate the early stages of 
podocyte development through the use of embryo explant models (Pavenstädt et al., 
2003). While these studies have provided useful insights they cannot provide information 
regarding the later stages of podocyte maturation as the endothelial population dies and as 
such, a complete GBM cannot be formed (Loughna et al., 1998). Podocytes rely on 
interactions with the GBM to achieve the later stages of maturation (Abrahamson, 2009) an 
idea further backed up by studying the ‘capillary loop’ stage of development. It is at this 
point that many processes associated with vasculogenesis occur and it is also the stage 
when podocytes begin to form structures associated with a mature morphology e.g. foot 
processes (Abrahamson, 2009). It is possible that an explant culture in which endothelial 
cells were able to survive could be used to study these later stages of podocyte maturation.  
1.17.5 Neonatal Mouse Kidneys 
Previous studies have indicated that under appropriate conditions, endothelial cells derived 
from adult mouse kidneys can survive in culture (Loughna et al., 1998); however, this tissue 
cannot be used to study nephrogenesis as it does not contain any MM or UB cells. It is not 
clear why endothelial cells within embryonic mouse kidneys undergo rapid cell death 
following explantation, whereas endothelial cells from adult kidneys can survive, but this 
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could possibly be due that the fact that the adult cells are more mature, and/or may have a 
different origin. The neonatal kidney provides a potential solution as it is more mature than 
the embryo kidney, and it is thus possible that the endothelial cells present within the 
neonatal tissue might have different properties than those of the embryo kidney that might 
enable them to survive in culture. An advantage of the neonatal kidney tissue over adult 
tissue is that the former is still undergoing nephrogenesis, and therefore contains MM and 
UB cell populations (Dickinson et al., 2005). The fate of endothelial cells in neonataI mouse 
kidney explant culture has not been previously investigated and will provide an interesting 
study as renal vasculogenesis was previously not though to occur ex-vivo (Bernstein et al., 
1981). 
1.17.6 Generating an Explant Model of Nephrogenesis Using Neonatal Mouse Kidneys  
An ideal method for establishing an explant culture using Neonatal Mouse Kidneys is the 
disaggregation-reaggregation technique first published by Unbekandt and Davies 2010. This 
method has the advantage of simultaneously providing the opportunity to study the activity 
of endometrial epithelial cells when introduced to kidney explant culture as any cell 
population can be introduced into the culture after the disaggregation step to produce a 
chimeric explant (Unbekandt and Davies, 2010). Chimeras have previously been generated 
by a student in The University of Liverpool using endometrial cells and embryonic mouse 
kidneys confirming the technique is feasible (Simic, 2010).  
1.17.7 Disaggregation and Reaggregation of Mouse Kidneys 
In the Unbekandt and Davies study, E11.5 mouse kidneys were disaggregated, and then 
reaggregated in the presence of an exogenous cell type in order to produce fine grained 
chimeras where the fate of the exogenous cells could be investigated (Figure 8). The 
method also allows the investigation of siRNA-mediated knockdown of specific target genes 
in the introduced cells. One key innovation contributing to the success of the method was 
the use of a Rho-Kinase (Uehata et al., 1997) inhibitor for 24 hours at the start of culture, 
which reduced the degree of cell apoptosis previously observed within such ‘fine grained 
chimeras’ thought to be attributable to loss of tissue derived cell signalling (Coles et al., 
1993), or anoikis resulting from the removal of the nascent epithelial cells from their 
basement membranes. The inhibitor is removed after 24 hours of culture because ROCK is 
known to be essential for nephron formation and by this point the cell-cell signalling 
associated with growth is sufficient to prevent apoptosis (Unbekandt and Davies, 2010).  
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Using this system the authors were able to culture fine grained chimeras demonstrating 
structures associated with normal renal development e.g. comma shaped bodies  
(Unbekandt and Davies, 2010).This method differs from that described by Auerbach and 
Grobstein as no ‘whole’ exogenous tissues are introduced to the kidney structure which 
would have the limiting factor of incomplete integration and perfusion of the cells of 
interest (Auerbach and Grobstein, 1958). 
Figure 8: Disaggregation and Reaggregation of Neonatal Kidneys Allows Formation of 
Chimeras and Neonatal Explants  
1.18 Specific Markers of Nephron Development and Endometrial Cells 
In order to assess the development of potential nephron structures including endothelial 
cell populations within the mouse neonatal kidney explant cultures and to track the survival 
and proliferation of the human endometrial cells within the chimeras, specific markers 
were selected for analysis. 
1.18.1 Kidney Explant Culture 
1.18.2 Wilms Tumour Protein (Wt1) 
Wt1 is a transcription factor well characterised in the mammalian kidney and first 
investigated due to its association with nephroblastoma, also known as Wilms Tumour 
(Armstrong et al., 1993). Other than a low degree of expression in the spinal cord, Wt1 is 
expressed in mesodermally derived tissues and is thought to play some role in 
mesenchymal to epithelial transition (MET). In the mouse, it is first expressed in the MM 
Fig8. Disaggregation-Reaggregation protocol developed by Unbekandt and Davies allows generation of fine grained chimeras 
in order to study developmental processes and the specific action of an introduced cell population of interest (Unbekandt 
2012) For the present study the population of interest will consist of endometrial epithelial cells (Purple). Image reproduced 
from (Unbekandt 2012). 
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(Armstrong et al., 1993). Expression then increases as the MM condenses and forms the 
epithelial cells of the nephron (Armstrong et al., 1993). Correspondingly, studies of mouse 
kidney development have found little expression at the mesonephros stage but strong 
expression in the metanephros, with Wt1 being confined to the presumptive podocytes by 
the s-shaped body stage (Armstrong et al., 1993). For this reason Wt1 will be used in this 
study to identify developing kidney structures in explant culture. 
1.18.3 Synaptopodin  
Synaptopodin is an actin-associated protein found to be expressed in neural dendrites and 
renal podocytes (Mundel et al., 1997). Development of synaptopodin expression occurs as 
the capillary loop stage and is associated with loss of mitotic activity meaning that it can be 
taken as a marker of more mature podocytes (Burrow, 2000).  For this reason analysis and 
identification of mature podocytes in this study will be performed using this marker. 
1.18.4 Laminin 
Laminin is a matrix protein which can be found in the glomerular basement membrane and 
has been demonstrated to be important for glomerular maturation. While this protein is 
found in many tissues the characteristic staining in association with podocytes makes it a 
useful tool in identifying putative glomerular structures in the culture (Kikkawa et al., 2003). 
1.18.5 Platelet Endothelial Cell Adhesion Molecule 1 (Pecam) 
Pecam is a cell surface molecule which can be reliably used to identify endothelial cells  
(Baldwin et al., 1994). It is also present on reticuloendothelial cells, platelets, monocytes, 
neutrophils (GeneID, Accessed 2013) and in Kaposi’s Sarcoma (Ganjei-Azar P, 2006). These 
characteristics make PECAM a useful marker in identifying endothelial structures as a 
characteristic pattern of expression will be observed. 
1.18.6 Calbindin 
Calbindin28k is a calcium binding protein used to identify ureteric bud structures in analysis 
of chimeric mouse embryo kidney explants (Michos, Michos, 2012). Previous studies have 
shown that it can be identified in tissues before nephrogenesis has begun (Davies, 1994), 
that expression does not decrease with branching of the UB and that it can be used to 
identify collecting duct structures of mature nephrons (Davies, 1994). This makes Calbindin 
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an ideal structure for UB tubulogenesis in the kidney explant culture and in aiding the 
identification of mature nephron structures.   
1.19 Chimera Culture 
1.19.1 Mucin1 
Mucin 1 (MUC1) is a glycoprotein first proposed as a window of implantation marker in the 
endometrium, possibly playing a role in the first stage of embryo implantation (Aplin et al., 
1998). MUC1 has been identified on the luminal epithelium with constant expression 
increasing in the secretory phase (Aplin et al., 1998).  
The expression of MUC1 appears to vary in the endometrium as multiple splice variants 
give the molecule different functions depending on the location, a fact evidenced by the 
loss of MUC1 from uterine pinopodes in the mid-secretory phase (Horne et al., 2005). For 
this reason MUC1 cannot be a specific marker for a particular process within the human 
endometrial cells but can be used as a quantitative measure to assess their presence. If a 
specific process were to be identified the products from PCR analysis would need to be 
sequenced in order to identify the splice variant. 
1.19.2 Progesterone Receptor 
Progesterone receptor A and B arise from the same gene and expression is dependent on 
the cellular compartment of the endometrium with a general increase towards the 
secretory cells as oestrogen primes the endometrial cells (Isaac et al., 2001). Progesterone 
acts to prevent further growth of epithelial cells and stimulates decidualization.  There is a 
documented drop in expression in epithelial glands of functionalis in the period of 
transition between proliferative and secretory phases. This contrasts with persistent 
expression in the stroma (Beier-Hellwig et al., 1994, Roberts et al., 1989). The pattern of 
expression in the basalis is different as and progesterone receptor is more persistently 
documented throughout the cycle in the glands and stroma of this area (Beier-Hellwig et 
al., 1994). 
1.19.3 Human Specific Antibody 
In order to locate the human endometrial cells within the chimera a human specific 
antibody will be used. Several potential antibodies are available including: anti-
55 
 
Mitochondrial, anti-Cytoplasmic and anti-Nuclear, and determining which will be the most 
useful will form the basis of a pilot study. 
 
1.19.4 Laminin 
Laminin will be used in the chimeras to assess the proliferation of the human endometrial 
cells by their ability to form glandular structures within the culture.  Glandular structures 
are surrounded by a laminin rich membrane and although the antibody used is not human 
specific a measure of glandular structure formation may be obtained. As polarised 
glandular cells typically are aligned along a basement membrane, co-staining for Laminin 
and a human specific antibody will allow investigators to assess the ability of endometrial 
cells to form glandular structures in the chimera (Abrahamson, 2009).  
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1.20 Aims and Objectives of the Study 
1.20.1 Aims 
Research into the endometrium and endometriosis is still in its early stages. Though the 
endometrium has long been a source of fascination to clinicians it is only in recent years 
that attempts have been made to deconstruct its workings through scientific investigation. 
Endometriosis represents a pathological endometrial condition where the high proliferative 
potential characteristic of the endometrium is observed. The aspects of this study focussing 
on the endometrium aim to increase understanding of these processes either in the 
laboratory setting or through in silico investigation. In the laboratory investigation it is 
hoped that characteristics of an ASC i.e. proliferation and multipotency may be observed in 
a kidney chimera model. For the bioinformatics investigation it is hoped that some of the 
cellular and molecular mechanisms governing processes in normal endometrium and 
patients with endometriosis may be elucidated via analysis of transcriptomic datasets.  
A separate section of this study will investigate renal events in the neonatal kidney explant 
culture. It is hoped that an explant culture can be established in which the endothelial cell 
population is viable such that late maturation processes of podocytes and other nephron 
structure may be investigated further. This is an area in which progress would be useful as 
the podocyte represents the functional unit of the glomerulus and renal pathologies often 
affect this cell; understanding normal physiology may help to investigate and improve 
management of pathological conditions. 
1.20.2 Objectives 
Endometrial-Kidney Chimera 
 To establish methods of effectively tracking a population of human endometrial 
cells when cultured in a chimeric model with neonatal mouse kidneys. 
 
 To investigate possible phenotypic changes within a population of human 
endometrial cells when cultured in a chimeric model with neonatal mouse kidney 
cells using immunofluorescence and RT-qPCR. Specific assessment will be made of:  
o The endometrial cells’ ability to survive and proliferate in culture.  
o The endometrial cells' ability to form glandular structures in culture 
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 To investigate possible phenotypic changes within a population of neonatal mouse 
kidney cells when cultured in a chimeric model with Human Endometrial cells using 
Immunofluorescence and RT-qPCR. 
Kidney Explant Model 
 To establish a neonatal kidney explant model using either partial or complete 
disaggregation of neonatal mouse kidney tissue. 
 
 To investigate the ability of this neonatal explant model to form nephron structures 
in culture using Immunofluorescence and RT-qPCR for renal markers: WT1, Laminin 
and Calbindin 
 
 To investigate the ability of this neonatal explant model to form mature podocytes 
and endothelial structures using Immunofluorescence and RT-qPCR for renal 
markers WT1, PECAM, Synaptopodin, Alkaline Phosphatase and Calbindin. 
Bioinformatics 
 To use published transcriptomic datasets to identify differentially regulated genes 
within the ‘Normal’ endometrium at different phases of the menstrual cycle. 
 
 To analyse these differentially regulated genes using a ‘Systems Biology’ approach 
with a view to identifying molecular networks of interest and enabling further 
research. 
 
 To compare data obtained from the ‘Normal’ endometrium with that obtained 
from patients with endometriosis with a view to identifying potential biomarkers 
and drug targets. 
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Chapter 2: Materials and Methods 
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2.1 Sample Collection and Processing 
2.1.1 Sample Collection 
Patient operating lists were routinely consulted at the Liverpool Womens Hospital and 
suitable patients for inclusion in ongoing research trials identified. Patients were 
approached and fully informed voluntary consent was obtained to collect an endometrial 
sample.  Information provided by researchers included benefits and risks of taking part in 
the study including the fact that patients could choose to withdraw at any time without this 
affecting their standard of care. Examples of Consent forms and Patient Information 
provided are included in the appendix. 
Samples were obtained under the study: “The role of the identified regulators of cell fate 
(RCF) and metastasis-inducing-proteins (MIP) in endometrial stem/progenitor cells (SPC) in 
endometriosis” LREC Ethics Reference Number: 09/H1005/55. 
All Patients:  
 Two blood samples obtained before induction of anaesthesia: one Full Blood 
sample and one Serum samples 
Patients Undergoing Surgery for Benign Indications:  
 Full thickness endometrial biopsy obtained using a sterile scalpel and forceps after 
making a midline incision at the anterior aspect of the uterus.  
Once samples were obtained they were divided into several collection tubes depending on 
their future use: 
 Neutral Buffered Formalin (NBF)  (Sigma Aldrich) 
 Phosphate Buffered Saline (PBS) (Sigma Aldrich) 
 RNALater (Applied Biosystems) 
 ‘Sample Collection Medium’ (Endometrial Scraping)   
The composition of ‘Sample Collection Medium’ may be found in the Appendix Section 6.7. 
2.1.2 Sample Processing 
All sample processing was conducted in a class II cell culture hood, all waste coming into 
contact with human tissue was sterilised with 1% Virkon (Antec). Identifying information 
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was removed from samples to preserve patient anonymity and a unique laboratory sample 
number and code was assigned to each sample depending on the patient details. 
Sample Categories 
 SPCE – Endometriosis of any stage with no ‘SPCEX’ indicators applying 
 SPCN – No documented Endometriosis or any of the ‘SPCEX’ indicators applying 
 SPCEX – Hormone therapy, Nulliparous, Previous endometrial ablation, Previous 
Dilatation and Curettage. Patient may or may not have Endometriosis. 
 EP- Post-menopausal patients. 
This code is followed by a number depending on when the patient was recruited to create a 
unique sample ID e.g. ‘SPCE 112’ 
Collection medium, Hanks solution and RNA Later samples were labeled with sample code 
and placed in the fridge in ‘Tissue Culture’ laboratory to be used for ongoing studies in the 
University of Liverpool. NBF samples were labeled, dated and placed in the fridge in the 
Histology laboratory. 
Whole blood samples were separated into two 2ml cryotubes and stored in the appropriate 
box space in the -80ᵒC freezer depending on the sample code after which the storage 
location was entered into a labeled box plan in the freezer log. ‘Serum’ blood samples were 
obtained by centrifugation at 3000rpm for 10 minutes and pipetted into two micro test 
tubes and stored at -80ᵒC, PBS samples were snap frozen and stored at -80ᵒC. Examples of 
paperwork required to be completed for sample processing are included in the appendix. 
Relevant patient demographic details were also recorded for samples used in the study. 
Information included: Sample ID, Sample Type, Patient Age, Patient BMI, Indication for 
surgery, Presence or absence of endometriosis, Menstrual Cycle Phase as well as any 
additional information e.g. Hormonal Contraception. 
2.2 Primary Culture of Endometrial Cells 
Once an endometrial scraping was obtained and stored in collection media, primary culture 
was employed to cultivate a population of endometrial epithelial cells which could then be 
placed in the chimera. Endometrial tissue was removed from ‘Sample Collection Medium’ 
and transferred to a 10cm culture dish where it was finely dissected using 2 sterile scalpel 
blades (Swann Morton) to increase surface area for enzymatic digestion until 1 mm3 pieces 
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were achieved. The sample was then transferred to a 30ml universal tube with Dulbecco’s 
Modified Eagle Medium (DMEM), washing the culture dish with DMEM ensure the entire 
sample was transferred. To collect the cells the sample was placed in a centrifuge (Sigma 
Aldrich 4K15) at 500 Relative Centrifugal Force (g) for 5 minutes. The supernatant was 
removed and the cells re-suspended in 4ml DMEM. 
To achieve a single cell suspension enzymes and co-factors were added for an initial 
digestion: 
 Collagenase (20 mg/ml, 500μl) (Sigma Aldrich) 
 Dispase (10 mg/ml, 500μl) (Roche) 
 DNase (4 mg/ml, 100μl) (Invitrogen) 
 MgCl2 (50μl 100mM) 
The cells were transferred to a shaking water bath at 37ᵒC for 1.5 hours. 
2.2.1 Crude Fractionation of Epithelial and Stroma Cell Populations 
After initial incubation the resulting digest was filtered through a 40 μm cell strainer into a 
50ml test tube. The flow-through was washed with DMEM and represented the stromal 
population. The retentate represented the epithelial population and was transferred to a 
second 50ml test tube by backwashing with 30-40ml DMEM. Gentle pipetting was used to 
dislodge adherent cells. 
Epithelial Fraction Culture 
The Epithelial Fraction (EF) was centrifuged at 500g for 5 minutes to collect the cells after 
which the supernatant was discarded and the EF re-suspended in 1ml DMEM with further 
enzyme added to digest the intact epithelial glands: 
 Trypsin (1ml 0.25%) (Sigma Aldrich) 
 DNase (4mg/ml, 100μl)  
The EF was then incubated at 37ᵒC for 20 minutes in the shaking water bath. After this final 
digestion the EF was gently pipetted for 3 to 5 minutes in order to liberate single cells after 
which the Trypsin was inactivated with 1 ml DMEM. To remove the Trypsin the EF was then 
centrifuged at 500g for 5 minutes to pellet cells with the supernatant being discarded. The 
EF was then re-suspended in 10ml ‘Endometrial Culturing Medium’ and plated onto a 10 cm 
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culture dish. The composition of ‘Endometrial Culturing Medium’ is included in the 
Appendix Section 6.7. 
Stromal Fraction Culture 
The stromal fraction did not require further enzymatic digestion and subsequently could be 
centrifuged to discard the Trypsin containing medium and re-suspended in ‘Endometrial 
Culturing Medium’ before plating onto a 10cm culturing dish. 
Selective Adherence 
The stromal population would adhere preferentially to the 10cm culturing dish over the 
epithelial population so after 15-20 minutes the fraction was re-plated to increase isolation 
of the two individual populations. 
2.2.2 Vybrant Labeling of Human Endometrial Cells  
In order to identify the human endometrial cells after incorporation into the neonatal 
mouse kidney chimera they were first labeled using the ‘Vybrant CFDA SE Cell Tracer Kit’  
(Invitrogen) which consisted of Carboxy fluorescein diacetate, succinimidyl ester (CFDA SE) 
and Dimethylsulfoxide (DMSO). This kit marked the cells with green fluorescence, allowing 
investigators to validate the human specific antibodies used in the study. The protocol was 
followed according to the manufacturer’s instructions. 
The CFDA SE was allowed to warm to room temperature after which a 10mM stock solution 
was prepared by adding 90ul of DMSO to one vial of 500μg CFDA SE. This solution was then 
diluted with Phosphate Buffered Saline (PBS) (Sigma Aldrich) to give a final concentration of 
20μM CFDA SE. 
Labeling Human Epithelial Cells 
To label the human cells with Vybrant, the ‘Endometrial Culture Medium’ was removed 
from the a 10cm culture dish containing adherent cells and replaced with 6ml of a 20μM 
CFDA SE solution pre-warmed to room temperature. The dishes were then returned to the 
incubator for 15 minutes at 37ᵒC after which the CFDA SE solution was removed and 
replaced with pre-warmed Endometrial Culture Medium’ and incubated for a further 30 
minutes at 37ᵒC. During this time the CFDA SE underwent acetate hydrolysis after which the 
fluorescent signal could be observed within the cells.  
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2.2.3 Trypsinisation of Human Endometrial Cells 
In order to introduce the human endometrial cells into the chimera they first needed to be 
removed from the culture dishes to which they adhered. To achieve this, the cells were 
washed twice with 10ml pre-warmed PBS before 10ml 1× Trypsin was added. The plate was 
then incubated for 10 minutes at 37°C during which time the cells detached from the dish. 
After incubation the Trypsin was inactivated using 10ml DMEM with 10% Fetal Bovine 
Serum (FBS) and the cells in suspension were transferred to a 15ml conical tube. 
A ratio of 1 in 5 human to mouse cells was used for the study. In order to calculate the 
volume of human endometrial cell suspension to introduce to the chimera the live cells 
were counted using an automated cell counter (Biorad) and Trypan Blue (Sigma Aldrich).To 
count the live cells 10μl of cell suspension was transferred to a cell counting plate and 10μl 
Trypan Blue added. The two solutions were mixed and 10μl transferred to a 
haemocytometer which was placed in an automated cell counter. 
2.3 Disaggregation of Neonatal Mouse Kidneys 
Neonatal Mice (2-3 day’s old) were sacrificed according to Schedule 1 Home Office 
Protocol, CD1 and C57BL/6 ‘Black6’ mice were used for the study. The kidneys from the 
neonatal mice were isolated using a dissecting plate, forceps, surgical scissors and stored 
on ice in Minimum Essential Medium Eagle (MEME) (Sigma Aldrich) in a 1.5ml microfuge 
tube. The kidneys were transferred to a cell culture hood and dissected in a 10cm culture 
dish until 1mm3 sections were achieved. The sections were transferred to a 20ml test tube 
and the culture dish washed thoroughly with MEME to ensure all kidney sections were 
transferred. 
The kidney sections were allowed to settle at the bottom of the test tube and the medium 
removed and replaced with 20ml Ca2+ free PBS (Sigma Aldrich). 
 Trypsin Protocol 
After 1 minute the PBS was removed and the tissue re-suspended in 3ml 1×Trypsin solution 
with 20μl DNase (5mg/ml) and placed in a water bath for 20 minutes at 37°C. After 
incubation the sample was gently pipetted for 1 minute to aid disaggregation and 
incubated for a further 5 minutes at 37ᵒC after which 10ml DMEM with 10% FBS was added 
to inactivate the Trypsin. 
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 Collagenase Protocol 
After 1 minute the PBS was removed and the tissue re-suspended in 2ml Collagenase  
(Sigma Aldrich) (2mg/ml) with 20μl DNase (5mg/ml) and incubated for 45 minutes at 37°C. 
After incubation 10ml DMEM with 10% FBS was added to inactivate the collagenase. 
After this initial digestion the tissue was centrifuged for 3 minutes at 1000g, the medium 
discarded and DMEM with 10% FBS used to wash the tissue. The tissue was centrifuged 
again for 3 minutes at 1000g and re-suspended in 6ml Kidney Culture Medium (KCM), the 
composition of which can be found in the Appendix Section 6.7. The live kidney cells in 
suspension were at this point counted using a cell counter with Trypan Blue. Based on the 
results appropriate calculations were made to ensure a ratio of 1 in 5 endometrial to kidney 
cells. The final volume was dependent upon the mass of kidney tissue obtained at the start 
of the experiment and the volume of medium used during the protocol.  
2.4 Re-aggregation of Human Endometrial and Mouse Kidney Cells 
The ratio of Human to Mouse cells used in this study was 1 in 5 and as the size of the cell 
pellets produced was 1.5x106 this meant 1.2x106 kidney cells would be transferred to a 
number of microfuge tubes to be mixed with 0.3x106 human cells. The number of pellets 
able to be generated from each experiment was dependent on the number of neonatal 
mice available. 
For each experiment, two conditions were generated.  
1. Pellets with human and mouse cells termed Endometrial/Kidney (E/K) 
2. Pellets containing only kidney cells termed Kidney/Kidney (K/K) 
Once the cell suspensions were transferred to the microfuge tubes they were re-aggregated 
to form cell pellets by centrifuging for 2 minutes at 700g. The pellets were gently pipetted 
to dislodge them from the tube, gently expelling medium from the base upwards. The 
pellets were then removed from the microfuge tubes inside the cell culture hood and 
placed onto a triangular section of Millipore Isopore Membrane Filter (Millipore) on a metal 
grid in a 3cm culture dish with 1ml Kidney Culture Medium. To prevent apoptosis 1µl ROCK 
inhibitor (5mM) (Calbiochem) was added to the medium for the first 24 hours of culture 
after which it was removed by replacing the medium with Kidney Culture Medium. 
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Kidney Culture Medium was changed every 48 hours. Neonatal kidney explants and 
chimeras were fixed after 2 hours (Day 0), 3 Days and 7 Days of culture by placing in either 
Trizol (Invitrogen) or Spectophotometric Grade Methanol (Sigma Aldrich) and stored at -
20ᵒC. 
2.5 Gelatine Fixing and Sectioning of Chimeras 
2.5.1 Preparation of Gelatine Solution 
In order to be sectioned for analysis the fixed cell pellets needed to be fixed in a gelatine 
sucrose solution. The solution consisted of 15g Sucrose (Sigma), 7.5% Gelatine from Porcine 
Skin (Sigma) made up to 100ml with PBS. The solution was mixed in a glass conical flask and 
placed on a heating plate with a magnetic stirrer. Once the solution was adequately mixed 
and melted it appeared clear. At this point it was transferred to a water bath at 37ᵒC with 
foil placed over the top to prevent evaporation. 
2.5.2 Preparing Fixed Rudiments 
The fixed chimeras were stored in methanol at -20ᵒC and were transferred through a series 
of methanol dilutions, and finally to PBS before gelatine embedding. To this end, the 
explant was removed from the 100% methanol fixing solution and transferred to a 1.5ml 
microfuge tube containing 1ml 75% methanol solution.  The explant was allowed to rest for 
2 minutes after which the 75% methanol solution was replaced with solutions of 50%, 25% 
and 10% methanol respectively at 2 minute intervals. After the explant was transferred to 
10% methanol solution it was washed 3 times with 1ml 1xPBS. At this point the 1ml PBS 
was removed and 1ml sucrose/gelatine solution was added to the rudiment, the 
composition of gelatin sucrose solution may be found in Appendix Section 6.7. The 
microfuge tube was placed in the water bath for 30 minutes to allow the sucrose to 
permeate the tissue.  Gelatine solution was also transferred to the bottom of two weighing 
boats to provide a surface upon which the cell pellet could be mounted after the sucrose 
had permeated the tissue. 
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2.5.3 Gelatine Embedding and Generation of Frozen Sections 
The cell pellet was removed from the microfuge tube and placed with the Millipore 
Membrane at 90ᵒ to the gelatine surface of the weighing boat so it was ‘standing up’ and 
was held in place with tweezers. Molten gelatine was then dripped over the section to ‘fix’ 
it in this erect position. Once the gelatine was set the rudiment was dissected out using a 
scalpel blade and placed onto a labelled cork disk identifying the sample. The sample was 
then covered with ‘Bright Cryo-M-Bed’ compound (Bright Instrument Company) and placed 
on dry ice to set. Once the sample became opaque it was ready for sectioning. Samples 
were sectioned using a cryostat and mounted onto ‘Superfrost’ slides (Menzel Glӓzer) and 
stored at -20ᵒC. 
2.6 Immunofluorescence 
2.6.1 Slide Preparation 
Once the conditions for the staining run were decided, slides with the appropriate sections 
were located from those stored at -20ᵒC. The slides were then labelled with the 
experimental condition (e.g. particular antibody to be applied or designated as control) and 
sections were encircled with a hydrophobic marker pen to ensure applied solutions stayed 
on the section. 
Blocking 
To prevent nonspecific binding of applied antibodies, sections for immunostaining were 
first ‘blocked’ using a ‘blocking solution’ which consisted of 1% Normal Goat Serum (NGS)  
(Sigma Aldrich) made up with 1x Phosphate Buffered Saline (Sigma Aldrich). The blocking 
solution was centrifuged at 13400g for 5 minutes to minimise transfer of impurities to the 
samples and 100µl were applied per sample for 40 minutes at room temperature.  
2.6.2 Primary Antibodies 
When incubation was complete the blocking solution was removed and primary antibody 
solutions were applied. The primary antibody solution consisted of 1% NGS made up using 
1xPBS and the primary antibody of interest at the appropriate concentration e.g. 1 in 200. 
Primary antibody solutions were centrifuged for 5 minutes at 13400g and 100µl applied per 
sample. Incubation was overnight at 4°C in a humidified chamber. 
67 
 
Table 1: Primary Antibodies Used in the Study 
Target 
Molecule 
Animal 
Raised in 
and 
Clonality 
Species 
Specificity 
Concentration 
 
Manufacturer Reference/ID 
Number 
Pecam Rat 
Polyclonal 
Non 
Specific 
1:200 BD 
Pharmingen 
550274 
Synaptopodin Mouse 
Monoclonal 
IgG1 (Clone 
G1D4) 
Non 
Specific 
1:2 Acris Gmbh BM5086 
WT1 Mouse 
Monoclonal 
IgG1 
(Clone 6F-
H2) 
Non 
Specific 
1:250 Millipore 6FH2 05-753 
Mitochondria Mouse 
Monoclonal 
IgG1 
(MTC02) 
Human 1:200 Abcam Ab3298 
Nuclear Mouse 
Monoclonal 
IgG1 (Clone 
235-1) 
Human 1:200 Millipore MAB1281 
Cytoplasm Mouse 
Monoclonal 
IgG1  
Human 1:200 STEM 121 AB-121-U-
050 
Laminin Rabbit 
Polyclonal 
Non 
Specific 
1:1000 Sigma Aldrich L9393 
Calbindin Mouse 
Monoclonal 
IgG1 (Clone 
CB-955) 
Non 
Specific 
1:200 Abcam Ab 82812 
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2.6.3 Secondary Antibodies 
After incubation with the primary antibody solution was complete, the primary antibody 
was removed and samples washed by applying and removing 100µl of PBS three times. 
After the third wash the Secondary Antibody solution was applied which consisted of 1% 
NGS made up using 1xPBS and the Secondary Antibody of interest at the appropriate 
concentration e.g. 1:1000. 
The Secondary Antibody should correspond to the animal the Primary Antibody was raised 
in, for example:  
Primary: Wt1 Rabbit Polyclonal, Secondary: Alexa Fluor-488 labelled Goat anti-Rabbit 
After the Secondary Antibody was applied the samples were incubated for 2 hours at room 
temperature in a dark humidified chamber. All secondary antibodies were used at a 
concentration of 1:1000 and supplied by Invitrogen, Paisley UK.  
Table 2: Secondary Antibodies 
Antibody Conjugated 
Fluorophore 
Reference/ID 
Goat anti 
Rat IgG 
594 (Red) Alexa fluor A11007 
Goat anti 
Mouse IgG1 
488 (Green) Alexa fluor A22121 
Goat anti 
Mouse IgG1 
594 (Red) Alexa fluor A21125 
Donkey anti 
Rabbit IgG 
488 (Green) Alexa fluor A21206 
 
2.6.4 DAPI Staining and Mounting 
After incubation was complete the secondary antibody solutions were removed and 3X 
100μl PBS washes applied to the samples. After the third PBS wash, the nuclear stain 4',6-
diamidino-2-phenylindole (DAPI) was applied to the samples to stain cell nuclei. The DAPI 
was used at a 1 in 100,000 dilution of a 1mg/ml stock in PBS. This solution was added to 
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samples and incubated for 5 minutes in a darkened humidified chamber. The DAPI solution 
was removed after incubation and one PBS wash applied.  
To mount the slides the PBS wash was removed and 1 drop of immunofluorescence 
mounting medium (Dako) applied, a cover slip (50x24mm) was then placed over the 
section. To make the mounting more permanent and prevent spoiling the edges of the 
slides were fixed with nail varnish. 
2.7 Polymerase Chain Reaction 
Cell Pellets were immersed in 500µl Trizol whilst attached to the Millipore membrane in 
1.5ml microfuge tubes. Before RNA extraction was carried out the membrane was removed 
and the tissue homogenised; this was achieved using a hand-held homogeniser (Pellet 
Pestle, Sigma). Trizol is a potential carcinogen and was handled inside a cell culture hood. 
The homogeniser was then placed into the tube with the sample and activated in short 
bursts until the sample was no longer visible. After this the Millipore membrane was 
removed with tweezers and safely disposed of.  
2.7.1 RNA Extraction and Quantification 
To begin the extraction 200µl Chloroform (Sigma Aldrich) was added to the sample in Trizol, 
the lid of the microfuge tube tightly closed, and the sample shaken vigorously for 15 
seconds. The samples were then centrifuged for 15 minutes at 11400g. After the 
centrifugation, the samples were observed to have separated into 3 visible layers. The 
topmost clear layer containing the RNA was transferred to a new microfuge tube, being 
careful not to transfer any of the middle or lower layers. 500µl isopropanol (Sigma Aldrich) 
was then added and the sampled were inverted 5-6 times and incubated at room 
temperature for 10 minutes. To increase the yield of RNA the samples were stored 
overnight in the freezer at -20ᵒC. 
To pellet the RNA, the samples were centrifuged for 10 minutes at 12000g after which an 
RNA pellet was visible at the bottom of the tube. After removing the isopropanol, the pellet 
was then washed in 75% ethanol (Sigma Aldrich) using nuclease free water for dilution. The 
sample was then centrifuged for 5 minutes at 7,500g. If the RNA was to be stored, the 
ethanol supernatant was discarded and replaced with a further 1000µl of 75% ethanol and 
stored at -20°C. Once the RNA was extracted it was quantified using the nanodrop 
spectrophotometer. In order to do this a 1μl sample of nuclease free water was initially 
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placed on the instrument and measured as a ‘blank’ to create a baseline measurement. 
Once this was performed each RNA sample was quantified using 1μl samples. Results are 
recorded in appendix. 
2.7.2 DNase Treatment of RNA 
DNase treatment is a necessary step in RNA extraction to remove potential genomic DNA 
which may affect PCR results. The ethanol supernatant was discarded and the RNA pellet 
allowed to dry. The pellet was then dissolved in 10-50µl nuclease free water. Gentle 
pipetting was used to avoid shearing the RNA. Once dissolved, 8μl of this RNA solution was 
transferred to a 200μl microfuge tube and 1μl DNAse buffer (Promega) added. To 
commence the reaction 1μl DNAse enzyme (Promega) was added and the sample 
incubated at 37ᵒC for 30 minutes. After incubation the reaction was stopped by adding 1μl 
‘Stop’ buffer (Promega). To denature any excess enzyme the contents of the microfuge 
tube were incubated for 15 minutes at 60ᵒC. If cDNA synthesis followed immediately, the 
samples were placed on ice in preparation for this, if not they were stored at -20ᵒC. 
2.7.3 Complementary DNA Synthesis: Preparation Stage 
Complementary DNA (cDNA) was synthesised from the DNase treated RNA. Reactants were 
assembled in a 200µl microfuge tube and consisted of: 
 8μl DNase Treated RNA 
 1μl Random Hexamers (100ng/µl)  (Qiagen) 
 1μl Deoxyribonucleotide Triphosphate (dNTP) (10mM) (Invitrogen) 
 4µl Nuclease Free Water (Fisher Bioreagents) 
The reaction volume at this point was 14µl and the sample was incubated at 65ᵒC for 5 
minutes and placed on ice for 1 minute. 
2.7.4 Complimentary DNA Synthesis: Enzymatic Stage 
Reactants for the enzymatic stage were added to the solution in the 200µl microfuge tube 
as follows: 
 1µl 5x Buffer (Invitrogen) 
 1µl 0.1M Dithiotheritol (DTT) (Invitrogen) 
 1µl Superscript III (Invitrogen) 
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The sample was incubated at 25ᵒC for 5 minutes then transferred to the thermocycler 
(Applied Biosciences) where it was incubated at 50ᵒC for 60 minutes followed by a step at 
70ᵒC for 15 minutes to denature the Superscript III. After the incubation was complete the 
cDNA was stored in a freezer at -20ᵒC 
2.7.5 PCR Primers  
Table 3: Chimera Primers 
Primer Sequence Tm 
(°C) 
Product 
Size 
(bp) 
Specificity Source 
M PGR F: 5-CCTTGCTTGCACGCTTGG-3 
R: 5-CTGGAATTTCTGCCTCCTTC-3 
60.05 
56.10 
229 Mouse In 
house 
M Muc 1 F: 5-GAGGGTACTTTTAGTGCCTC-3 
R: 5-CCAGGGCAAGGAAATAGACG-3 
55.17 
58.33 
217 Mouse In 
house 
h PGR F: 5-CAGTGGGCGTTGGAAATGA-3 
R: 5-TGGTGGAATCAACTGTATGTCTTGA-3 
58.36 
60.22 
83 Human In 
house 
Tata Box 
Protein 
(Human) 
F 5-GACGAGTTCCAGCGCAAGGGTT-3 
R 5-GCACCCTGAGGGGAGGCCAA-3    
65.54 
66.54 
110 Human In 
house 
h MUC1 F: 5-CGATCGTAGCCCCTATGAGA-3 
R: 5-TGAGCAGCCCACCTGAACTC-3 
58.18 
62.12 
220 Human (Shyu 
et al., 
2011) 
Tata Box 
Protein 
(Mouse) 
F: 5-GTGCGTCAGGCGTTCGGTGG-3 
R: 5-AATAGTGATGCTGGGCACTGCGGA-3 
66.58 
66.59 
113 Mouse In 
house 
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Table 4: Neonatal Kidney Explant Primers  
Gene Name Primer Sequence Tm 
(°C) 
Product 
Length (bp) 
Source 
WT1 F 5-CCAGTGTAAAACTTGTCAGCG-3 
R 5-TGGGATGCTGGACTGTCT-3 
 
57.75 
57.43 
234 In House 
Synaptopodin F 5-CGCCAGGGACCAGCCAGATAG-3 
R 5-CTGCCCAAGCAGTCTCCTTTC-3 
64.61 
61.22 
164 In House 
PECAM F 5-CAGGACCACGTGTTAGTGTT-3 
R 5-ACTCCTGATGGGTTCTGACT-3 
57.67 
57.77 
81 (Murad et 
al., 2003) 
Alkaline 
Phosphatase 
 
F 5-AGGGTACACCATGATCTCAC-3 
R 5-TCTCCCAGGAACATGATGAC-3 
56.32 
56.62 
189 In House 
Calbindin F 5-AGAACTTTCTAAAGGACCTA-3 
R-AAGCCTTATTGAACTCTTTC-3 
50.34 
51.02 
213 In House 
Tata Box 
Protein 
(Mouse) 
F 5-GTGCGTCAGGCGTTCGGTGG-3 
R 5-
AATAGTGATGCTGGGCACTGCGGA-3 
66.58 
66.59 
113 In House 
 
2.7.6 Polymerase Chain Reaction Conditions 
Reactants were assembled in a 200µl tube with a final reaction volume of 20µl with the 
following constituents per reaction: 
 10μl SYBR Taq (Sigma Aldrich),  
 7μl Nuclease free water,  
 1μl Template e.g. cDNA or Nuclease Free Water for ‘no template’ controls 
 1μl Forward Primer (6.25pmol/μl)  
 1μl Reverse Primer (6.25pmol/μl) 
A ‘No Template Control’ (NTC) was used in each experiment and a housekeeping gene 
employed to normalise gene expression. The samples were loaded into the PCR machine 
Rotorgene 3000 (Corbett) and the reaction started using the following parameters: Hold 
73 
 
95ᵒC 6 minutes. Cycling 95ᵒC 6 Seconds, 58ᵒC 20 seconds, 72ᵒC 30 seconds. For this study 
45 cycles were used.  
In each PCR series 3 technical replicates were obtained for housekeeping genes and 2 
technical replicates obtained for genes of interest. For both the neonatal kidney explant 
and chimera investigations 3 biological replicates were analysed.    
2.7.7 Gel Electrophoresis 
Gel electrophoresis was performed using the products of a PCR reaction to determine the 
number of products produced and the approximate size of each product. 
Gel Preparation 
A ‘double gloving’ technique was used throughout this method as the procedure involves 
the use of ethidium bromide, a known carcinogen, and care was taken to avoid skin 
exposure. A 1% Agarose Gel was used for electrophoresis and this was produced by mixing 
1g Agarose (Bioline) with 99ml Tris-Acetate EDTA (TAE) buffer, the composition of which 
may be found in the Appendix Section 6.7. This mixture was heated in an 800W microwave 
(Sanyo) for 1 minute 30 seconds to produce the gel solution. Once this had occurred a clear 
colourless solution was observed. The solution was allowed to cool and 3μl Ethidium 
Bromide (0.5μg/ml) (Sigma Aldrich) added. An appropriately sized electrophoresis cassette 
was prepared by taping the open ends to create a structure into which the gel could be 
poured and allowed to set. The electrophoresis comb was set in place to create the wells 
for the PCR products. The gel was allowed to set for 40 minutes then placed into an 
Electrophoresis Chamber (SCIE-PLAS) and covered adequately with TAE. 
Product Solution Preparation, Analysis and Image Capture 
A final volume of 15μl product solution was added to each well within the Agarose gel. The 
solution consisted: 
 3μl 5xDNA Loading Buffer (Bioline) 
 10μl PCR product 
 2μl Nuclease Free water 
Product solutions were prepared in separate microfuge tubes and pipetted into a separate 
well once the gel had been placed into the Electrophoresis Chamber. To provide a 
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reference for the product size, 5μl of Hyperladder IV (Abcam) was pipetted into a separate 
well. The Electrophoresis Chamber was connected to the power supply (Consort EV231) 
and activated. The parameters used for this study were 100 volts for 40 minutes. After the 
gel had run the power supply was switched off and the gel examined under ultraviolet light, 
capturing the image with an appropriate camera (GENE FLASH).  
2.7.8 Calculation of Relative Gene Expression 
Once all the qPCR runs were complete the 
data necessary to calculate relative gene 
expression in the Kidney Explants and 
Chimeras was analysed. The Relative 
Gene Expression was calculated using the 
cycle at which the PCR reactions become 
exponential; in order to do this a constant 
‘Threshold’ is set for each experimental 
condition (Figure 9). For Kidney Explants 
the Threshold was 0.020804 and for the 
Chimeras 0.012. These points were set by 
the user based on the observed 
characteristics of the reactions in the series.  
For each reaction the number of cycles it takes for the reaction to become exponential or 
‘Cycles to Threshold’ (Ct) for a gene of interest is compared to the Ct value for the 
housekeeping gene to determine relative expression. Biological and technical replicates 
were averaged to give an ‘Average Ct’ for each primer set on each day. Then Average 
Standard Deviation was also calculated for each primer set on each day.    
2.7.9 Relative Quantity 
Day 0 was taken as the baseline value for each gene of interest and the housekeeping 
genes, with the relative change in expression calculated at Day 3 and Day 7 using the 
formula: 
Relative Quantity = 2(Average Ct at Day 0 – Average Ct at Day 3 or 7) 
 
Figure 9: Threshold Value for Quantification 
of Relative Gene Expression  
Fig9. A ‘Threshold’ value is required to generate Ct values 
for analysis of relative gene expression. Threshold is user 
defined and consistent for all RT-qPCR series. 
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2.7.10 Relative Gene Expression  
The previous calculations give the relative quantity of each gene on Day 3 and Day 7 
compared to Day 0 but to determine relative expression these values need to be compared 
to the relative quantity of the housekeeping gene, this is calculated using the formula: 
Relative Gene Expression (ΔΔCt) = (Relative Quantity (RQ) of Gene of Interest on Day x)   
                                                                         (RQ of Housekeeping Gene on Day x) 
 
2.7.11 Standard Deviation of relative Gene Expression and Standard Error 
 
The Standard Deviation (SD) of the ΔΔCt values at Day x is calculated using the formula: 
 
SD ΔΔCt = ΔΔCt (RQ Housekeeping Gene) 
                          (SD RQ Housekeeping Gene) 
 
Where: RQ=Relative Quantity 
              SD= Standard Deviation 
 
The Standard Error is necessary to plot error bars for relative expression and gives 
information about the variability of results. It is calculated using the formula: 
Standard Error = SD ΔΔCt 
                                  √3 
In instances where the Standard Deviation of only 2 biological replicates of a gene of 
interest was available the Standard Error was calculated using the formula: 
Standard Error = SD ΔΔCt 
                                  √2 
In instances where the Standard Deviation of only one biological replicated of a gene of 
interest was available no calculation of Standard Error was performed. 
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2.8 Bioinformatics Methods 
2.8.1 ‘Normal Endometrium’ Literature search 
To identify suitable microarray data for inclusion in the study the search term ‘Normal 
Human Endometrium’ was submitted to the ‘GEODatasets’ database on National Centre for 
Biotechnology Information (NCBI) returning 280 datasets grouped into 37 data series. 
These data series were individually assessed against a group of inclusion and exclusion 
criteria to determine their use in the study.  
Inclusion Criteria 
 Study of Human Endometrium 
 Full thickness endometrial biopsy taken 
 Premenopausal Patients  
 Benign Endometrium free of pathology e.g. Endometriosis 
 Patients free of hormonal treatment 3 months prior to biopsy 
Exclusion Criteria 
 Endometrial Pathology studied, Benign or Malignant 
 Hormonal Treatment e.g. Combined Oral Contraceptive Pill 
 Primary culture of human cells prior to analysis 
 Isolation of Specific Cell Populations 
 Study of endometrial cell lines 
 Epigenetic Study 
Further information of series not included in the study along with reason for exclusion may 
be found in the appendix. 
This search identified the data series ‘GSE4888’ as suitable for inclusion in the study as it 
analysed biopsies collected from normally cycling patients undergoing hysterectomy/biopsy 
for benign indications between the ages of 23 and 50 who had not received hormonal 
therapy in the past 3 months (Talbi et al., 2006). This dataset has also been used extensively 
by previous publications to represent the ‘normal endometrium’ or as control data when 
studying gene expression in endometrial pathology (Savaris et al., 2011, Aghajanova and 
Giudice, 2011, Aghajanova et al., 2010).  
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2.8.2 Further ‘Normal Endometrium’ Dataset Refinement 
The dataset GSE4888 was provisionally identified for use in the study as it best matched the 
inclusion/exclusion criteria; however it contained some samples that would not be 
appropriate for analysis of ‘Normal’ endometrium. For this reason further refinement was 
carried out. 
 Pipelle biopsy samples were removed from the dataset as this form of biopsy may 
not represent full thickness endometrium. 
 Biopsies obtained from patients with endometriosis or adenomyosis were removed 
from the dataset as their pathologies are associated with abnormal endometrium 
 One biopsy obtained from a patient prescribed ‘Thyroxine’ was removed from the 
study as this medication may alter gene expression in the endometrium 
This refinement resulted in a dataset of 15 biopsies suitable for inclusion in the study 
(Figure 10) consisting of:  
1. Proliferative Phase Endometrium (n=1)  
2. Early Secretory Phase Endometrium (n=3) 
3. Mid Secretory Phase Endometrium (n=5)  
4. Late Secretory Phase Endometrium (n=6) 
Figure 10: Number of Patient Samples Within Each Phase of the Menstrual Cycle: Normal 
Endometrium 
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Fig10. Samples from the transcriptomic dataset GSE4888 
were separated into menstrual cycle phase at which 
biopsies were obtained.  
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To carry out gene expression analysis one biopsy was required to be selected as a control 
value to compare gene expression across the dataset, ‘Patient ID 598’ which corresponds to 
the proliferative phase endometrial sample 1. This sample was used as a control in the 
original study from which the dataset is taken and represents the only proliferative phase 
sample.   
2.8.3 Endometriosis Literature Search 
To identify suitable microarray data for inclusion in the study the search term ‘Human 
Endometriosis’ was submitted to the ‘GEODatasets’ Database on NCBI which returned 334 
datasets arranged into 26 data series. These series were individually assessed against a 
group of inclusion and exclusion criteria for their suitability for inclusion in the study. 
Inclusion Criteria 
 Human Endometrium Studied 
 Patients Suffering from Endometriosis 
 Premenopausal Patients  
 Full thickness endometrial biopsy 
 Patients free of hormonal treatment 3 months prior to biopsy 
Exclusion Criteria 
 Non Endometrial Tissue  
 Primary cell culture of endometrial biopsies 
 Isolation of specific cell populations 
 Study of malignancy 
 Study of non-human tissue 
 Epigenetic study carried out 
 Study of endometrial cell lines 
A summary of the data series investigated and the reasons for exclusion are included in the 
appendix. After selection there remained 5 data series which could potentially be used in a 
study of gene expression in Human Endometriosis: GSE5108, GSE6364, GSE7305, GSE12768 
and GSE37837.  
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These datasets were analysed with a set of further restriction criteria designed to ensure 
the data accurately reflected gene expression across different phases of the menstrual 
cycle and was comparable to the dataset gathered for ‘Normal’ endometrium. 
Further Restriction Criteria 
 Eutopic Endometrium Studied 
 Secretory Phases Samples Predominantly studied 
 Secretory Phase samples documented as ‘Early’, ‘Mid’ or ‘Late’ 
Based on this selection the series ‘GSE6364’ was selected for analysis in the study, 
GSE5108, GSE7305, GSE12768 and GSE37837 were discarded and not used in any further 
analysis.  
Detailed investigation of the data series is included in the appendix. 
 
2.8.4 Further Endometriosis Dataset refinement 
The Data Series ‘GSE6364’ had been provisionally identified as suitable for inclusion in the 
study however not all of the samples within the Data series were appropriate. For example 
of the 37 samples in the series only 21 represented eutopic endometrium of patients with 
endometriosis. These useful samples were extracted from the series and categorised 
according to which phase of the menstrual cycle they represented (Figure 11). 
1. Proliferative Phase Endometrium (n=6 ) 
2. Early Secretory Phase Endometrium (n=6) 
3. Mid Secretory Phase Endometrium (n=9)  
 
Figure 11: Number of Patient Samples Within Each Phase of the Menstrual Cycle: 
Endometriosis 
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Fig11. Samples from the transcriptomic dataset GSE6364 
were separated into menstrual cycle phase at which 
biopsies were obtained. No data was available for the late 
Secretory phase  
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The sample ‘GSM150195’ was selected as a control as it represents a proliferative phase 
eutopic endometriosis sample; this is in line with the previous analysis of ‘Normal’ 
endometrium. The 5 remaining ‘Proliferative Phase Endometrium’ samples were discarded 
from the analysis in order to make the analysis of ‘Endometriosis’ data comparable with 
that of ‘Normal’ endometrium which used 1 Proliferative phase sample as a control. It was 
hoped that by making these study designs identical data obtained from ‘Normal’ and 
‘Endometriosis’ analysis would be comparable; however it is recognized that creating an 
average of these 6 Proliferative phase samples may be useful for future study when 
considering the ‘Endometriosis’ data alone. 
 
2.8.5 Identification and Isolation of Differentially Regulated Genes 
After identifying data suitable for inclusion in the study the relevant ‘.gz’ files were 
obtained from NCBI. For each patient biopsy gene expression data and gene identifying 
information e.g. Gene Ontology terms were extracted from the dataset using the ‘R’ 
statistics package version 2.15.1.  
These gene expression values were then compared to those of the control sample to 
identify up or down regulated genes within the ‘Early’, ‘Mid’, and ‘Late’ Secretory phase of 
the menstrual cycle. A mean log fold change of + or – 2 was considered statistically 
significant.  
This transformation generated a set of up and down regulated genes for the Early, Mid and 
Late Secretory Phase in the ‘Normal’ endometrium and Early and Mid Secretory phase in 
the ‘Endometriosis’ endometrium. The use of a ‘Z-score’ was trialled for gene selection 
however the number of differentially regulated genes yielded by this approach was too 
small for further analysis and the Log2 fold change used was considered sufficiently 
significant. The ‘R’ code used to generate both sets of differentially regulated genes is 
included in the appendix. 
2.8.6 Analysis of Differentially Regulated Genes and Cellular Networks in ‘Normal’ and 
Endometriosis’ Data Series 
Differentially regulated genes identified for ‘Normal’ and ‘Endometriosis’ samples  were 
submitted to Ingenuity Pathways Analysis (IPA) to identify up and down regulated 
functional networks of interest as well as individual up and down regulated genes. The 
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parameters for Ingenuity analysis included Human Species and limiting to 140 reactions in 
readout. 
Other tools used for analysis include: Database for Annotation Visualisation and Integrated 
Discovery (DAVID), Cytoscape and STRING. 
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Chapter 3: Optimization and 
Validation of Methods 
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Before the main experiments could be carried out in this study several pilot investigations 
were performed. The purpose of these experiments was to optimise the explant protocol, 
as neonatal kidneys and human endometrium had not previously been grown in chimeric 
culture and to optimise the proposed RT-qPCR. 
3.1 Optimisation of ‘Vybrant’ Labelling 
In order to investigate the activity of the human cells in the chimera is was necessary to 
reliably identify them during the analysis. To achieve this, two different methods were 
used: first the cells were labeled with a CFDA-SE ‘Vybrant’ stain prior to inclusion in the 
chimera and secondly, human specific immunofluorescence detection was used after 
fixation and sectioning.  
Optimisation of the ‘Vybrant’ labeling protocol was required as previous research in the 
Liverpool laboratory (Simic, 2010) indicated that when fixing chimeras cultured using the 
Davies technique (Unbekandt and Davies, 2010) methanol should be used, as fixing with 
Paraformaldehyde causes the explant to detach more easily from the Millipore membrane 
making both sectioning and staining more difficult. As it was not known if fixing with 
methanol would attenuate the ‘Vybrant’ labeling a pilot study was carried out that involved 
fixing  ‘H6’ kidney cells (Fuente Mora et al., 2012) in either 100% methanol or 4% 
paraformaldehyde (Figure 12). Cells were observed at Day 4 and Day 7 after fixation to 
check for attenuation of fluorescence. The findings of this pilot study are summarised in 
Figure 12 and do not demonstrate a clear difference between the fixation methods. It 
should be noted that the Day 4 samples were imaged at a lower magnification than the Day 
7 samples. 
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Figure 12: No difference can be demonstrated between Methanol and Paraformaldehyde  
Fixation 
 
 
 
 
 
 
 
 
 
 
Fig12. Vybrant labelled cells from ‘H6’ kidney cell line were fixed with either 100% Methanol or 4% Paraformaldehyde. Cells were 
observed at Day 4 and Day 7 post fixation to detect attenuation of fluorescence. Human endometrial cells cultured for 7 days after 
Vybrant labeling were used as a control.  Scale Bar day 7 methanol image 50μm, all other images 100μm 
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3.1 Optimisation of Human Specific Antibody Staining 
3.2 Optimisation of Human Specific Antibodies 
The second method of identifying human cells was via immunofluorescence using a human 
specific antibody. As a number of potential antibodies were available it was necessary to 
evaluate their use for inclusion in the main study. To achieve this, immunofluorescence 
staining of Day 0 Vybrant labelled cells in the CD1 chimera was performed. Human specific 
antibodies trialled were: Human anti -nuclear, Human anti-mitochondrial and Human anti-
cytoplasmic antibodies (Figure 13). Human anti nuclear stain demonstrated poor 
localisation however good staining was achieved for both human anti mitochondrial and 
human anti cytoplasmic. As thin (10m) sections were used for this study and the 
mitochondria were not always evenly distributed throughout the cell it was decided that 
the anti-cytoplasmic antibody would be used for further experiments.  
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Figure 13: Trialing Human Specific Antibodies 
 
 
 
 
 
Fig13. Human endometrial epithelial cells were labeled with Vybrant (Green) and cultured for 2 hours in a chimeric explant with CD1 
mouse kidneys before fixation, sectioning and immunostaining with human specific antibodies (Red) and DAPI (Blue). Human specific 
antibodies used included: Anti human cytoplasmic, anti human mitochondrial and anti human nuclear antibodies. Both anti 
cytoplasmic and anti mitochondrial localise human cells well, this is not demonstrated with anti nuclear staining. Scale Bar 100µm.  
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3.3 Optimisation of Kidney Explant Model: Complete or Partial Disaggregation 
As neonatal kidneys had not been used in an explant culture of this type before it was 
necessary to consider the disaggregation process used. As the neonatal kidney is more 
mature than that of the embryo, it was thought that a complete disaggregation may result 
in widespread apoptosis. Two protocols for neonatal kidney disaggregation were trialled, 
one providing a partial disaggregation and another which produced a more complete 
disaggregation.  Outcomes were assessed using immunofluorescence for PECAM and 
Synaptopodin as well as (Figure 14); the aim was to assess which method of disaggregation 
would provide the optimum environment for the human cells and allow nephrogenesis to 
occur. Immunofluorescence for PECAM and Synaptopodin demonstrates that vessel-like 
structures that stained for positively for PECAM, and clusters of podocytes were present in 
samples prepared using the ‘trypsin’ protocol. While this is only a qualitative assay the 
degree of specific staining observed in the trypsin protocol appeared to be greater than in 
the collagenase protocol it was for this reason that the trypsin protocol was selected for 
inclusion in the main study. 
Figure 14: Pecam/Synaptopodin Immunofluorescence: Complete or Partial Disaggregation? 
Fig14. Intact neonatal kidney and kidney explants cultured for 7 days at an air-medium interface were Immunostained for Pecam 
(Red), Synaptopodin (Green) and DAPI (Blue). Sections generated after partial disaggregation we compared with those 
generated after complete disaggregation. Partially disaggregated sections showed more evidence of Pecam and Synaptopodin 
positive structures (arrows). An intact neonatal kidney section was also stained as a control value. Scale bar 50µm. 
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Fig15. Immunofluorescence images comparing WT1 (Red) and Laminin (Green) Staining from Day 3 of the pilot 
experiment are presented compared with images obtained from Day 0 of a subsequent experiment. It can be noted a 
difference in the number of WT1 positive organized structures between Day 0 and Day 3 highlighting the importance 
of analyzing images at Day 0 to identify whether structures are developing in vitro or are the result of incomplete 
disaggregation. Scale bar 50μm 
 
3.3.1 Further Modifications to Disaggregation-Reaggregation Protocol 
The kidney explants generated from this original experiment were fixed in methanol or 
treated with Trizol after 3, 5 or 7 days of culture. From the results of the experiment it 
would seem that a partial disaggregation was more favourable and this was selected for use 
in the main experiment. This decision meant it was necessary to modify the protocol and fix 
some explants after just 2 hours of culture in the main experiment in an attempt to identify 
whether structures visualised at Day 3 and Day 7 were forming in culture or were simply 
the result of incomplete disaggregation, Figure 15 demonstrates the difference in 
structures present between Day 0 and Day 3 of subsequent experiments. The fixation 
protocol for the main experiment was therefore set at: 2 Hours of Culture (Designated Day 
0), 3 Days of Culture, and 7 Days of Culture.  
Figure 15. Comparison between Day 0 and Day 3 Kidney Explant Immunofluorescence 
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3.4 RT-qPCR 
3.4.1 Validation of RNA extraction and cDNA synthesis 
In order to validate the efficacy of the DNase treatment step and cDNA synthesis step of 
the qPCR analysis, a PCR series was carried out on one of the samples from the kidney 
explants, in this case an explant fixed after 2 hours (0 Days) of culture. The PCR was run 
with the same parameters as the main study with 3 different templates: RNA extracted 
from the sample, DNase Treated RNA from the sample and cDNA synthesised from the 
DNase treated RNA. The primers used were the housekeeping genes (Figure 16). After RNA 
extraction was carried out genomic DNA is likely to be present in the sample; in this case a 
peak will be seen on the melt curve. The DNase step is intended to remove the genomic 
DNA and if it is successful, the sample will come to threshold much later and a template-
specific peak will not be produced on melt curve analysis. Synthesis of cDNA is the final step 
in the process and the resulting template should come to threshold early and produce a 
large peak on melt analysis. Analysis was performed for both Kidney explant and 
Endometrial-Kidney Chimeras (Figure 16). 
Figure 16: RT-qPCR Analysis of RNA, DNase Treated RNA and cDNA from Neonatal Kidney 
Explant  
 
 
 
 
 
 
 
 
 
Fig16. Samples obtained from a neonatal kidney explant cultured for 7 days were tested at different stages of complimentary DNA synthesis to 
investigate the efficacy of the process using Real time Quantitative PCR. Samples included: RNA (Red), Dnase Treated RNA (Green), 
complimentary DNA (Blue). The RNA sample becomes exponential producing a melt curve peak. The DNase sample becomes exponential 15 
cycles later and does not produce a melt curve. Complimentary DNA becomes exponential early in the reaction and forms a melt curve.  
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3.4.2 Identification of Human and Mouse Specific Primers 
Human and Mouse specific Primers for: Tata Box Protein (Tbp) (Housekeeping Gene), 
Progesterone Receptor (PGR) and Mucin1 (Muc1) were identified in-house as they were 
used by a previous student undertaking analysis of chimeric explants using mouse embryos. 
It was necessary to verify that these stock aliquots had not become contaminated and were 
indeed species-specific. RT-qPCR was carried out for each primer set (6 in total) with a 
positive control for human cells, a positive control for mouse cells and an NTC. 
3.4.3 Human and Mouse Specific Housekeeping Genes 
 The human and mouse specific housekeeping genes used in this study were validated at 
different times and as a result different positive controls were used. These conditions are 
summarised in Table 5 below. 
Table 5: Positive Mouse and Human cDNA Controls 
Primer Set Positive Mouse Control Positive Human Control 
Human Specific Tbp cDNA synthesised from a 
mouse uterus in the 
Sherrington Laboratory 
cDNA synthesised from a 
‘Normal’ endometrial sample 
at Liverpool Womens 
Hospital 
Mouse Specific Tbp cDNA synthesised from a 
mouse kidney in the 
Sherrington laboratory 
cDNA synthesised from an 
‘Endometriosis’ endometrial 
sample at Liverpool Womens 
Hospital 
 
Both human and mouse specific Tbp produced an exponential curve on RT-qPCR for the 
relevant positive control and a band indicating an appropriate product size on Gel 
electrophoresis according to results of a ‘Primer BLAST’ assessment (Figure 17). The primers 
were also tested for species specificity by performing an RT-qPCR reaction with cDNA of a 
differing species e.g. Mouse Tbp with Human (H) cDNA. No product was detected in these 
lanes indicating that the primers were species specific.  
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Figure 17: Gel Electrophoresis of Housekeeping Genes 
 
 
 
3.4.4 Genes of Interest: Progesterone Receptor and Mucin1 
Human and mouse specific primer sets for PGR and Muc1 (4 in total) were tested for 
contamination and species specificity with positive control for human cells being cDNA 
synthesised from a ‘Normal’ endometrial sample at Liverpool Womens Hospital and 
positive control for mouse cells being cDNA synthesised from a mouse uterus in the 
Sherrington Laboratory. Human specific PGR and Mouse specific PGR and Muc1 produced 
an exponential curve on RT-qPCR for the relevant positive control and a band indicating an 
appropriate product size on Gel electrophoresis according to results of a ‘Primer BLAST’ 
assessment (Figure 18).  
Figure 18: Identification of Mouse Specific MUC1, Progesterone Receptor and Human 
Specific Progesterone Receptor primers 
Fig18. Human and Mouse specific Mucin1 (MUC1) and Progesterone Receptor (PR) were located from in-house stocks and tested for species 
specificity and contamination using Real Time Quantitative PCR and Gel Electrophoresis. Positive control for Human was normal human 
endometrial cDNA extracted from a ‘Normal’ patient sample obtained at Liverpool Womens Hospital. Positive control for Mouse was cDNA 
synthesised from a mouse uterus at the Sherrington laboratory.  Bands produced analysed against ‘Hyperladder IV’ correlate with expected 
size of products and NTC lane shows no signs of contamination as well as no signs of cross species reactivity indicated by no product in lanes 
where species specific primers were reacted with cDNA of a different species e.g. Human PR with Mouse (M) cDNA. Human MUC1 did not 
produce a satisfactory product.  
Fig17.  Human and Mouse specific housekeeping genes (Tata Box Protein) were located from in-house stocks and tested for 
species specificity and contamination. Positive control for Human was ‘Normal’ endometrial cDNA synthesised from a patient 
sample obtained at Liverpool Womens Hospital. Positive control for Mouse was Mouse Kidney cDNA extracted in the 
Sherrington laboratory. Hyperladder IV was used to analyse the PCR products after gel electrophoresis to check against the 
predicted size and species specificity.  No products were found in No Template Control lanes or lanes where a differing species 
cDNA was used e.g. Human Tbp with M cDNA. This indicated the primers were free from contamination and species specific. 
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It was observed that the product produced for human specific Muc1 was not the expected 
size indicating that the correct product had not been produced (Figure 18). This could either 
be due to non-specificity of the primers or, given the size of the product, a primer dimer. 
On repeat analysis a suitable product was not produced. A literature search was carried out 
and it was noted that human Muc1 exhibits multiple splice variants (more than 15) and a 
primer BLAST assessment indicated that in-house Muc1 primers would only identify 4 of 
these (Zhang et al., 2013). A literature search was undertaken to identify human specific 
Muc1 primers that would cover more splice variants (Shyu et al., 2011) was identified and 
the primer sequences assessed with ‘Primer BLAST’ indicating 20 splice variants may be 
produced. These primers were then assessed using RT-qPCR and Gel Electrophoresis using 
the same conditions as previously (Figure 19). The primers were free from contamination 
and produced a product of expected size observed on Gel Electrophoresis. 
Figure 19: Identification of Human Specific MUC1 Primers 
 
 
 
 
 
 
 
 
 
3.4.5 Kidney Explant PCR, House Keeping Genes and Genes of Interest 
Primers for: Tbp (Housekeeping Gene), Wt1, Synaptopodin, Pecam and Calbindin were 
identified in-house as these Genes of Interest are frequently assessed by researchers at the 
Sherrington laboratory. It was necessary to verify that these stock aliquots had not become 
contaminated and would produce appropriate products on RT-qPCR. 
Fig19. New Human MUC1 primers obtained from a literature search were tested for species specificity and contamination 
using RT-qPCR and Gel Electrophoresis. Positive control for Human was ‘Normal’ cDNA synthesised from a patient sample 
obtained at Liverpool Womens Hospital. Positive control for Mouse was cDNA synthesized from a mouse uterus at the 
Sherrington laboratory. The primers were specific and free from contamination producing a product consistent with the 
expected size of 220 base pairs (bp) 
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RT-qPCR was carried out for each primer set with cDNA synthesised from mouse kidney 
used as a positive control and an NTC (Figure 20).  
Figure 20: Identification of Specific Primers for Kidney Explant Analysis 
 
 
Both the housekeeping gene and genes of interest produced an exponential curve on RT-
qPCR for the positive control and a band indicating an appropriate product size on Gel 
Electrophoresis according to results of a ‘Primer BLAST’ assessment. There was no sign of a 
product in the NTC lane (Figure 20). 
 
 
 
 
 
 
 
 
 
Fig20. Primers for genes of interest: Wilms Tumour 1 (WT1), Synaptopodin, PECAM, Calbindin and Tata box protein (Tbp) 
were located from in house stocks and tested for specificity and contamination using Real Time Quantitative PCR and Gel 
Electrophoresis. Positive control for Mouse was cDNA synthesised from a mouse kidney at the Sherrington laboratory.  The 
bands produced correlate with expected size of products and No Template Control lanes show no signs of contamination. 
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Chapter 4: Results 
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4.1 Chimera Results 
4.1.1 Migration of Human Cells through the Chimera 
Initial analysis was performed on unstained frozen sections made from chimeras containing 
Vybrant-labelled endometrial cells fixed at 2 hours (Day 0), 3 days and 7 days respectively 
(Figure 21), three of the explants generated from each time point (Day 0, Day 3, Day 7) 
were sectioned in preparation for analysis with two immunofluorescence runs performed 
per section. The results presented are representative samples. It can be observed that the 
distribution of the Vybrant labelling alters as time in culture increases. At Day 0, after only 2 
hours of culture, cells displaying bright green fluorescence were located at the periphery of 
the section, where they could be seen at the base of the tissue pellet, attached to the 
membrane filter, and also on the pellet surface. By Day 3 the cells appeared to have 
permeated the tissue such that the full thickness of the section contained green fluorescent 
cells. At this time point, the fluorescent population comprised cells that displayed bright 
fluorescence, and cells that displayed weak fluorescence.  By Day 7, fluorescence was still 
present throughout the full thickness of the section, but in comparison to Day 3, it 
appeared that there were fewer bright green fluorescent cells. Furthermore, it was difficult 
to tell if the weak fluorescent signal observed throughout the section was from human cells 
that had depleted their level of fluorescence due to cell division, or whether it was simply 
background autofluorescence.  
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Figure 21: Distribution of Vybrant Staining Changes With Increased Time in Culture 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig21. Frozen sections of chimeric explants containing endometrial cells labelled with Vybrant prior to culture were analysed 
using fluorescence and phase microscopy. Sections demonstrate the distribution of Vybrant fluorescence as at the indicated 
time points. Arrows mark the membrane on which the chimeras were cultured. Scale bar 100μm. 
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4.1.2 Minimal Co-Localisation is Detected Between Vybrant and the Human-Specific Anti-
Cytoplasmic Antibody at Day 7 of Culture 
One of the observations from analysis of the Vybrant sections of endometrial epithelial-
neonatal kidney chimeras was that fewer positive staining areas could be identified on Day 
7 than on Day 0. There are a number of possible explanations for this, the most likely being 
that either the endometrial cells are losing the Vybrant label due to cell division or the 
Vybrant signal is decreased because the endometrial cells were dying. To distinguish 
between these two possibilities, frozen sections were immunostained with human specific 
anti-cytoplasmic antibody at Day 0, Day 3 and Day 7 with the aim of identifying cells co-
staining for this antibody and Vybrant (Figure 22). As expected, at Day 0 most cells 
displayed both green and red fluorescence, indicating that all Vybrant-labelled cells 
expressed the human-specific cytoplasmic protein. By Day 3, many of the cells expressing 
the anti-cytoplasmic protein appeared to display weak green fluorescence. By Day 7, there 
were noticeably fewer cells expressing the anti-cytoplasmic protein and these tended to 
have little or no green fluorescence. These areas did not often co-localise with red 
fluorescence, suggesting that was most likely due to background autofluorescence. The 
observation that many cells expressing the human-specific cytoplasmic protein within the 
Day 3 chimeras displayed weak green fluorescence suggested that some of the endometrial 
cells had proliferated between Day 0 and Day 3. The observation that there were noticeably 
fewer cells expressing the human-specific cytoplasmic protein within the Day 7 chimera 
suggested that many endometrial cells died between Day 3 and Day 7. However, the fact 
that the few human cells present at Day 7 displayed lower levels of green florescence than 
those at Day 3, suggested that surviving human cells were likely to have gone through at 
least one cell division between the two time points. 
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Figure 22: Anti Cytoplasmic Immunofluorescence Staining of Vybrant Labelled Chimeras 
 
 
 
 
 
 
 
 
Fig22.  Frozen sections of chimeric explants containing endometrial cells labelled with Vybrant fluorescence prior to culture were 
immunostained with anti-cytoplasmic antibody (A-HCP) (Red) and the nuclear stain DAPI (Blue). Co-localisation can be readily 
observed after 2 hours of culture (Day 0). At Day 3 and Day 7 co-localising cells are less readily identified and areas of staining for 
either Vybrant or anti-cytoplasmic antibody that do not co-localise are observed. Arrows identify potentially co-staining cells. 
Biological and technical repeats were conducted with the images shown being representative. Scale bar 50μm.  
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4.1.3 ‘Bright’ Vybrant Staining Present at Day 7 Does Not Represent Viable Cells 
Another observation from the sections of chimeras containing Vybrant-labelled human 
endometrial cells was that there were a number of intense green fluorescent spots present 
in the day 7 sample that did not co-stain for the human-specific cytoplasmic protein. 
Further analysis under higher power showed that these spots did not contain a nucleus, 
suggesting that they were not representing viable cells (Figure 23). 
Figure 23: Day 3 and Day 7 Vybrant Labelled Chimera Frozen Sections Stained With Human 
Anti-Cytoplasmic Antibody 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Fig 23. Frozen section from a Day 7 chimera containing Vybrant labelled endometrial cells 
(Green) was immunostained with anti-cytoplasmic antibody (Red) and the nuclear stain DAPI 
(Blue). Areas of non co- staining fluorescence may be identified which are not associated will a 
cell nucleus. It is possible that these areas represent cell fragments. Scale bar 50μm. 
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4.1.4 Endometrial Chimera Experiment Including the Stromal Fraction 
It was observed from anti-cytoplasmic staining of chimeras including endometrial epithelial 
cells that few positively co-localising cells could be identified at Day 7 of culture.  
This finding was not consistent with a previous study, where cells from disaggregated 
endometrial tissue containing the whole, non-fractionated population, were present 
beyond a 7 day period following transplantation into the kidneys of adult SCID mice 
(Masuda, 2012).  To investigate if the demise of the endometrial epithelial cells in the 
neonatal kidney chimeras was due to an absence of endometrial stromal cells, both the 
epithelial and stromal fractions isolated from human endometrium were included in a 
subsequent chimeric culture (Figure 24).  Due to their small size, chimeras from Day 7 of 
this experiment could not be sectioned so immunofluorescence from Day 0 and Day 3 is 
presented. On Day 0 only two cells positive for Vybrant can be identified and the 
cytoplasmic stain shows a more diffuse pattern than previously. At Day 3 the Vybrant signal 
was less discrete and distributed throughout the full thickness of the tissue section. The 
areas of positive co-staining at Day 3 appear to be few in number. Though this is a 
qualitative assay it can be asserted that increased numbers of human cells are were not 
observed when the stromal population was added to the chimera.  
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Figure 24: Anti-Cytoplasmic Immunostaining of Chimeras cultured with Both Stromal and 
Epithelial Population 
 
 
 
 
 
 
 
 
Fig24. Human endometrial epithelial cells were labelled with ‘Vybrant’ fluorescence (Green) and cultured for 2 hours, 3 days and 7 
days in a chimeric explant with CD1 neonatal mouse kidneys. Frozen sections were stained with human specific anti-cytoplasmic 
antibody (Red) at the indicated time points. In this biological replicate no images were able to be obtained for Day 7 of Culture. 
Technical replicates were obtained with the images shown being representative. Scale bar 50μl. 
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4.1.5 Human Cells Do Not Form Glandular Structures within the Chimera 
 A previous study has shown that human endometrial cells appear to differentiate and form 
gland-like structures following their introduction into adult mouse kidney. A key aim of the 
current study was to investigate if human endometrial cells would behave similarly if 
exposed to the environment of mouse neonatal tissue. In order to test this, chimera 
sections from Day 0, Day 3 and Day 7 were stained with an anti-laminin antibody in order to 
identify basement membranes (Figure 25). A No Template Control was also stained. If 
human gland-like structures had formed, they would consist of polarised Vybrant-stained 
cells organised with their basal surface atop a basement membrane (Valentijn et al., 2013). 
At Day 0 of culture a well organised Laminin architecture was observed with Vybrant 
positive cell aggregates interspersed in an unorganised fashion, most of which were located 
in close proximity to the membrane with some more centrally located within the section 
(Figure 25A). By Day 3, the number of Vybrant stained cells was noticeably greater within 
the centre of the section, but there was no evidence that glandular-like structures had 
formed (Figure 25B).  At Day 7, few positive aggregates remained and the organised 
Laminin architecture could not be readily identified (Figure 25C).  Interestingly, considering 
the Laminin staining, it seemed to become more disrupted over the course of the culture. 
At Day 3 there still seem to be intact Basement Membranes (BMs) present though thinner 
than at Day 0. At Day 7, although there was plenty of laminin immunostaining, it did not 
appear to be organised into BMs.   
 
 
 
 
C 
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Figure 25: Day 0, Day 3 and Day 7 Vybrant Labelled Chimera Frozen Sections Stained With 
Anti-Laminin Antibody 
 
 
 
4.1.6 Laminin Structures in Chimeras Appear Disorganised Compared With Kidney 
Explants 
The unexpected finding of apparent disruption within the Laminin architecture associated 
with increased time in culture was investigated further by comparing the chimeras with the 
reaggregated kidney explants (Figure 26). Sections from Day 0 and Day 7 were assessed and 
in both the chimera and the neonatal kidney explants, laminin structures appeared 
different in morphology on Day 7 than Day 0. It was noted that the Laminin structures in 
the chimera seemed more disorganised than in the kidney explant. This observation is 
reminiscent of a previous study in which human and mouse mesenchymal cells were 
demonstrated to have a detrimental effect on the development of renal structures in 
embryonic mouse kidney rudiments (Kuzma-Kuzniarska et al., 2012), possibly through the 
secretion of growth factors such as Transforming Growth Factor Beta (TGFβ).  
 
Fig25. Human endometrial epithelial cells were labelled with Vybrant fluorescence (Green) and cultured for 2 hours (A), 3 days (B) and 
7 days (C) in a chimeric explant with CD1 neonatal mouse kidneys. Frozen sections were stained for Laminin (Red) and DAPi (Blue) at 
these specific time points as well as a No Template Control (D). No glandular-like structures are identifiable in these sections. 
Biological and technical repeats were conducted with the images shown being representative.  Scale Bar 50μm. 
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Figure 26: Comparison of Chimera and Kidney Explant Frozen Sections Stained With Anti-
Laminin Antibody at Day 0 and Day 7 of Culture 
 
 
 
 
 
 
 
  
 
 
 
 
 
4.1.7 Relative Gene Expression within the Chimera 
To investigate for evidence of survival and differentiation of the endometrial epithelial cell 
population included in the chimeric culture, Real Time quantitative PCR (RT qPCR) was 
performed using species specific primers for PGR and Mucin1 (Muc1) (Figure 27). 
Progesterone Receptor is documented as a marker of a more differentiated phenotype in 
endometrial cells (Jabbour et al., 2006) and Muc1 is a marker of endometrial cells thought 
to be associated with the implantation window (Aplin, 2006). If the endometrial cells were 
surviving and differentiating within the chimera it would be expected that both of these 
markers will be upregulated. Progesterone Receptor and Muc1 were also assessed with 
mouse specific primers to investigate whether the endometrial cells were inducing 
expression of these markers in the kidney cells.       
Fig26. Frozen sections from neonatal kidney explants and chimeras were immunostained for laminin 
(Green) and DAPI (Blue). Comparison of Day 0 and Day 7 sections identified a more organized laminin 
architecture at Day 7 in neonatal kidney explant compared to chimeras despite and organized laminin 
architecture observed in chimeras at day 0. This highlights the possibility that endometrial cells in the 
chimera disrupt basement membrane structure, possibly through the secretion of growth factors e.g. 
TGF-β. Biological and technical repeats were conducted with the images shown being representative. 
Scale bar 50μm. 
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RT qPCR was carried out on cDNA extracted from 3 biological replicates of the chimera with 
one biological replicate consisting of Day 0, Day 3 and Day 7 explants.  The housekeeping 
genes used were human-specific and mouse-specific Tbp which have been validated in 
human and mouse tissues (Wu et al., 2013, Wei et al., 2013, Pernot et al., 2010). Two 
technical replicates were carried on each gene of interest in each reaction series (Figure 
26). 
Interpretation of this data is limited, as with several of the primers (e.g. human 
progesterone receptor) there was insufficient data collected to perform statistical analysis. 
It was also the case that there was insufficient data to calculate the standard error; when 
this situation arose standard error bars were omitted from the graph. These missing data 
are due to the samples not reaching the threshold value in the RT-qPCR which in itself is a 
finding as it implies that there was very little RNA present in the samples at the time of 
fixation. This was particularly the case with the human-specific genes of interest. 
Trends can be described in the remainder of these data, but with the caveat that the 
experiments have been performed only a few times and might not therefore be 
reproducible. Human progesterone receptor demonstrated an initial downregulation at Day 
3 followed by a large upregulation at Day 7. Mouse progesterone receptor exhibited a 
sustained downregulation from Day 3 onwards. Human Muc1 was initially upregulated at 
Day 3 followed by downregulation at Day 7 and mouse Muc1 was substantially 
downregulated both at day 3 and day 7. It would seem that endometrial associated genes 
are not detected in the mouse cells after Day 0 and that Progesterone Receptor is 
upregulated in the endometrial cells at Day 7. It is not possible however to take any solid 
evidence from this PCR study as none of the findings were statistically significant. There are 
a number of possible reasons for this one of which may be the low number of both 
biological and technical repeats and it is possible that performing a greater number of 
technical repeats on a greater number of biological repeats would have helped more 
accurately identify what was happening in the chimeras.     
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Figure 27: Relative Gene Expression of Human and Mouse Genes of interest within the 
Endometrial – Neonatal Mouse Kidney Chimera 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig27: Relative Expression of Genes of Interest in the Endometrial – Neonatal mouse kidney chimera. Error bars are not 
included for several samples as standard error was not able to be calculated due to missing data. Relative expression of 
mouse progesterone receptor and mouse Muc1 demonstrated a substantial sustained decrease in expression after Day 0. 
Human Progesterone Receptor demonstrates downregulation at Day 3 followed by upregulation at Day 7. Mouse 
Progesterone Receptor demonstrates a substantial sustained down regulation. Interpretation of these findings is limited by 
lack of statistical analysis     
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4.2 Immunofluoresence Analysis of Neonatal Kidney Explants  
Frozen sections generated from neonatal kidney explants were immunostained for a variety 
of renal markers. Three of the explants generated for each time point (Day 0, Day 3, Day7) 
were sectioned for analysis with at least two immunofluorescence runs completed for each 
stain. The results presented are representative. The aim was to investigate the presence of 
kidney structures forming ex vivo following disaggregation and reaggregation and to 
determine the fate of endothelial cells in the explants. Frozen sections were stained from 
explants fixed after 0, 3 and 7 days of culture.  
4.2.1 Wt1/Laminin  
At Day 0, only a few Wt1 positive cells could be identified, and were typically localised 
within Wt1 positive cell clusters that were encircled by a well-defined basement 
membrane, as indicated by laminin immunoreactivity (Figure 28 A). By Day 3 it appeared 
that the number of Wt1 positive cell clusters had increased. These Day 3 clusters appeared 
to have a smaller diameter than those present at Day 0, and were not always encircled by a 
basement membrane. In the cases where a basement membrane was present it appeared 
to have decreased in thickness and regularity.  At Day 7, Wt1 positive cell clusters were also 
identified, and in most cases, were encircled by a basement membrane (Figure 28 B). There 
appeared to be more of these aggregates than at Day 3 and the positive Laminin staining 
appears to have increased in intensity whilst maintaining a proximity to the Wt1 positive 
aggregates. The organization of these structures is decreased however. These findings may 
be suggestive of the demise of incompletely disaggregated glomeruli as culture progresses 
and development of new glomerular structures.  
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Figure 28 A: Wt1/ Laminin Immunofluorescence of Kidney explant Frozen Sections 
 
 
 
 
Fig 28 A: Frozen sections from neonatal explants were immunostained for Wt1 (Red), Laminin (Green) and DAPI (Blue). 
Variations in the morphology of Wt1 and laminin positive staining structures are observed as culture progresses. Biological 
and technical repeats were conducted with the images shown being representative. Scale bar 50µm.  
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Figure 28 B: Enlarged Images of Glomeruli from Wt1/Laminin Immunofluorescence 
 
4.2.2 Pecam/Synaptopodin  
At Day 0, positive staining for the endothelial cell marker, Pecam, could be observed in the 
section; however, the Pecam positive cells appeared to be randomly dispersed throughout 
the section and were not organised into vessel-like structures (Figure 29 A). A few 
Synaptopodin positive cell clusters were also observed at this time point. By Day 3, Pecam 
positive cells appeared to be organised into vessel-like structures. Positive staining was also 
observed within clusters of Synaptopodin positive cell clusters, which was in contrast to the 
situation with Day 0 sections, where the synaptopodin positive clusters appeared to lack 
endothelial cells.  At Day 7, the staining pattern for Pecam and Synaptopodin was similar to 
that at Day 3.  The most striking difference in staining was consistently observed between 
Day 0 and Day 3 of culture (Figure 29 B). At Day 0, the Synaptopodin aggregates appear 
‘hollow’ with a distinctly different morphology to those seen at Day 3, which appear to 
contain cells staining positively for Pecam. Pecam staining also appeared to change from 
single cell staining at Day 0 to the appearance of cord like structures at Day 3. These 
findings may suggest that structures observed at day 0 are the product of incomplete 
disaggregation and the aggregates observed on day 3 and day 7 are podocytes proliferating 
ex vivo. 
 
 
 
 
Fig28B. Enlarged views of neonatal explant frozen sections immunostained for: Wt1 (Red), Laminin (Green), and DAPI (Blue). Stained 
structures from different durations of culture are presented. A: Day 0, B: Day 3, C: Day 7.  
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Figure 29 A: PECAM/Synaptopodin Immunofluorescence of Kidney Explant Frozen Sections 
Fig29 A. Frozen sections from neonatal kidney explants were immunostained for Pecam (Red), Synaptopodin (Green) and DAPI 
(Blue). At day 0 positive staining for Pecam is identified but it does not appear to be organised into discernible structures. At day 3 
and day 7 cord like structures positively staining for Pecam are readily identified. Synaptopodin positive aggregates at day 0 vary 
considerably in their morphology from day 0 compared to day 3 and day 7. Biological and technical replicates were obtained with 
these images being representative. Scale bar 50µm.  
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Figure 29 B: Enlarged Glomeruli Images from Day 0 and Day 3 Pecam/Synaptopodin 
Immunofluorescence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 29 B. Enlarged views of neonatal explant frozen sections were immunostained for: Pecam (Red) 
and Synaptopodin (Green). Stained structures from different durations of culture are presented. A: 
Day 0, B: Day 3. At day 0 a structure staining positively for synaptopodin may be identified with 
morphology differing from synaptopodin positive aggregates observed at day 3. At day 3 Pecam 
aggregates are observed in close proximity to synaptopodin staining, the architecture of which 
appears more disorganised than day 0.   
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4.2.4 Calbindin/Laminin  
The calbindin staining does not appear to change much during the time course (Figure 30). 
One notable exception to this was the staining on the ‘black 6’ strain mouse which 
produced a large lumen lined with Calbindin positive staining cells at Day 7. However this 
was not a consistent finding and was in the different ‘black6’ strain mouse; this result is 
found in the appendix.  
Figure 30: Comparison of Day 0 and Day 3 Culture of Calbindin/Laminin Immunostaining 
Fig 30. Neonatal mouse kidneys (CD1 Strain) were disaggregated, reaggregated and cultured at an air medium interface 
for: 3 hours, 3 days and 7Days. Frozen sections were stained for Calbindin (Red), Laminin (Green) and DAPI (Blue). 
Biological and technical replicates were obtained with these images being representative. Scale bar 50µm.  
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4.2.5 Relative Gene Expression in Kidney Explants 
RT qPCR was carried out on cDNA extracted from 3 biological replicates of the kidney 
explants with one biological replicate consisting of Day 0, Day 3 and Day 7 explants.  The 
housekeeping gene used was mouse-specific Tbp which has been validated in mouse 
tissues (Pernot et al., 2010). Two technical replicates were carried on each gene of interest 
in each reaction series (Figure 31). 
Whilst trends in the relative expression of the genes of interest may be discussed, 
interpretation is limited due to the large standard error of gene expression in neonatal 
kidney explants (Figure 31). When analysing the data there seem to be two possible 
explanations for this. Firstly, variation was observed between many of the technical 
replicates in each reaction. A second source of variation was observed between the 
biological replicates for each gene of interest. It is likely that a combination of these factors 
have led to the large standard errors observed. Observing Calbindin some product is 
detected on Day 0 but is undetectable by Day 7. Both Wt1 and Pecam appear to decrease 
from Day 0 to Day 7, but both transcripts are detectable at all time points.  Synaptopodin 
demonstrates a potentially interesting pattern of expression, initially decreasing from Day 0 
to Day 3 but then increasing again from Day 3 to Day 7. However, it is not possible to 
conclude anything in regard to relative expression levels over the time course due to the 
large error bars and the small sample size and it is possible that carrying out more technical 
replicates on a larger number of explants would increase the likelihood of correctly 
identifying any trends which may exist in the data.  
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Figure 31: Analysis of Relative Gene Expression in Neonatal Mouse Kidney Explants 
4.3 Bioinformatics Results 
4.3.1 Cycle Phase Specific Differentially regulated Genes: Normal Endometrium 
Using the ‘R’ statistics package, differentially regulated genes were calculated in each of the 
study cycle phase relative to the proliferative phase for the ‘Normal’ endometrium dataset. 
As the secretory phase progresses it is observed that the number of differentially regulated 
genes increases relative to the proliferative phase (Figure 32). 
 
 
 
 
 
 
 
Fig31. Relate expression of genes of interest in the neonatal kidney explant. Further statistical analysis was not performed 
due to the large standard error associated with the experiment. Wt1 and Pecam demonstrate a steady decrease in gene 
expression, Calbindin demonstrates a dramatic and sustained decline in gene expression. Pecam demonstrates an initial 
decrease at Day 3 followed by an increase in genes expression at Day 7. 
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Figure 32: Cycle Phase Specific Differentially Regulated Genes: Normal Endometrium 
 
 
 
 
 
 
 
 
 
 
4.3.2 Cycle Phase Specific Differentially Regulated Genes: Endometriosis 
Using the ‘R’ statistics package, differentially regulated genes were calculated in each of the 
study cycle phases relative to the proliferative phase for the endometriosis data set (Figure 
33). It is noted that in endometriosis the number of differentially regulated genes relative 
to the proliferative phase is substantially more in both the early and mid secretory than was 
observed in the normal endometrium. Similar to analysis of normal endometrium there is 
an increase observed as the cycle progresses. 
 
 
 
 
 
 
Fig32. Differential gene expression was calculated for different phases of the menstrual cycle compared to the proliferative 
phase after microarray analysis. The ‘R’ statistics package was used for analysis with a cut of +/- 2 log mean fold change 
considered significant. As the cycle progresses the number of differentially regulated genes increases. 
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Figure 33: Cycle Phase Specific Differentially Regulated Genes: Endometriosis 
 
 
 
 
 
 
 
 
 
 
 
4.3.3 Ingenuity Pathways Analysis Output  
Ingenuity Pathways Analysis was used to investigate differentially regulated genes from the 
Early, Mid and Late Secretory Phase of the ‘normal’ endometrial transcriptomic datasets. A 
large amount of data was generated from this analysis and the greatest challenge of this 
bioinformatics study is to focus on clinically and physiologically relevant data in order to 
draw valid conclusions. For each cellular compartment of each dataset information is 
produced on a number of relevant processes e.g. ‘Canonical pathways’. This is 
demonstrated in Table 6 using ‘Early Secretory’ phase as an example. 
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Fig33. Differential gene expression was calculated for different phases of the menstrual cycle compared to the proliferative 
phase after microarray analysis. The ‘R’ statistics package was used for analysis with a cut of +/- 2 log mean fold change 
considered significant. As the cycle progresses the number of differentially regulated genes increases, this is similar to 
endometriosis however there is an increase in the total number of differentially regulated genes. 
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Table 6: Output Data from Ingenuity Pathways Analysis 
Dataset Analysed Cellular Compartment Output Analysis 
 
 
 
 
 
 
 
 
 
Early Secretory 
Intracellular Compartment Molecular Networks 
Biofunctions 
Canonical Pathways 
Molecules  
Upstream Regulators 
Toxicology Lists 
Toxicology Functions 
Extracellular Compartment Molecular Networks 
Biofunctions 
Canonical Pathways 
Molecules  
Upstream Regulators 
Toxicology Lists 
Toxicology Functions 
Merged compartments Molecular Networks 
Biofunctions 
Canonical Pathways 
Molecules  
Upstream Regulators 
Toxicology Lists 
Toxicology Functions 
 
This output was thoroughly analysed and using background knowledge of molecules and 
pathways currently under investigation in endometrial disease with networks and specific 
molecules of interest being identified. 
4.3.4 ‘Normal’ Endometrium: Super Oxide Radicals Degradation 
Within the Mid Secretory Intracellular dataset ‘Superoxide Radicals Degradation’ was 
identified as the top enriched canonical pathway (ratio = 2/6) (Figure 34). Individual 
molecules involved in this pathway were analysed and Superoxide Dismutase 2 (SOD2) was 
identified as a gene specifically upregulated in the endometrial dataset. SOD2 is an 
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oestrogen-mediated gene thought to prevent accumulation of Reactive Oxygen Species 
(ROS) which provides an avenue for further research regarding its function in the 
endometrium during the implantation window.  
Figure 34: Top Enriched Canonical Pathways to the Mid Secretory Intracellular Dataset and 
Super Oxide Radicals Degradation Pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig34. Ingenuity Pathways Analysis for Normal Endometrium. Top Canonical Pathways output from Mid-Secretory Intracellular Datset, 
‘Superoxide Radicals Degradation’ is the top enriched pathway in this dataset. (B) Diagram of ‘Superoxide Radicals Degradation’ 
pathway 
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 4.3.5 ‘Normal’ Endometrium: Tryptophan Degradation to 2-amino-3-carboxymuconate 
Semi Aldehyde  
Tryptophan Degradation to 2-amino-3-carboxymuconate Semi Aldehyde represents the top 
canonical pathway enriched to the Late Secretory intracellular transcriptomic dataset for 
normal endometrium (ratio = 3/7) (Figure 35). Further analysis of individual enzymes in this 
pathway using STRING software (Networks, 2013) identified the Indoleamine 2,3-
dioxygenase (IDO) as being upregulated within the endometrial dataset. This gene has been 
previously identified within murine endometrium (Jeddi-Tehrani et al., 2009) and provides a 
potential further avenue in the study of normal endometrium.  
Figure 35: Top Enriched Canonical Pathways to Late Secretory Intracellular Dataset and 
Tryptophan Degradation to 2-amino-3-carboxymuconate Semi Aldehyde Pathway 
Fig35. Ingenuity Pathways Analysis for Endometriosis dataset. (A) Top Canonical Pathways output from Late-Secretory Intracellular 
Datset, ‘Tryptophan Degradation to 2-amin-3-carboxymuconate Semialdehyde is the top enriched pathway in this dataset. (B) 
Diagram of Tryptophan Degradation to 2-amin-3-carboxymuconate pathway 
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4.3.6 Endometriosis Results 
As with the normal endometrium the ‘Endometriosis’ datasets were submitted to IPA for 
analysis with a large amount of output data generated for analysis. As there were many 
more differentially regulated genes in Endometriosis, additional analysis into clusters of 
molecules was performed using Cytoscape. This analysis revealed several highly 
interconnected clusters within the differentially regulated genes, particularly in the mid-
secretory phase. The top cluster is pictured below (Figure 36) and is representative of the 
level of connectivity of these clusters containing 28 nodes and 330 edges. Another cluster 
of interest from this output contained several molecules from the Fibroblast Growth Factor 
(FGF) family: FGF9, FGF18, FGF16, FGF20, FGF7, and FGF1. 
Figure 36: Cytoscape Output Cluster from Mid-Secretory Dataset  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig36. Cytoscape output from mid secretory dataset for endometriosis microarray samples. The ‘Top Cluster’ is pictured and 
comprises 28 Nodes with 330 Edges. This highly connected cluster identifies molecules of interest for further research in an 
attempt to characterise the endometrium of endometriosis patients. 
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Chapter 5: Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
122 
 
The main aim of this study was to investigate the potential of neonatal mouse renal tissue 
to provide a suitable micro-environment to support the growth and glandular 
differentiation of human endometrial cells in vitro, the long-term goal being to investigate 
behavioural differences between normal endometrial epithelial cells, and those isolated 
from patients with endometriosis. A second aim was to investigate if endothelial cells 
within the explanted neonatal mouse kidney tissue were able to survive and generate cord-
like structures reminiscent of immature blood vessels; this is an important question 
because it is known that endothelial cells in embryo-derived kidney explants are unable to 
survive and die quite rapidly in vitro (Loughna et al., 1998). The final aim of the study was to 
use bioinformatics to investigate variation in gene expression throughout the menstrual 
cycle in eutopic normal endometrium and endometrium from patients with the 
endometriosis with the future aim of identifying potential biomarkers and drug targets. 
The main findings were that human endometrial cells displayed little or no potential to 
grow and differentiate into glandular-like structures within the environment of the mouse 
neonatal kidney in vitro, and thus, the culture system appears to be unsuitable for 
investigating the behaviour of human endometrial cells.  Interestingly, from analysis of non-
chimeric mouse neonatal kidney explants, it was found that endothelial cells within the 
tissue were able to survive in vitro, and appeared to generate primitive vessel-like 
structures. Molecular networks of interest were identified in the bioinformatics 
investigation which warrant further study, these included: ‘Super Oxide Radicals 
Degradation’, ‘Tryptophan Degradation to 2-amino-3 Semi Aldehyde’ and Wnt/β Catenin 
Pathway. 
The discussion will consider each of the 3 main topics investigated during the MPhil project 
in turn. 
5.1 Impaired Survival of Endometrial Cells 
When analysing immunofluorescence images from chimera experiments it was noted that 
the Vybrant intensity decreased throughout the 7 day time course and apart from some 
very intense spots, was barely detectable by Day 7. Analysis with a human-specific anti-
cytoplasmic antibody showed that there were still human cells remaining at day 7, but they 
appeared to be fewer in number than at day 3. It may be inferred that the more intense 
‘bright’ staining observed on Day 3 and Day 7 was actually cell debris. This is an idea backed 
up by the relative low intensity of positively co-staining cells identified on Day 7 and the 
123 
 
fact the previous work with Vybrant in endometrial cells shows that it cannot distinguish 
between live and dead cells (Defrère et al., 2006). While no quantitative analysis was 
performed on these images it would seem that there has not been an increase in 
endometrial cell number from Day 0 to Day 7 and in fact the population may have 
decreased in number. This observation also backs up the idea of the endometrial cells dying 
in the culture.  
There are several potential explanations to account for the apparent death of endometrial 
cells in culture: one possibility is that the cells were the subject of attack from the neonatal 
mouse immune system. This outcome has not been considered in previous assays using 
mouse embryonic kidney as mouse embryos do not exhibit immune activity in the same 
way as adult mice, and SCID mice are used in xenotransplantation studies. There is little 
evidence in the literature regarding the immune activity of neonatal mice though some 
have suggested it is reduced compared to adult mice (Toth, 1968). It may be reasonable to 
suggest though, that for the neonatal mice to survive in the extra-uterine environment a 
degree of immune-competency must be established. However, it is possible that many of 
the immune cells were lost from the kidney during the disaggregation process and no 
literature regarding immune activity using the current reaggregation protocol is available. 
This suggests that, while neonatal mice have not been previously used, immune attack 
remains a possible but unlikely explanation for the death of the endometrial cells in culture. 
An alternative explanation for the apparent decrease in number of the endometrial 
population is that the Vybrant cell tracking stain could cause cell death through toxicity. A 
literature search identified a previous publication using a mouse model of endometriosis 
induction which demonstrated that this method was not toxic to human endometrial cells 
(Defrère et al., 2006). This would seem to demonstrate that the Vybrant labelling was not 
responsible for cell death; however, the concentration used in the 2006 study was 8μM 
whereas the concentration used in the present study was 20μM. This is more than double 
the concentration previously used and it is possible that this could affect viability; however, 
it is also the concentration recommended by the manufacturer (Invitrogen) and no obvious 
evidence of cell death was observed in preliminary studies labeling ‘H6’ or endometrial 
cells.  
Another possibility is that the primary endometrial epithelial cells employed in this study 
were mainly differentiated cells, which do not usually survive in long term culture. There 
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are many challenges associated with the culture of primary human endometrial epithelial 
cells and relatively little is known about this population compared with the stroma despite 
the fact that it is thought to be instrumental to endometrial function. This deficiency is 
highlighted by performing a literature search for ‘Human Endometrial Epithelial Culture’ on 
the Pubmed search engine which retrieves only 94 publications compared to 1088 
publications for the term ‘Human Endometrial Cell Culture’. Within the 94 publications 
identified in this search many utilised endometrial epithelial cancer cell lines rather than 
benign primary endometrial cells, as was used in this study. Given the relative difficulty of 
studying this population in vitro, evidenced by the fact that only a few laboratories in the 
world are able to establish growth of short-term cultured primary endometrial cells, it 
would have been useful to establish a parallel model to study the survival of these cells 
after Vybrant labelling at Day 0, Day 3 and Day 7. The lack of comparison this control 
condition would have offered represents a limitation of this study. 
A fourth explanation is that this co-culture environment lacks the essential support needed 
for endometrial cell survival. As mentioned above, primary endometrial epithelial cells are 
known to be challenging to isolate and culture and it is possible that the endometrial 
population underwent apoptosis due to loss of cell-cell contact. The addition of the ROCK 
inhibitor for 24 hours to the culture was designed to prevent this (Unbekandt and Davies, 
2010) but has not been optimised for the endometrial cells and may not be sufficient to 
encourage endometrial cell survival. Apoptosis may be triggered by disruption of the 
endometrial tissue necessary to select the epithelial population removes the other 
important cell types e.g. stromal cells as well as extracellular factors such as basement 
membrane proteins which in themselves may be essential for cell survival.  Previous studies 
have documented unspecified ‘human endometrium deposits’ surviving for up to 4 weeks 
in a Heterologous mouse model (Grümmer et al., 2001), however this model used the 
peritoneum as a microenvironment and it is possible that the kidney is not conducive to 
endometrial cell survival. Interestingly the ‘human endometrial deposits’ used in this study 
were intact endometrial fragments, meaning that tissue architecture was preserved. This 
may serve to highlight the importance of cell-cell contact within the endometrial cells 
suggesting that singly dispersed cells, as used in this study, may not be the optimal culture 
condition.  
It is also possible that production of various substances by neonatal kidney cells during 
culture may produce a hostile environment for endometrial growth. Another indication that 
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this environment may not be optimal for the survival of endometrial cells is that 
endometriotic deposits are not reported in the kidney in women despite being widely 
found throughout the abdominal cavity and beyond (Impey, 2012). 
While a large proportion of the endometrial population appears to have died, a small 
number of positively co-staining cells were identified at Day 7 of culture. This finding 
indicates that some cells survived and offers another explanation for the apparent decrease 
in endometrial population. As the only selection performed was crude fractionation for the 
epithelial population and no cell sorting was performed in this experiment it is likely that 
the cells included in the chimera represented a mixed population. As it is known that ASCs 
are likely to be rare cells in the endometrium and it is possible that the terminally 
differentiated population of cells died and the surviving, small, fraction are a progenitor 
population (Snippert and Clevers, 2011).  
5.2 Invasion and Formation of Glandular Structures 
Observations of unstained chimera sections on Day 0, Day 3 and Day 7 have demonstrated 
that Vybrant positive cells appeared to migrate, eventually becoming distributed 
throughout the full thickness of this tissue after 3 days in culture. It is known that the 
culture medium used in this experiment contains a Phenol Red compound which exhibits 
some oestrogenic effects (Croxtall et al., 1990). It is possible that this migration and 
invasion seemingly demonstrated by the epithelial cells in culture is similar to the migration 
observed in vivo by the luminal epithelium in the proliferative phase of the menstrual cycle. 
While this behaviour is interesting and may demonstrate some of the properties of 
epithelial cells it does not demonstrate a high proliferation potential within the endometrial 
population.  
As well as assessment of cell survival, investigation was undertaken into the ability of the 
endometrial cells to form glandular structures in the chimera using an anti-laminin 
antibody. When assessing the Day 7 immunofluorescence images a ‘glandular structure’ 
would have been identified as a low intensity of green Vybrant staining surrounded by 
laminin immunoreactivity. It was observed that Vybrant positive cells were few and 
sparsely distributed throughout the tissue and did not seem to be associated with laminin 
positive basement membranes. Taken together with the human specific antibody studies it 
may be asserted that the endometrial cells have not demonstrated a capacity to survive 
and differentiate to form glands in the neonatal mouse kidney chimera. 
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It is interesting to note a difference in Laminin immunoreactivity when comparing the 
chimeras and the neonatal explant tissue. Structures in the day 7 chimeras positively 
staining for laminin appeared disorganised when compared with structures in the neonatal 
kidney explants at day 7.This is consistent with previous reports that introduction of a 
human cell population in a chimeric model of this type can affect nephrogenesis (Kuzma-
Kuzniarska et al., 2012). In this particular case human mesenchymal stem cells were used 
and the authors hypothesised the disruption of nephron formation may occur via secretion 
of growth factors e.g. TGF-β (Kuzma-Kuzniarska et al., 2012). This raises the possibility that 
the presence of the endometrial cells in the neonatal kidney impairs the ability of this tissue 
to form organised structures and backs up the idea that interaction is taking place between 
the two cell populations. 
An alternative explanation for the lack of proliferation observed by the endometrial cells is 
that even if the micro environment were optimal the chimera explants may be too small to 
demonstrate this. The progenitor population in the endometrium is postulated to 
constitute a rare group of cells with ASC characteristics. The chimeras contained 150000 
cells at a ratio of 1 human cell to 5 neonatal kidney cells. This means a population of 
approximately 25000 endometrial cells was present in each chimera. A combination of a 
rare progenitor population and impaired survival of the endometrial cells may have 
substantially affected proliferative potential any progenitor cells. 
5.3 Experimental Refinements and RT-qPCR Analysis 
While only a crude fractionation was performed the experiments up to this point had used 
what was primarily an epithelial population. The possibility was considered that in order to 
proliferate the epithelial cells required interaction with the stromal population. In an 
attempt to more accurately reconstitute this ‘niche’ a further experiment was performed in 
which both the epithelial and stromal fraction were cultured in the chimera. This is 
consistent with work from xenotransplantation studies which have demonstrated an 
increased proliferative potential in a mixed population of endometrial cells compared with 
a sorted population (Masuda et al., 2007). Immunofluorescence images of the mixed 
epithelial and stromal chimeras failed to demonstrate an obvious improvement in the 
capacity for cell survival and proliferative potential in the endometrial cell population. As 
progenitor cells are thought to reside within both the epithelium and the stroma this is 
unlikely to be due to a decreased concentration of progenitor cells within the endometrial 
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fraction; one explanation for these findings is experimental error. This is evidenced by the 
fact that frozen tissue sections on Day 0 appear smaller than in previous experiments on 
Day 0 even though they supposedly contain the same number of cells. There also appear to 
be fewer Vybrant staining cells in these sections. It was noted during this experiment the 
cell pellets produced were more liable to fragment resulting in incomplete transferral to 
the Millipore membrane. 
Analysis of relative expression of human and mouse Progesterone Receptor and Mucin 1 
was also performed at Day 0, Day 3 and Day 7 of culture. One factor limiting statistical 
analysis is the large quantities of missing data, particularly for the human specific genes. 
These data are missing because the exponential signal in the PCR channel did not reach the 
user defined threshold in many cases. This finding could be indicative of a small amount of 
human gene expression possibly due to a lack of viable human cells in the chimera at Day 3 
and Day 7. This being said there are trends in the data which may be worth describing, 
albeit in this limited context.  The expression of human Progesterone Receptor appears to 
decrease between Day 0 and Day 3 of culture before then increasing dramatically at Day 7. 
Progesterone receptor is known to be a marker of more differentiated cells in the 
endometrium (Jabbour et al., 2006). It is possible then that between Day 0 and Day 3 of 
culture there is widespread death of the more differentiated human cell populations within 
the culture leaving only the more undifferentiated populations remaining e.g. ASCs. As the 
culture progresses from Day 3 to Day 7 these cells become more differentiated and start 
expressing progesterone receptor. It has previously been documented that 
Phenolsulfanphthalein, which is present in DMEM F12 culture medium has an oestrogenic 
action which in this case might serve as the differentiation stimulus (Sigma Aldrich) (Croxtall 
et al., 1990). Mouse progesterone receptor demonstrates a sustained downregulation from 
Day 0 of culture indicating that the endometrial cells have not induced expression of this 
marker in the mouse progenitor population, a finding which contradicts previous work from 
the University of Liverpool studying endometrial cells in a mouse embryo chimera (Simic, 
2010). What is interesting is that there appears to be some expression on Day 0 in the 
mouse, given the small amount of data this can actually be attributed to a single result and 
as such experimental error cannot be ruled out in generating this trend. 
Human Mucin 1 demonstrated an initial upregulation at Day 3 followed by substantial 
downregulation at Day 7.  Muc1 was originally proposed as a marker of implantation in the 
human endometrium and when implantation occurs cell-cell contact mechanisms stimulate 
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the downregulation of Muc1 from luminal epithelium. It could be argued that these same 
cell-cell signalling mechanisms are the reason down regulation can be observed in the 
chimeras at Day 7. Mucin1 is also a progesterone mediated gene and the lack of 
progesterone in the culture medium may also have contributed to its downregulation; 
however these hypotheses would not explain the initial upregulation at Day 3 (Aplin, 2006). 
Mouse MUC1 demonstrates a sustained downregulation from Day 0 and it is also possible 
that cell-cell contact mechanisms are responsible for this. 
5.4 Neonatal Kidney Explant 
Investigation of the immunofluorescence images generated from the neonatal explant 
experiments produced interesting observations. Several trends of gene expression can be 
observed in the RT-qPCR analysis; however the large standard error of the samples means 
that statistical analysis was not possible, limiting the interpretation of these findings. 
 The RT-qPCR data was investigated in order to find the source of the large standard error 
and two possible explanations identified. Firstly variation is observed between technical 
replicates and as only 2 were performed per gene in each PCR series increasing this number 
would allow the gene expression within each biological replicate to be more accurately 
assessed. Another source of standard error is the observed variation between the biological 
replicates. As the standard error is calculated based on the number of biological replicates, 
in this case 3, an increase of this number would increase accuracy of findings. There are 
also experimental factors that could explain the variation between these replicates. As each 
replicate is cultured separately it is possible that slight and unavoidable variations in the 
experimental procedure, e.g. variation in culture medium change intervals, will affect gene 
expression. Another potential source of error relates to the size of the explants; while 
150000 cells were included there was difficulty associated with transferring the explants 
from the micro test tube to the section of Millipore filter. This resulted in some explants 
fragmenting and being incompletely transferred which may have affected gene expression.   
Wt1/Laminin staining appeared to demonstrate an increase in the number of Wt1 positive 
cells which may be an indication that active nephrogenesis was occurring in the tissue. In 
the Day 0 sections few sparse glomeruli were visualised with morphology different to those 
seen on Day 3 and Day 7. It is suggested that these structures represent intact glomeruli 
present due to impartial disaggregation which may die as the culture progresses, to be 
replaced by ‘new’ developing glomeruli. This would be expected from a tissue such as the 
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rodent neonatal kidney which still has nephrogenic potential (Dickinson et al., 2005). This 
finding was not backed up by RT-qPCR findings though which demonstrated a steady 
decrease in Wt1 expression throughout the culture, although some expression was still 
present at Day 7. However, the differences in Wt1 expression levels were not statistically 
significant. 
Calbindin and Laminin staining was included in the analysis as a marker of ureteric bud. 
Immunofluorescence did not demonstrate a discernible trend in expression of Calbindin.  
RT-qPCR demonstrates a substantial and sustained downregulation of Calbindin. One 
explanation for this downregulation could be that, as Calbindin is a ureteric bud marker 
‘used up’ by nephrogenesis, the decreasing quantity of ureteric bud and consequently 
Calbindin expression would be expected of a nephrogenic culture (Gilbert, 2010). 
One of the key aims of the investigation of neonatal mouse kidney explants was to identify 
if endothelial cells were able to survive and if so, whether they could be found in close 
proximity to podocytes such that a double layered glomerular basement membrane might 
be formed in vitro. The markers selected for this analysis were Pecam and Synaptopodin. 
Analysis of immunofluorescence revealed that Pecam staining could be observed on Day 7 
of culture and gene expression was detected on Day 7 using RT-qPCR. These findings 
suggest that a proportion of the endothelial population have survived in culture. The 
pattern of Pecam expression was also analysed with a change noted from Day 0 to Day 3 
suggestive of re-organisation of the endothelial cells. At Day 0 positive staining is observed 
but it is confined to single cells whereas at Day 3 ‘cord like’ structures were consistently 
observed, possibly representing the formation of capillaries. Additionally, positive Pecam 
staining was identified in close proximity to Synaptopodin positive cell aggregates. This is an 
interesting observation because it is known that endothelial cells within embryonic kidneys 
die shortly following explantation (Loughna et al., 1998). 
There are a number of possible explanations for the survival of this population. Previous 
studies where the fate of endothelial cells in explant culture has been investigated have not 
used the disaggregation-reaggregation method employed in this study (Loughna et al., 
1998) and it is possible that this factor contributed to survival of this population. It is also 
possible that cells in the neonatal kidney are more terminally differentiated than in the 
embryo which would increase the likelihood of the endothelial cells surviving in the explant 
environment. A third possibility is that endothelial cells in the neonatal kidney have a 
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different origin to endothelial cells in the embryo. The origin of glomerular endothelial cells 
has been extensively investigated and the relative contribution of endogenous cells and 
those migrating from the vasculature is currently unclear (Abrahamson, 2009). If the 
endothelial population differs in its origin at these time points it may affect the likelihood of 
this population surviving in explant culture.    
As was identified in the Wt1/Laminin stained sections, few structures resembling glomeruli 
were identified at Day 0 with an increase in Synaptopodin positive cell aggregates 
resembling immature glomeruli at Day 3. The change in morphology observed suggests that 
the structures at Day 0 are the result of incomplete disaggregation and actually decompose 
before progenitor cells give rise to the new structures. An interesting observation that can 
be made with the Synaptopodin staining is that these ‘glomeruli’ appear to be hollow 
structures at Day 0 but by Day 3 cells staining positive for Pecam can be identified, a finding 
suggestive of nephrogenesis. These findings are not corroborated by RT-qPCR investigation 
however; the relative PECAM gene expression, even with the large standard error, suggests 
that there is downward trend in expression levels by Day 7. Some gene expression is still 
detected however indicating that while proliferation may not be occurring the endothelial 
population has survived in culture.  The trend in synaptopodin expression indicates an 
initial downregulation, possibly due to the disaggregation process, followed by upregulation 
which may indicate that this population is proliferating and that some nephrogenesis is 
occurring. However this value has the largest standard error and is not statistically 
significant. 
When combined the analysis of the neonatal kidney explants provides conflicting evidence 
with regards to nephrogenesis occurring in the culture. The immunofluorescence from 
WT1/Laminin and PECAM/Synaptopodin staining would seem to suggest this process is 
occurring but this is not backed up by RT-qPCR. Immunofluorescence findings relating to 
Calbindin/Laminin do not demonstrate a discernible trend however RT-qPCR demonstrates 
a sustained downregulation. Analysis of PECAM/Synaptopodin seems to indicate that 
endothelial cells have survived in culture and that these cells are in close proximity with 
podocytes. 
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5.5 Bioinformatics 
This bioinformatics study analysed the most suitable datasets available from microarray 
experiments of normal eutopic endometrium and eutopic endometrium from patients with 
endometriosis.  The defined selection criteria were as explicit and exclusive as possible in 
order to fully consider the multiple pitfalls in the large number of existing published 
datasets.  
Preliminary analysis of the selected datasets has revealed some interesting findings. When 
identifying differentially regulated genes it was noted that the number of genes increased 
as the cycle progressed both in the ‘Normal’ endometrium and patients with 
endometriosis. This is plausible as different stages of the secretory phase are known to be 
associated with different cellular functions and processes (Talbi et al., 2006). For example, 
the main function of the human endometrium is to accept an embryo for implantation and 
facilitate further progression of pregnancy. This being the case, the endometrium does not 
allow implantation of the best quality embryo except for a few days in the mid secretory 
phase of the cycle (Talbi et al., 2006). The changing cellular processes responsible for this 
function in normal endometrium are of interest as well as in endometriosis where many 
authors have reported aberrations in the expression of a variety of proteins, genes and 
resulting abnormal cellular functions (Aghajanova and Giudice, 2011, Burney et al., 2007). 
In keeping with those reports, it was also noted that the number of differentially regulated 
genes in endometriosis relative to the control was substantially more than in normal 
endometrium, an almost tenfold increase. This may reflect the different cellular processes 
involved in endometriosis.   Given that this study was performed on eutopic endometrium, 
this finding is consistent with the clinical finding of associated infertility with endometriosis 
thought to be due to the prevention of embryo-implantation. It also supports the 
retrograde menstruation theory, as an abnormal eutopic endometrium that is shed and 
deposited in the pelvic cavity could have an increased propensity to establish lesions. 
In analysis of the ‘Normal’ endometrium two pathways of interest were identified as being 
significantly upregulated in their respective phases and compartments. Super Oxide 
Radicals Dismutase identified and closer investigation identified the enzyme SOD2, a 
component of this pathway significantly upregulated in the dataset. SOD2 is thought to 
prevent the accumulation of intracellular Reactive Oxygen Species (ROS), a product of 
normal cellular metabolism (Bürkle, 2002).  When ROS are allowed to accumulate they can 
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result in DNA damage and mutations. Cells have several mechanisms to prevent this 
accumulation and interestingly one of the well described mechanisms, Telomerase action, 
is thought to be downregulated in the mid secretory phase endometrium (Williams et al., 
2001). The mid secretory phase represents the implantation window, a time when 
mutations would be extremely unfavourable as if an embryo were to implant a great deal 
of cellular proliferation would take place. If telomerase is downregulated then a 
compensatory mechanism would be expected and SOD2 represents an interesting 
candidate.  
The second pathway of interest was ‘Tryptophan Degradation to2-amino-3-
carboxymuconate Semi Aldehyde. Within this pathway the enzyme IDO was significantly 
upregulated within the dataset. IDO has been previously studied within murine 
endometrium (Jeddi-Tehrani et al., 2009) and is important in tolerance of self, fetal and 
tumour antigens.  It is logical that this gene should be upregulated in the secretory phase as 
this is a time when implantation may occur and tolerance of foreign antigens is important. 
The regulation of ‘self tolerance’ is interesting in relation to autoimmune disease and it is 
thought that one reason behind the higher prevalence of these diseases in females is due to 
the altered immune environment associated with pregnancy in which the maternal host 
must prevent rejection of the fetal ‘allograft’. 
In addition to these two ‘Top Canonical Pathways’ The Wnt/Beta Catenin pathway was 
noted to be upregulated in both the mid and late secretory ‘whole’ datasets. The Wnt/Beta 
Catenin pathway, when activated, is associated with cellular proliferation and the 
maintenance of an undifferentiated state (Valentijn et al., 2013). Activation of the Wnt 
pathway results in stabilisation of the Beta Catenin complex with localisation to the cell 
nucleus resulting in the activation of a group of downstream proteins. This pathway has 
been well characterised in intestinal epithelium (Fevr et al., 2007) and recently work has 
been commenced in the endometrium (Valentijn et al., 2013, Nguyen et al., 2012). An 
intact Wnt pathway has recently been demonstrated in pre- as well as post-menopausal 
endometrium and given that the postmenopausal maintains proliferative potential, the 
conservation of this pathways suggests that it may have a role in the regenerative capacity 
of the endometrium (Nguyen et al., 2012).  Investigation is ongoing and work at the 
Liverpool Womens Hospital aims to characterise some of the downstream proteins of this 
pathway in the endometrium with one notable example being SOX9 (Valentijn et al., 2013). 
As endometriosis is a proliferative disease it is likely that the Wnt/Beta Catenin pathway is 
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involved in some way in its pathogenesis. It will be interesting then to perform further 
analysis on both the ‘Normal’ and ‘Endometriosis’ transcriptomic datasets as this has the 
potential to identify Wnt related molecules which may be differentially regulated between 
the two. Preliminary identification using this in silico approach may then provide the basis 
for further ‘wet’ laboratory investigation.  
5.6 Bioinformatics: Endometriosis 
Analysis of transcriptomic datasets from the eutopic endometrium of patients with 
endometriosis yielded a greatly increased number of differentially regulated genes 
compared with normal endometrium such that analysis could be performed using 
Cytoscape. Cytoscape is a software platform for visualizing molecular interaction networks 
and biological pathways. These networks are then integrated with annotations, gene 
expression profiles and other state data (Cytoscape, 2013). This program was used in this 
study in the context of investigating pathways within the Heparan Sulfate Interactome. 
Several highly interconnected network clusters of interest were identified within the 
dataset, one example is pictured in Fig33 with 28 nodes and 330 edges. One of these 
clusters contained several molecules belonging to the group ‘Fibroblast Growth Factors’ 
(FGFs). These molecules are associated with a wide variety of cellular processes including 
angiogenesis, wound healing and embryonic development (Goetz and Mohammadi, 2013) 
and are the subject of active investigation within the endometrium. In humans there are 22 
described members of the FGF family (Ornitz and Itoh, 2001) and investigation into FGF 
function in the endometrium has been performed, e.g. basic FGF has been linked to the 
growth of stromal Colony Forming Units (CFU) (Gargett et al., 2008). Full characterisation of 
FGFs and FGF receptors has not yet been performed in the endometrium and represents an 
interesting potential for future investigation. 
One particular area the FGFs have been considered in is embryo implantation, a process 
that is impaired in endometriosis (Sak et al., 2013). While FGF-1 was identified upregulated 
in this dataset it has previously been demonstrated downregulated in endometriosis (Sak et 
al., 2013). A previous study using PCR has also shown no difference in the expression of 
FGF2 in eutopic endometrium of patients with endometriosis and controls (Lee et al., 
2007).  
Clearly angiogenesis is an interesting process in endometriosis as it is aberrantly thought to 
be involved in lesion establishment. The identification of this highly interconnected cluster 
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provides an interesting avenue for further investigation of FGFs in the endometrium. One 
possible example would be to look at angiogenesis processes known to be associated with 
these FGFs and use immunohistochemistry to compare expression between women with 
and without endometriosis. It would also be useful to characterise FGF receptor expression 
within the endometrium using either immunohistochemistry or other methods such as 
Fluorescence in Situ Hybridisation (FISH). As many of the processes associated with FGFs 
are dysregulated in endometriosis it would also be interesting to investigate the expression 
both of FGFs and FGF receptors in ectopic endometriotic lesions. 
5.7 Limitations of the Study 
There are several limitations of this study outlined throughout the discussion section.  The 
PCR analysis is limited by missing data and variation observed between both technical and 
biological replicates in the kidney explant analysis. As a result of this, statistical analysis on 
both the chimera and neonatal kidney explant RT-qPCR data was not possible which 
severely restricts interpretation of these findings. Further biological replicates for both the 
chimeras and neonatal explants would have been carried out but were limited by the 
availability of neonatal kidneys. As these specimens need to be 2-3 days of age, the window 
for preparing the endometrial cultures was relatively short and on several occasions the 
kidneys were not able to be obtained due to either pseudo pregnancy or infanticide.  
One factor limiting the analysis of the chimeras was a lack of a control culture of 
endometrial epithelial cells labelled with the Vybrant fluorescent dye. This would have been 
useful in assessing the viability of the endometrial cells in culture after labelling, as it is 
currently not clear which factor causes the apparent decrease in cell number. A second 
benefit that would have been gained from this control would be immunofluorescence 
staining using the anti-laminin antibody used in the study. This would definitively establish 
whether the endometrial cells were producing Laminin structures or whether those 
structures observed originated entirely from the neonatal mouse kidney tissue. 
When preparing the endometrial epithelial cells for inclusion in the chimera a 2D culture 
method was used. There are documented limitations of this approach as the 2D 
environment does not represent the in vivo conditions, particularly for epithelial cells which 
are known to act in a more physiologically relevant manner when cultured in 3D spheroid 
culture (Valentijn et al., 2013). It is possible however that culturing the cells in spheroids 
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with Matrigel before disaggregation and inclusion into the chimera may have placed too 
much stress upon the cells resulting in a change of morphology.  
A limitation of the chimera experiment including both epithelial and stromal cells was the 
poor viability of Day 7 chimeras such that analysis was not able to be completed using 
immunofluorescence. This is likely to be due to experimental error as difficulty was 
experienced transferring these particular chimeras to the Millipore membrane as they 
exhibited an increased propensity to fragment meaning that not all tissue was transferred 
to the membrane.  
In the bioinformatics analysis of endometrium from patients with endometriosis it would 
have been useful to analyse samples from the Late Secretory Phase. The absence of these 
samples limits the interpretation of the data however a comprehensive literature search 
was carried out and Late Secretory phase transcriptomic datasets obtained on a 
comparably microarray platform could not be identified. The absence of this data in the 
literature suggests that this limitation could not be accounted for by the investigators.  
5.8 Further Work 
Given the paucity of statistically significant findings in this study there is considerable 
potential for further work. Refinements could be made to the kidney chimera model to 
improve study of the human cell population. Vybrant staining could be optimised to 
improve visualisation of the cells as high intensity staining presented difficulty in image 
interpretation. Further investigation into the fate of the endometrial cells in the chimera 
could be performed by immunostaining for either markers of cell death e.g. Caspases or 
mouse specific leukocyte markers to attempt to identify if an immune response was 
occurring. If a neonatal mouse immune response were identified then further 
experimentation could include a chimera culture using neonatal kidney obtained from SCID 
mice as this would allow endometrial cell survival. 
Refinements could be made to the chimera model of endometriosis by considering the 
culture medium used. It is known that the angiogenic activity of endometrial cells is 
increased if cultured in peritoneal fluid of women with endometriosis (Oosterlynck et al., 
1993). It is possible then that this aspect of the microenvironment might be important in 
the cells proliferative potential. The model could be refined to include conditioned medium 
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from primary culture of endometrial cells from patients with endometriosis; however 
immune aspects would have to be considered and possibly embryos or SCID mice used. 
While the findings from the chimera experiment seem to indicate a limited use for this 
model in the investigation of endometriosis one avenue for further work may be 
considered. Previous models have investigated the attachment of endometrial cells in the 
process of lesion formation and have demonstrated the in both epithelial and stromal 
populations attachment occurs within 1 hour with invasion a similarly quick process 
completed within 24 hours (Witz et al., 2001). This is consistent with the findings of this 
study which found endometrial cells throughout the full thickness of the chimera by day 3 
of culture. Further characterisation of this model could be undertaken investigating these 
processes at time points within the first 24 hours of culture which may yield some findings 
before a large increase in the endometrial population occurs.  
Analysis of neonatal kidney explants seemed to demonstrate the formation of glomerular 
structures on culture. To elucidate with greater accuracy the processes occurring, an 
increased number of biological and technical repeats would be useful in RT-qPCR analysis 
and quantitation of immunofluorescence images could be performed. As it is hypothesised 
that cell populations capable of forming mature glomerular basement membrane are 
surviving in culture, one further experiment would be to attempt to characterise these 
structures using both immunofluorescence and RT-qPCR for markers of mature GBM e.g. 
Laminin 5II and Type IV collagen (Takemoto et al., 2006).  
When investigating the survival of endothelial cells in the culture one explanation is that 
the disaggregation-reaggregation protocol could be responsible for their survival, as 
previous investigation into this cell population in explant culture did not use this method  
(Loughna et al., 1998). A useful further investigation would be to compare endothelial cell 
survival in explants generated from embryonic kidneys with those from neonatal kidneys in 
order to help establish whether the neonatal environment in some way responsible for the 
survival of this population.  
In this preliminary in silico analysis normal endometrium and endometrium from patients 
with endometriosis has been investigated. The next step in this work would be to combine 
these analyses, overlaying pathways of interest, in order to find upstream mediators which 
may be in some way responsible for the aberrant proliferation seen in endometriosis and 
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which could be targeted for wet laboratory investigation and eventually clinical 
intervention. 
In analysis of ‘Normal Endometrium’ the canonical pathway ‘Superoxide Radicals 
Degradation’ was upregulated within which ‘SOD2’ was identified as a molecule of interest.  
A ‘wet’ laboratory experiment may be designed to investigate the role of SOD2 in 
preventing ROS accumulation in secretory phase endometrium. Tissue samples from ‘SPCN’ 
patients gathered at the Liverpool Womens Hospital could be immunostained for SOD2 and 
ROS to assess correlation of these two molecules. Telomerase could also be stained for and 
quantitative analysis may help to demonstrate a potential correlation. 
In analysis of endometrium from patients with endometriosis transcriptomic datasets from 
comparable microarray platforms were not obtained for the Late Secretory Phase 
endometrium. This represents a deficiency in the literature and one possible further 
investigation would be to perform a microarray experiment on a Late Secretory phase 
endometrial sample from a patient with endometriosis fulfilling the inclusion/exclusion 
criteria outlined in the ‘Methods’ section. Obtaining this data would allow further 
investigation into the cellular and molecular mechanisms associated with this proliferative 
disease.  
Endometriosis can be considered a benign disease showing metastatic behaviour as the 
eutopic endometrium spreads to distant sites (Impey, 2012). To investigate this further 
transcriptomic datasets from microarray experiments may be analysed to identify common 
molecular pathways between patients with endometriosis and patients with endometrial 
cancer. A literature search has already been carried out and a suitable dataset identified. 
Early limiting factors have been identified in this analysis as cancer samples are almost 
always collected from post-menopausal patients and as such cannot be separated 
according to menstrual cycle phase. This introduces a large confounding factor into any 
analysis. One possible way around this would be to compare both cancer and 
endometriosis datasets to a post menopausal dataset used as a control. 
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5.9 Conclusions 
It is difficult to make final and solid conclusions from this study and a large amount of 
further work is required to confirm the preliminary findings outlined. However when 
analysing the endometrial cell activity in the neonatal mouse kidney chimeras it can be 
asserted that the cells did not proliferate or form glandular structures in culture and it is 
likely that widespread cell death occurred. Possible explanations for this include: a hostile 
niche provided by the neonatal kidney, Vybrant toxicity, cell death due to lack of cell-cell 
contact, apoptosis of more terminally differentiated cells leaving the progenitor population 
and immune attack by resident murine leucocytes. The analysis does seem to indicate that 
some endometrial cells survived and this was combined with an increase in progesterone 
receptor expression at Day 7, suggesting that these were the less well differentiated cells, 
possibly an ASC or TA population. When considering the neonatal kidney explant study 
examination of immunofluorescence images seems to indicate that a degree of 
nephrogenesis took place in the neonatal kidney explants, although RT-qPCR findings to not 
corroborate this. It appeared that a population of endothelial cells had survived to Day 7 of 
neonatal kidney explant culture and were in close proximity to podocytes, a finding which 
warrants further investigation. The bioinformatics approach to the endometrium and 
endometriosis has yielded several interesting results and leads for potential for future ‘Wet’ 
laboratory investigation. This approach to hypothesis generation is becoming more 
widespread and represents an exciting prospect for the future.  
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6.3 Patient Consent Form 
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6.4 Patient Clinical Data Collection Form 
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6.5 Patient Demographic Information 
 
Sample 
ID 
Sample 
Type 
Patient 
Age 
Patient 
BMI 
Reason for 
Surgery 
Endometriosis Cycle phase 
 
Additional 
information 
SPCN125 Full 
Thickness 
47 32.6 Pelvic Pain No Day 4 – 
Proliferative 
 
SNCN128 Full 
Thickness 
47 23.3 Prolapse No Day – 
Proliferative 
 
SPCEX118 Full 
Thickness 
42 34.8 Menorrhagia No Unknown Provera 
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6.6 Additional Immunofluorescence Images 
 
Figure 37: CD1 Chimera: Anti Cytoplasmic Staining Repeat 1 
 
Figure 38: CD1 Chimera: Laminin Staining Repeat 
 
 
 
 
 
 
 
Fig37. Human endometrial epithelial cells were labelled with ‘Vybrant’ fluorescence (Green) and cultured for 2 hours, 3 days 
and 7 days in a chimeric explant generated with the Disaggregation-Reaggregation technique developed by Davies et al with 
CD1 neonatal mouse kidneys. Frozen sections were stained with human specific anti-cytoplasmic antibody (Red) and DAPI 
(Blue). A. 2 hours (0 days) of culture. B. 3 Days of Culture. C. 7 Days of Culture. Scale bar 50μl 
Fig38. Human endometrial epithelial cells were labelled with ‘Vybrant’ fluorescence (Green) and cultured for 2 hours (Day 0), 
3 days and 7 days in a chimeric explant using the Disaggregation-Reaggregation technique developed by Davies et al with CD1 
neonatal mouse kidneys. Frozen sections were stained for Laminin (Red) DAPI (Blue) at these specific time points.  . A. Day 0, 
B. Day 3. Scale Bar 50μm 
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Figure 39: CD1 WT1 Laminin Repeat 1 
 
 
 
 
 
 
Figure 40: CD1 WT1 Laminin Repeat 2 
 
 
 
 
 
 
Figure 41: Black 6 WT1 Laminin Repeat 1 
 
Fig39. Immunofluorescence stain of neonatal explant cultured from CD1 Strain mice after disaggregation and reaggregation using the 
technique developed by Davies et al. Explants were stained with WT1 (Red), Laminin (Green) and the nuclear stain DAPI (Blue). A 
Sample fixed after 2 hours of culture (Day 0. B Day 3. C Day 7. Scale bar 50µm 
 
Fig40. Immunofluorescence stain of neonatal explant cultured from CD1 Strain mice after disaggregation and reaggregation using the 
technique developed by Davies et al. Explants were stained with WT1 (Red), Laminin (Green) and the nuclear stain DAPI (Blue).. A 
Sample fixed after 2 hours of culture (Day 0). B Day 3. C Day 7. Scale bar 50µm 
 
Fig41. Immunofluorescence stain of neonatal explant cultured from Black 6 Strain mice after disaggregation and reaggregation using 
the technique developed by Davies et al. Explants were stained with WT1 (Red), Laminin (Green) and the nuclear stain DAPI (Blue).. A 
Sample fixed after 2 hours of culture (Day 0. B Day 3. C Day 7. Scale bar 50µm 
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Figure 42: CD1 PECAM Synaptopodin Repeat 1 
 
Figure 43: CD1 PECAM Synaptopodin Repeat 2 
 
Figure 44: CD1 PECAM Synaptopodin Repeat 3 
 Fig42. Immunofluorescence stain of neonatal explant cultured from CD1 Strain mice after disaggregation and reaggregation using the 
technique developed by Davies et al. Explants were stained with PECAM (Red), Synaptopodin (Green) and the nuclear stain DAPI 
(Blue). A Sample fixed after 2 hours of culture (Day 0. B Day 3. C Day 7. Scale bar 50µm 
 
Fig43. Immunofluorescence stain of neonatal explant cultured from CD1 Strain mice after disaggregation and reaggregation using the 
technique developed by Davies et al. Explants were stained with PECAM (Red), Synaptopodin (Green) and the nuclear stain DAPI 
(Blue).. A Sample fixed after 2 hours of culture (Day 0. B Day 3. C Day 7. Scale bar 50µm 
Fig44. Immunofluorescence stain of neonatal explant cultured from CD1 Strain mice after disaggregation and reaggregation using the 
technique developed by Davies et al. Explants were stained with PECAM (Red), Synaptopodin (Green) and the nuclear stain DAPI 
(Blue).. A Sample fixed after 2 hours of culture (Day 0. B Day 3. C Day 7. Scale bar 50µm 
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Figure 45: CD1 Calbindin Laminin Repeat 1 
Figure 46: CD1 Calbindin Laminin Repeat 2 
 
Figure 47: Black 6 Calbindin Laminin Repeat 1 
Fig 45. Immunofluorescence stain of neonatal explant cultured from CD1 Strain mice after disaggregation and reaggregation using the 
technique developed by Davies et al. Explants were stained with Calbindin (Red), Laminin (Green) and the nuclear stain DAPI (Blue). A 
Sample fixed after 2 hours of culture Day 0. B Day 3. C Day 7. Scale bar 50µm 
 
Fig46. Immunofluorescence stain of neonatal explant cultured from CD1 Strain mice after disaggregation and reaggregation using the 
technique developed by Davies et al. Explants were stained with Calbindin (Red), Laminin (Green) and the nuclear stain DAPI (Blue).. A 
Sample fixed after 2 hours of culture (Day 0. B Day 3. C Day 7. Scale bar 50µm 
 
Fig47. Immunofluorescence stain of neonatal explant cultured from Black6 Strain mice after disaggregation and reaggregation using 
the technique developed by Davies et al. Explants were stained with Calbindin (Red), Laminin (Green) and the nuclear stain DAPI 
(Blue).. A Sample fixed after 2 hours of culture (Day 0. B Day 3. C Day 7. Scale bar 50µm 
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Figure 48: Black 6 Calbindin Laminin Repeat 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig48. Immunofluorescence stain of neonatal explant cultured from Black6 Strain mice after disaggregation and reaggregation using 
the technique developed by Davies et al. Explants were stained with Calbindin (Red), Laminin (Green) and the nuclear stain DAPI 
(Blue).. A Sample fixed after 2 hours of culture (Day 0. B Day 3. C Day 7. Scale bar 50µm 
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6.7 Reagent Formulations 
Sample Collection Medium: 
 Dulbecco’s Modified Eagle Medium (DMEM) (Sigma Aldrich) 
 1% Fetal Bovine Serum (FBS) (Gibco) 
 Primocin 1:500 Dilution in Medium (Invitrogen) 
Endometrial Culturing Medium: 
 500 ml DMEM F12 Ham (Sigma Aldrich)       
 10 ml L-glutamine 2mM (Gibco)        
 1 ml Primocin        
 50 ml FBS  
 50 µl recombinant human EGF 10ng/ml (Sigma Aldrich) 
Kidney Culture Medium 
 10% DMEM FBS 
 L-Glutamine (2mM; 1:100)  
 Penicillin Streptomycin (1:100) (Sigma Aldrich) 
Gelatine Sucrose Solution 
 15g Sucrose, Reagent Grade (Sigma Aldrich) 
 7.5g Gelatine from Porcine Skin Type A (Sigma Aldrich) 
 Made up to 100ml with PBS  
Tris-Acetate EDTA (TAE) 
 Tris (2M) 
 EDTA (0.05M) 
 Acetic Acid to pH 7.8 
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6.8 Reagent Specifications 
Reagents Company City Country       Catalogue number 
Acetic Acid AnalaR UN175121 
Agarose Bioline, London, UK BIO-41025 
5x FS Buffer  Invitrogen, Paisley, UK Y02321 
5xDNA Loading Buffer  Bioline BIO-37045 
Bright Cryo-M-Bed Bright Instrument Company 
Limited 
N.A. 
Chloroform Sigma Aldrich, Dorset, UK 101146896 
Collagenase Invitrogen, Paisley, UK 17104-019 
Collagenase Sigma Aldrich, Dorset, UK 1001375121 
DAPI Sigma Aldrich, Dorset, UK D9542-10mg 
Dako Fluorescent Mounting 
Medium 
Dako North America, 
Carpinteria USA 
S3023 
Dispase Gibco 17104-041 
DNase Roche, Germany 
 
11284932001 
DNase1 from bovine 
Pancreas  
Sigma Aldrich, Dorset, UK D4263-IVL CAS 9003-98-9 
DNase Reaction Buffer  Promega M198A 
DNase Stop Solution  Promega M199A 
dNTP Invitrogen  Carlsbad Ca 10297-018 
DTT  Invitrogen, Paisley, UK Y00147 
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Dulbecco’s Modified Eagle 
Medium (DMEM)  
Sigma Aldrich, Dorset, UK D5546 
Dulbecco’s Modified Eagle 
Medium (DMEM)HAM F12 
Sigma Aldrich, Dorset, UK D6421 
EDTA Sigma-Aldrich, Dorset, UK 
 
E-5134 
Ethidium Bromide Molecular Sigma Biology, 
Dorset, UK 
 
E-7637 
Ethanol Sigma-Aldrich, Dorset, UK E7023 
Fast Red TR  Sigma Aldrich, Dorset, UK F8764-1G 
Fetal Bovine Serum  Gibco 10270-098 
Gelatine from Porcine Skin 
Type A  
Sigma Aldrich, Dorset, UK G1890-500G 
Goat Serum  Sigma Aldrich, Dorset, UK 1001390834 
Hanks Balanced Salt Solution Sigma Aldrich, Dorset, UK H9269 
Hyperladder IV  Abcam 50472 
Isopropanol  Sigma Aldrich, Dorset, UK I9516 
L-Glutamine Gibco 35050-038 
Methanol Sigma Aldrich, Dorset, UK M-3641 
MgCl2 BDH, Leicestershire, UK  
Minimum Essential Medium 
Eagle (MEME) 
Sigma Aldrich, Dorset, UK M5650  
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Napthol AS-MX phosphate  Sigma Aldrich, Dorset, UK N4875-500MG 
Neutral Buffered Formalin Sigma-Aldrich, Dorset, UK HT501320-95L 
Nuclease Free Water Fisher Bioreagents,  BP2470-1 
Penicillin, Streptomycin Sigma Aldrich, Dorset, UK P0781 SLBB9307 
Phosphate Buffered Saline  Sigma Aldrich, Dorset, UK D8537 
Phosphate Buffered Saline  
(Ca2+ free) 
Sigma Aldrich, Dorset, UK D8537 
Primocin Invitrogen, Paisley, UK P4417-100TA 
Random Hexamers  Qiagen, West Sussex, UK 79236 
Recombinant human EGF Sigma Aldrich, Dorset, UK  
RNALater Applied Biosystems, 
Warrington, UK 
 
79236 
RNase Free DNase  Promega M610A 
ROCK Inhibitor  Calbiochem  688001 
Sucrose, reagent grade 98%  Sigma Aldrich, Dorset, UK 179949 
Superstript III Reverse 
Transcriptase  
Invitrogen, Paisley, UK 56574 
SYBR Green Jumpstart Taq  Sigma Aldrich, Dorset, UK 1001469234 
Tris Gibco 15504-020 
Trizol Invitrogen, Paisley, UK 15596-026 
Trypan Blue Sigma Aldrich, Dorset, UK T8154 
Trypsin EDTA 1X Solution Sigma Aldrich, Dorset, UK T3924 
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Virkon Antec International  
Vybrant CFDA SE Cell Tracer 
Kit  
Invitrogen, Paisley, UK V12883 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
168 
 
6.9 Equipment Specifications         
Equipment Company, City Catalogue Number 
40µm Cell strainer   
Electrophoresis Chamber Consort  EV231 
Centrifuge 4K15 Sigma Aldrich, Dorset, UK  
GENE FLASH Syngene Bioprinting  
Hydrophobic Marker  ImmEdge H-4000 
Microtome Microm HM 505N 
Millipore Isopore Membrane 
Filters  
Millipore RTTP02500 
Pellet Pestle, disposable  Sigma Aldrich, Dorset, UK 2359971-1EA MW07345 
Scalpel Blades (Sterile)  Swann Morton N.A. 
Thermo Scientific Glaser Plus   Menzel Superfrost J1800AMNZ 
Electrophoresis Casette SCIE-PLAS HV10 
Hand-held homogenisor 
 
Qiagen, West Sussex, UK 
 
9001272 
Nanodrop 
Spectrophotometer 
 Thermoscientific Nanodrop 
Lite 
Weighing Scales Acculab VICON  
Thermal Cycler Applied Biosciences 2720 
Automated Cell Counter Biorad TC20 
Fluorescent Microscope Leica DM2500 
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6.10 Concentration of RNA Samples Used in Study 
Sample 
ID 
Type Concentration 
(ng/µl) 
Factor A260 
(10 
mm) 
A280 
(10 
mm) 
A3rd 
(10 
mm) 
A260/A280 
K0 (1) RNA 1157.6 40 28.941 16.011 0.018 1.81 
K3 (1) RNA 152.5 40 3.812 2.009 0.006 1.9 
K7 (1) RNA 255.4 40 6.385 2.804 0.003 2.28 
K0 (2) RNA 587.5 40 14.689 7.655 0.009 1.92 
K3 (2) RNA 211.5 40 5.287 2.956 0.011 1.79 
K7 (2) RNA 409.8 40 10.244 4.327 0.005 2.37 
EK0 (1) RNA 1075.7 40 26.892 7.723 0.006 3.48 
EK3 (1) RNA 828 40 20.7 7.358 0.003 2.81 
EK7 (1) RNA 1545 40 38.625 20.227 0.008 1.91 
EK0 (2) RNA 516.1 40 12.902 6.146 0.005 2.1 
EK3 (2) RNA 901.3 40 22.533 7.628 0.005 2.95 
EK7 (2) RNA 1145 40 28.625 10.632 0.01 2.69 
K0 (3) RNA 580.5 40 14.512 6.288 0.152 2.31 
K3 (3) RNA 512.8 40 12.821 6.111 0.002 2.1 
K7 (3) RNA 432.9 40 10.824 4.606 0.002 2.35 
K0 (4) RNA 410.2 40 10.256 4.459 0.002 2.3 
K3 (4) RNA 398.3 40 9.957 4.742 0.003 2.1 
K7 (4) RNA 786.4 40 19.66 7.154 0.247 2.75 
EK0 (3) RNA 499.1 40 12.477 5.116 0.003 2.44 
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EK3 (3) RNA 519.3 40 12.983 5.192 0.003 2.5 
EK7 (3) RNA 624.9 40 15.623 6.997 0.004 2.23 
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6.11 Appendices for Bioinformatics Study 
6.11.1 Data Series from ‘Normal Human Endometrium’ Literature Search Excluded from 
the Study 
Data Series Series Title Number of Samples Reason for Exclusion 
Gene expression profiling 
of human NK cells 
GSE24268 3 Cells Isolated 
Gene expression profiling 
of C/EBPβ- and STAT3-
deficient human 
endometrial stromal cells 
(HESC) 
GSE41473 8 Stromal cells Isolated 
CpG Methylation by 
Methyl 450K Bead Arrays 
from ENCODE/HAIB 
GSE40699 62 Epigenetic Study 
microRNA expression 
profile in endometrioid 
endometrial carcinoma 
(EEC) 
 GSE35794 
 
22 Epigenetic Study 
Altered Gene Expression 
Profile of Microvascular 
Endothelium in Placentas 
from IUGR/Preeclamptic 
Pregnancies 
GSE25861 10 Non endometrial tissue 
Open Chromatin by FAIRE 
from ENCODE/OpenChrom 
(UNC Chapel Hill) 
GSE35239 37 Cell Culture Study 
Unique Transcriptome, 
Pathways, and Networks in 
the Human Endometrial 
 GSE35287 
 
80 Cells Isolated 
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Fibroblast Response to 
Progesterone in 
Endometriosis 
Gene Expression Analysis 
of Stage I Endometrial 
Cancers 
GSE17025 103 Malignancy Study 
Perivascular Human 
Endometrial Mesenchymal 
Stem Cells Express 
Pathways Relevant to Self-
Renewal, Lineage 
Specification, and 
Functional Phenotype 
GSE31152 15 Cells Isolated 
Cervical carcinoma-
associated fibroblasts are 
DNA diploid and do not 
show evidence for somatic 
genetic alterations 
GSE29143 121 Non endometrial Study 
Open Chromatin by DNaseI 
HS from 
ENCODE/OpenChrom 
(Duke University) 
GSE32970 97 Non Endometrial Study 
Transcription Factor 
Binding Sites by ChIP-seq 
from ENCODE/HAIB 
GSE32465 339 Non Endometrial Study 
Expression data from 
patients with advanced 
ovarian cancer 
GSE19161 61 Malignancy Study 
A DNA Methylation 
Fingerprint of 1,628 
GSE28094 1628 Non Endometrial Study 
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Human Samples 
Gene expression profiles of 
endometriosis 
GSE23339 19 Normal endometrium not 
studied 
DNA Methylation 
Dynamics in Human 
Induced Pluripotent Stem 
Cells over Time (Agilent) 
GSE24677 16 Stem Cells Studied 
DNA Methylation 
Dynamics in Human 
Induced Pluripotent Stem 
Cells over Time 
GSE24676 47 Stem Cells Studied 
DNA Methylation by 
Reduced Representation 
Bisulfite Seq from 
ENCODE/HudsonAlpha 
GSE27584 202 Epigenetic Study 
Discovery of microRNAs 
and other small RNAs in 
solid human tumors: 
expression 
GSE20414 38 Epigenetic Study 
Discovery of microRNAs 
and other small RNAs in 
solid human tumors 
GSE20418 40 Epigenetic Study 
Affymetrix 500K Mapping 
Array data from ovary 
tumors 
GSE11960 114 Non Endometrial Study 
Cancer Genome Anatomy 
Project (CGAP) Human 
SAGE 
GSE15309 327 Malignancy Study 
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MOE430A Analysis of Dll3 
mutant vs. wild-type 9.5 
dpc somite-level tissue 
GSE15153 6 Non Endometrial Tissue 
MOE430A Analysis of Dll3 
mutant vs. wild-type 9.5 
dpc presomitic mesoderm 
GSE15152 6 Non Endometrial Study 
Endometrial profile of low-
dose estradiol and 
tamoxifen combination 
therapy 
GSE14518 16 Non Human Study 
Uterine stromal 
cell_cultured with uNK 
conditioned Medium 
GSE9718 14 Cell Culture 
Comparison of ES cells with 
relevant compartments of 
early embryos 
 
GSE8881 40 Stem Cell Study 
Differentially expressed 
genes in HEECs of eutopic 
endometrium of patients 
with endometriosis 
compared with control 
GSE7846 10 Cell Isolated 
Gene Profiling of 
Endometrium Reveals 
Progesterone Resistance 
and Candidate Genetic Loci 
in Women with 
Endometriosis 
GSE6364 37 Endometriosis Study. Useful 
samples included in the series 
are duplicated of those used 
Talbi et al 2006 
Human Uterine GSE5244 51 Epigenetic Study 
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Leiomyomata microRNA 
gene expression 
Human endometriosis vs 
normal endometrium 
study - transcriptional 
profiling 
GSE7305 20 Ovarian tissue studied. 
‘Normal’ endometrial samples 
from unknown source 
Human body index - 
transcriptional profiling 
GSE7307 677 Non Endometrial Study 
Comparison of gene 
expression profiles across 
the normal human body 
GSE3526 353 Non endometrial Study 
Actions of tamoxifen in the 
uterus and its molecular 
effectors in endometrial 
carcinogenesis. 
GSE3013 18 Malignancy Study 
Expression Project for 
Oncology (expO) 
GSE2109 2158 Non endometrial Study 
Cancer Genome Anatomy 
Project (CGAP) SAGE 
Libraries 
GSE14 765 Malignancy Study 
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6.11.2 Data Series from ‘Human Endometriosis’ Literature Search Excluded from the 
Study 
Data Series Series Title Number of 
samples 
Reason for Exclusion 
GSE40186  miRNA expression profiles in 
endometriotic cyst stromal cells (ECSCs). 
15 Cell isolation and Culture 
GSE31515  Transcriptome analysis of endometriotic 
stromal cells treated with hydrogen 
peroxide 
17 Cell Isolation 
GSE35287  Unique Transcriptome, Pathways, and 
Networks in the Human Endometrial 
Fibroblast Response to Progesterone in 
Endometriosis 
79 Cell isolation 
GSE17504 The PKA Pathway of Endometrial Stromal 
Fibroblasts Reveals Differentiation and 
Proliferative Potential in Endometriosis 
20 Cell isolation and Culture 
GSE11960  Affymetrix 500K Mapping Array data 
from ovary tumors 
2 Non endometrial tissue 
GSE16079 Promoter methylation profiles for 
ectopic vs. eutopic endometrium in SUP, 
VES and OME 
3 Epigenetic Study 
GSE11663  Human cleavage stage embryos are 
chromosomally unstable 
23 Cell Isolation 
GSE14 
GSE15309  
Cancer Genome Anatomy Project (CGAP) 
Human SAGE 
 
1 Malignancy Study 
 
GSE11691 
GSE11769  
Analysis of ectopic human endometrium 
and peritoneal tissues in nude mice 
8 Mouse Tissue 
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Euctopic and ectopic human 
endometrium (endometriosis) 
GSE7846 Differentially expressed genes 
in human endometrial endothelial cells 
derived from eutopic endometrium of 
patients with endometriosis compared 
with those from patients without 
endometriosis. 
 
10 Cell isolation and Culture 
 GSE7307 Human body index - transcriptional 
profiling 
29 Study Design not Available 
 GSE4888 Molecular phenotyping of human 
endometrium 
3 Normal Endometrium data 
GSE26346 Differential expression of microRNAs 
between eutopic and ectopic 
endometrium in ovarian endometriosis 
3 Epigenetic Study 
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6.11.3 Further analysis of datasets initially identified for inclusion in Endometriosis Study 
Data Series Series Title Study Comments Potential Samples for 
Inclusion in Study 
GSE5108 Whole genome 
deoxyribonucleic 
acid microarray 
analysis of gene 
expression in ectopic 
versus 
eutopic 
endometrium 
Tissue from different sources: 
Endometrioma, Peritoneal 
Explant and Endometriotic 
matched samples obtained at 
Hysteroscopy and dilatation 
and curettage. 
1 patient on GnRH anologue. 
 
11 eutopic and 11 ectopic 
samples 
 
GSE6364 Gene Expression 
Analysis of 
Endometrium 
Reveals 
Progesterone 
Resistance and 
Candidate 
Susceptibility 
Genes in Women 
with Endometriosis 
Patients surgically 
documented and histologically 
confirmed, moderate-severe 
endometriosis at laparoscopy. 
Biopsy specimens obtained by 
Pipelle or dilatation and 
curettage. 
 
21 Eutopic endometriosis 
samples 
GSE7305 Human 
endometriosis is 
associated with 
plasma cells 
and overexpression 
of B lymphocyte 
stimulator 
Tissues obtained from Zoion 
Diagnostics (Hawthorne, NY) 
20 Samples: 10 
endometriomas and  
10  matched eutopic samples 
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GSE12768 Gene Expression 
Profile for Ectopic 
Versus Eutopic 
Endometrium 
Provides New 
Insights into 
Endometriosis 
Oncogenic Potential 
Eutopic and Endometrioma 
samples 
 
Samples were luteal phase 
from patients operated for 
stage IV endometriosis 
 
 4 eutopic samples 
 
GSE37837 Genome-wide 
expressions in 
autologous eutopic 
and ectopic 
endometrium of 
fertile women with 
endometriosis 
26 normally cycling fertile 
women (age: 
24–45 y) with BMI (20–22 
k/m2) diagnosed ovarian 
endometriosis. Eutopic, 
Ectopic, Endometrioma 
samples collected 
 
 
36 samples endometrioma 
and eutopic 
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6.11.4 ‘R’ Code used to generate differentially regulated gene list for ‘Normal’ 
Endometrium 
Lines labelled ‘#’ Serve to explain the associated section of code.  
#read in data from selected patients 
geodata<-read.csv(file="GDS2052_full.csv")#assume header has been removed 
geodata<-geodata[-54676,]#last row is corrupted 
 
data<-log2(geodata[,c(3:10,12:17)])#log selected data 
ann<-geodata[,c(1:10,12:17,30:37)]#annotation data 
cyclePhase<-
factor(c("Proliferative","Early","Early","Mid","Mid","Mid","Mid","Late","Late","Late","Early","Mid","Late","Secretory"))#factor 
describing patient groups 
 
#series of indicies for location of sample groups 
ref<-which(cyclePhase=="Proliferative") 
early<-which(cyclePhase=="Early") 
mid<-which(cyclePhase=="Mid") 
late<-which(cyclePhase=="Late") 
 
#patient group data series 
ref.data<-data[,ref] 
early.data<-data[,early] 
mid.data<-data[,mid] 
late.data<-data[,late] 
 
#function to subtract log ref data from log patient data 
compRef<-function(x)(Talbi et al.) 
 
#patient ratio compared to reference and mean of these values for each patient group 
early.ratio<-apply(early.data,2,compRef) 
mean.early.ratio<-apply(early.ratio,1,mean) 
mid.ratio<-apply(mid.data,2,compRef) 
mean.mid.ratio<-apply(mid.ratio,1,mean) 
late.ratio<-apply(late.data,2,compRef) 
mean.late.ratio<-apply(late.ratio,1,mean) 
#selected up- and down-regulated probes from each patient group at log fold change +/-2 as defined by fc 
fc<-(2) 
up.early<-unique(which(mean.early.ratio>fc)) 
down.early<-unique(which(mean.early.ratio<(-fc))) 
up.mid<-unique(which(mean.mid.ratio>fc)) 
down.mid<-unique(which(mean.mid.ratio<(-fc))) 
up.late<-unique(which(mean.late.ratio>fc)) 
down.late<-unique(which(mean.late.ratio<(-fc))) 
#percentage up-regulated drops as percetage down-regulated rise from early to late 
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#interprate up- and down-regulated probes together (could seperate up- and down- by changing sub-setting) 
earlyDE<-
data.frame(ann[c(up.early,down.early),early+2],early.ratio[c(up.early,down.early),],mean.early.ratio[c(up.early,down.early)]) 
colnames(earlyDE)[4]<-paste("log ratio",names(data)[early[1]]) 
colnames(earlyDE)[5]<-paste("log ratio",names(data)[early[2]]) 
colnames(earlyDE)[6]<-paste("log ratio",names(data)[early[3]]) 
colnames(earlyDE)[7]<-"Mean Log Ratio" 
midDE<-data.frame(ann[c(up.mid,down.mid),mid+2],mid.ratio[c(up.mid,down.mid),],mean.mid.ratio[c(up.mid,down.mid)]) 
colnames(midDE)[6]<-paste("log ratio",names(data)[mid[1]]) 
colnames(midDE)[7]<-paste("log ratio",names(data)[mid[2]]) 
colnames(midDE)[8]<-paste("log ratio",names(data)[mid[3]]) 
colnames(midDE)[9]<-paste("log ratio",names(data)[mid[4]]) 
colnames(midDE)[10]<-paste("log ratio",names(data)[mid[5]]) 
colnames(midDE)[11]<-"Mean Log Ratio" 
lateDE<-data.frame(ann[c(up.late,down.late),late+2],late.ratio[c(up.late,down.late),],mean.late.ratio[c(up.late,down.late)]) 
colnames(lateDE)[5]<-paste("log ratio",names(data)[late[1]]) 
colnames(lateDE)[6]<-paste("log ratio",names(data)[late[2]]) 
colnames(lateDE)[7]<-paste("log ratio",names(data)[late[3]]) 
colnames(lateDE)[8]<-paste("log ratio",names(data)[late[4]]) 
colnames(lateDE)[9]<-"Mean Log Ratio" 
 
#write files  
write.csv(earlyDE, file="EndometriumEarlyDE.csv") 
write.csv(midDE, file="EndometriumMidDE.csv") 
write.csv(lateDE, file="EndometriumLateDE.csv") 
 
R’ Code used to generate differentially regulated gene list for ‘Endometriosis’ 
Endometrium 
#geodata<-read.csv(file="GSE6364 modified.csv")  
#data<-log2(geodata[,c(3:18)]) 
#ann<-geodata[,c(1:26)] 
 
geodata<-read.csv(file="GDS2737_full.csv", skip=114) 
ann<-geodata[,c(2,40:59)]  
data<-log2(geodata[,c(24:39)]) 
rownames(data)<-geodata[,1] 
samples<-colnames(geodata[,c(24:39)]) 
     
cyclePhase<-
factor(c("Proliferative","Early","Early","Early","Early","Early","Early","Mid","Mid","Mid","Mid","Mid","Mid","Mid","Mid","Mid
")) 
 
ref<-which(cyclePhase=="Proliferative") 
early<-which(cyclePhase=="Early") 
mid<-which(cyclePhase=="Mid") 
ref.data<-data[,ref]#note no row names 
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early.data<-data[,early] 
mid.data<-data[,mid] 
 
compRef<-function(x)  
early.ratio<-apply(early.data,2,compRef) 
mean.early.ratio<-apply(early.ratio,1,mean) 
mid.ratio<-apply(mid.data,2,compRef) 
mean.mid.ratio<-apply(mid.ratio,1,mean) 
 
#selected up- and down-regulated probes from each patient group at log fold change +/-2 as defined by fc 
fc<-(2) 
up.early<-unique(which(mean.early.ratio>fc)) 
down.early<-unique(which(mean.early.ratio<(-fc))) 
up.mid<-unique(which(mean.mid.ratio>fc)) 
down.mid<-unique(which(mean.mid.ratio<(-fc))) 
 
#interprate up- and down-regulated probes together (could seperate up- and down- by changing sub-setting) 
earlyDE<-
data.frame(ann[c(up.early,down.early),c(2,3,10)],early.ratio[c(up.early,down.early),],mean.early.ratio[c(up.early,down.early)]) 
colnames(earlyDE)[4]<-paste("log ratio",names(data)[early[1]]) 
colnames(earlyDE)[5]<-paste("log ratio",names(data)[early[2]]) 
colnames(earlyDE)[6]<-paste("log ratio",names(data)[early[3]]) 
colnames(earlyDE)[7]<-paste("log ratio",names(data)[early[4]]) 
colnames(earlyDE)[8]<-paste("log ratio",names(data)[early[5]]) 
colnames(earlyDE)[9]<-paste("log ratio",names(data)[early[6]]) 
colnames(earlyDE)[10]<-"Mean Log Ratio" 
rownames(earlyDE)<-geodata[c(up.early,down.early),1] 
midDE<-data.frame(ann[c(up.mid,down.mid),c(2,3,10)],mid.ratio[c(up.mid,down.mid),],mean.mid.ratio[c(up.mid,down.mid)]) 
colnames(midDE)[4]<-paste("log ratio",names(data)[mid[1]]) 
colnames(midDE)[5]<-paste("log ratio",names(data)[mid[2]]) 
colnames(midDE)[6]<-paste("log ratio",names(data)[mid[3]]) 
colnames(midDE)[7]<-paste("log ratio",names(data)[mid[4]]) 
colnames(midDE)[8]<-paste("log ratio",names(data)[mid[5]]) 
colnames(midDE)[9]<-paste("log ratio",names(data)[mid[6]]) 
colnames(midDE)[10]<-paste("log ratio",names(data)[mid[7]]) 
colnames(midDE)[11]<-paste("log ratio",names(data)[mid[8]]) 
colnames(midDE)[12]<-paste("log ratio",names(data)[mid[9]]) 
colnames(midDE)[13]<-"Mean Log Ratio" 
rownames(midDE)<-geodata[c(up.mid,down.mid),1] 
 
write.csv(earlyDE, file="Endometriosis2EarlyDE.csv") 
write.csv(midDE, file="Endometriosis2MidDE.csv") 
 
earlyGenes<-rownames(earlyDE) 
midGenes<-rownames(midDE) 
all<-union(earlyGenes,midGenes) 
overlap<-intersect(earlyGenes,midGenes) 
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